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Abstract  
 The extracellular environment plays an important and crucial role in orchestrating 
the behaviors of the cells in the central nervous system (CNS). In my thesis work, I 
studied how the extracellular environment regulates a subset of glial cells, 
Oligodendrocytes (OLs) and astrocytes. Moreover, I studied the relationship of the 
astrocyte and the OL, particularly for astrocytes to promote a favorable environment for 
OL maturation. The extracellular matric (ECM) is composed of a variety of factors, 
including glycoproteins and secreted extracellular proteins.  
In my thesis work, I focused on a subset of glycoproteins: Laminin (Ln), 
Tenascin-C (TnC), Fibronectin (Fn), and Vitronectin (Vn) and their regulation of 
astrocytes. As described in chapter 4 of my thesis, I concluded that the ECM 
differentially regulates astrocytes and their functions through β1 integrin. Additionally, I 
studied the effect of an extracellular factor, tissue inhibitor of metalloproteinase (TIMP)-
1 and its effect on both astrocytes and OLs. In chapter 5 of my thesis, I described how 
TIMP-1 is important for astrocytic behavior and astrocytes’ ability to respond to injury 
and inflammation. 
 Furthermore, I studied the effect of the extracellular environment on OL 
maturation. First, as described in chapter 6 of my thesis, I studied the direct effect of 
TIMP-1 on OL maturation and discovered a previously unreported mechanism of TIMP-
1 action on OL maturation. I also studied the effect of TIMP-1 on the astrocyte and how 
it affected OL maturation, specifically through the factors that astrocytes secrete in the 
absence of TIMP-1. As described in chapter 7 of my thesis, I found that TIMP-1 
regulates the factors astrocytes secrete, specifically a Fn fragment that inhibits OL 
maturation.  
In general, my thesis studies focused on the effect of the extracellular 
environment, particularly the ECM molecules, Ln, TnC, Fn, Vn, and the secreted factor, 
TIMP-1 on the glial cells, astrocytes’ and OLs’ functions.  
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Chapter 1. Multiple Sclerosis, Oligodendrocytes (OLs) and Remyelination 
I. Diagnosis and Clinical Forms of MS 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS) characterized by lesions or plaques of demyelinated 
axons that leads to significant disability. MS affects 2.5 million people worldwide, with 
an age of onset between 20-50 years of age; it is the most common neurological 
disability affecting young adults [7]. MS patients often present with heterogeneous 
symptoms, including visual problems and muscle spams, and the vast majority of 
patients will develop progressive decline in functions with difficulty speaking, swallowing, 
movement, and cognitive failure. The course of any given MS patient is often unique 
and unpredictable. Unfortunately, the cause of MS is unknown and there is currently no 
cure.  
In the majority of MS cases, autoreactive T cells drive the bouts of disease 
worsening, called clinical relapses that are associated with new or evolving immune-
mediated pathology within the CNS [9]. Current immune-modulatory therapies, like 
Interferon-β, manage the severity of relapses and their frequency, but they do not slow 
the progression of the disease [10]. This suggests that even with treatment the disease 
continues unabated with ongoing demyelination and only limited remyelination. Failure 
to fully remyelinate white matter lesions is a cardinal feature of MS, which contributes to 
interrupted axon conductance, can lead to axon degeneration, and neurodegeneration 
that contributes to the progressive decline seen in most patients. Demyelination strongly 
correlates with disease progression and clinical disability in MS patients [11, 12], thus 
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early therapeutic strategies to promote remyelination would be expected to provide 
long-term benefit for MS patients. 
Although the clinical presentation of MS is often varied (Figure 1-1), the 
pathological features remain consistent. The hallmark feature of MS is demyelinated 
plaques. MS is also characterized by glial scarring [7, 13]. The emergence of these 
plaques or lesions often have a propensity for certain areas of the CNS including: optic 
nerves, periventricular white matter, brain stem, cerebellum, and spinal cord [13, 14]. 
There are also inflammatory cells present, such as macrophages/microglia and 
lymphocytes, which surround lesions with some of these cells located within the lesion 
site [13, 14]. Briefly, there are four main types of MS lesions: reactive, active 
demyelinating, chronic active, and chronic inactive [15]. Reactive and active 
demyelinating plaques are described by having dense infiltrates of macrophages that 
contain myelin proteins, additionally these are the plaques found most predominately in 
the early stages of disease [15]. Chronic active plaques tend to have an inactive core, 
with little to no macrophage infiltration, but surrounded around the perimeter by active 
macrophages [15]. Finally, chronic inactive plaques have little to no macrophage 
infiltration in the entirety of the plaque [15].  
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Figure 1-1: Clinical disease courses in different types of MS. Representative graphs of 
clinical presentations of the different types of MS. Y axis depicting increasing disability; x axis 
representing time. Top left panel showing disease course of RRMS. Top right panel showing 
disease couse of SPMS. Bottom left panel showing disease course of PPMS. Bottom right 
paenl showing disease course of PRMS. Figure from the National MS Society: 
www.nationalmssociety.org/what-is-ms/types-of-ms 
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 The diagnosis of MS is based on several criteria: 1. Clinical 2. Imaging 3. 
Diagnostic oligoclonal banding. Specifically, 1. neurologic dysfunction “disseminated in 
space and time” meaning neurological disability for a period of time, 2. the presence of 
gadolinium(Gd)-enhancing lesions on MRI that indicate inflammatory demyelination; Gd 
is a large molecule that cannot normally pass through the blood brain barrier, therefore , 
GD positive MRIs show that there is active lesions and 3. positive oligoclonal banding 
[14]. When there is still uncertainty, tests on the cerebrospinal fluid are used, to look for 
increased intrathecal synthesis of immunoglobulins of restricted specificity with 
moderate lymphocytic pleocytosis [14].  
There are different clinical forms/courses of MS. The most common type is 
relapse remitting MS (RRMS), which represents about 80% of all the MS cases. In 
RRMS, symptoms present over a period of a few days then spontaneously resolve 
within a few weeks that can reoccur ever few weeks, months, or even years [14]. RRMS 
predominately affects young adults, with initial signs of disease in early 20s. RRMS is 
more common in women with a rising ratio of 2:1. In recent studies this difference does 
not reflect an underlying cause related to gender, but to decreases in the incidence of 
MS in men, potentially through the decreasing levels of male smokers [16]. RRMS 
generally presents with sensory disturbances including: optic neuritis, diplopia, trunk 
and limb parethesia, limb weakness, clumsiness, gait ataxia, and bladder and bowel 
symptoms [14]. Eventually there is cognitive impairment, depression, emotional lability, 
dysarthria, dysphagia, vertigo, progressive quadriparesis, sensory loss, ataxic tremors, 
pain, sexual dysfunction, spasticity, etc [14]. Approximately 70% of these cases will lead 
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into secondary progressive MS (SPMS) [14]. However, although MS is life-altering 
disease with severe disability, it does not generally shorten the life span of the patient.  
Primary progressive MS (PPMS) is a less common, but more aggressive form of 
MS. PPMS is described as gradual but progressively declining clinical course and there 
is no difference in incidence between the genders. Additionally, PPMS patients 
generally present with symptoms in their 40s. PPMS patients often present with upper 
motor-neuron syndrome of legs and gradually worsen to quadriparesis, cognitive 
decline, visual loss, brain-stem syndromes, cerebellar dysfunction, bowel and bladder 
dysfunction, and sexual dysfunction [14]. Moreover, PPMS does not involve the immune 
system, therefore, all current therapies remain useless, which will be discussed further 
in this chapter.  
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A.                                    B.  
Figure 1-2: Plaques in the MS brain. Representative images of MS brains. A. Coronal 
brain slice stained with luxol fast blue of an MS brain depicting lesioned sites. Green 
arrows showing chronic MS lesions; red arrows showing shadow plaques or areas of 
limited remyelination. Adapted from Franklin et al. [8] B. GD enhanced MRI of an MS 
brain depicting lesion sites in white. Adapted from 
http://emedicine.medscape.com/article/1146199-overview 
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II. Role of Immune System in MS 
 In most forms of MS, the immune system drives the clinical relapses and is 
thought to evoke most myelin injury. The MS immune response is driven by myelin 
antigens from the CNS, specifically by T cells. It is widely accepted that among most 
MS patients, there is an aberrant development of T cells that recognize “self-antigens”, 
which lead to autoimmunity and destruction of the host tissues. For the purposes of this 
thesis, we will broadly refer to the major classes of immune cell types (e.g. T-cell) and 
not delve deeper into the nuances and specifics of these immune cell types. In the 
immune system of an MS patient a variety of immune cell types are recognized to 
contribute to immunopathology. For instance, patients with RRMS have been reported 
to have an increased amount of myelin specific T cells, as compared to healthy patients 
or even SPMS patients [13]. In addition, myelin-reactive T Cells from MS patients have 
memory and an activated phenotype, where as in the healthy patient, they have a naïve 
phenotype [13]. Activated T cells adhere to the luminal surface of endothelial cells and 
migrate into the CNS after an insult to the blood brain barrier (BBB) [14, 17, 18]. 
Following the migration of these cells into the CNS, there is a significant immune 
response after the T cells become reactive to self myelin and non myelin antigens, 
including myelin basic protein (MBP), myelin- associated glycoprotein (MAG), myelin 
oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP) [14, 19]. Antigens on 
the myelin sheaths or oligodendrocytes can be recognized by these cells and cause 
demyelination [14, 19]. The complexity of the immune-response and the subsets of T 
cells, while important, exceed the scope of my thesis work. Other cells also can 
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contribute to the damage of oligodendrocytes and myelin, including microglia and 
macrophages. Activated microglia and macrophages can produce pro-inflammatory 
cytokines and generate reactive oxygen species [14]. 
III.  Current “Disease Modifying” Therapies for MS 
 Initially corticosteroids were used as a treatment during MS; which was believed to 
be caused by viruses, and thus resulted in the immune system targeting for MS 
treatments. However, currently steroids now are only prescribed for acute relapses. 
Steroids have been shown to work by limiting the amount of cytokines in the 
bloodstream, suggesting a mechanism of action of steroids by inducing an anti-
inflammatory effect and resulting in less activation of the peripheral immune cells [20]. 
 Current treatments for MS predominately focus on the immune system and abating 
the autoreactive T cell response. Generally treatments for MS are immunomodulatory, 
but are referred to as first disease-modifying therapies (DMT). The first DMT to be 
approved by the Federal Food and Drug administration (FDA) for treatment of MS was 
interferon (IFN)-β in 1993 and has been shown to reduce the frequency and duration of 
relapses [21, 22]. IFNs are a group of proteins that play a role in regulating the body’s 
immune response. IFN-β has a multifactorial influence on the immune systems leading 
to an anti-inflammatory effect, including: decreased antigen presentation, upregulation 
of interleukin 10 (IL-10), decreased expression of T helper-1 and -17, and reduce 
infiltration of immune cells across the BBB [14, 23].  IFN-β in randomized clinical trials 
was shown to decrease the amount and severity of relapses, as well as decreasing the 
T2 lesion volume, which show all lesions on MRI as white, a criteria for MS diagnosis, 
as compared to the placebo group [23].  
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Another therapy currently used for treatment of RRMS is glatiramer acetate (GA). 
GA is an active amino acid sequence that contains a large number of synthetic peptides 
that may compete with myelin basic protein (MBP) for presentation on MHC class II 
molecules, which leads to the inhibition of antigen-specific T cell activation [14, 23]. The 
mechanism of action for GA remains elusive, however, it is believed to act on antigen 
presenting cells (APC) incorporate the GA peptides and present them to lymphocytes 
and thus inhibits the multiplication of lymphocytes that are capable of reacting to MBP 
[23].  
 Natalizumab is a therapy that uses the interaction of integrins on the leukocyte to 
prevent the migration into the brain [23]. Natalizumab contains immunoglobulin 
monoclonal antibodies against α4 integrins and thus blocks α4 integrins, meaning the 
leukocytes containing α4 chains cannot interact with blood brain barrier (BBB) and enter 
into the brain [23]. It reduced the risk of sustained disability, the amount of clinical 
relapses, and the enlarging of emergence of T2 lesions [23]. Although very effective, it 
cannot be broadly used. Progressive multifocal leukoencephalopathy (PML) is an 
opportunistic viral brain disease that is caused by reactivation of the JC virus	 [24]. 
Unfortunately, treatment with natalizumab has resulted in a group of JC-virus positive 
MS patients to develop PML, which can result in fatality	 [24]. Because of the negative 
consequences and the prevalence of the JC virus in the population, natalizumab 
unfortunately cannot be widely used.  
 Fingolimod is the first oral therapy for treatment of MS. It is a sphingosine-1 
phosphate (SIP) receptor modulator and binds to the S1P1 receptors on lymphocytes 
thus leading to the internalization and its down regulation, preventing the release of 
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lymphocytes from the lymphnodes [21, 23, 25]. However, fingolimod has also shown to 
have a direct effect on neural cells, including the promotion of differentiation of OPCs 
through S1P1 receptor activation [21, 25].   
 Currently there is no therapy for PPMS. The current therapies used by physicians 
to treat MS are disease-modifying drugs, and treat primarily by reducing inflammation 
and the amount and severity of relapses, and thus improving the quality of life of those 
with RRMS; with PPMS relapses and inflammation are not a part of the disease and 
therefore are not effective in treating PPMS [26].  Therefore, research into studying the 
underlying cause of MS (failure to remyelinate), provides potential for therapeutics to 
treat PPMS and potentially to treat the underlying cause is all MS, as well.  
IV.    Oligodendrocytes (OLs), Myelin, and Remyelination 
1. Demyelination and Remyelination 
 Demyelination is a process where by the myelination surrounding the axons in the 
CNS are lost. Demyelination is a major pathological feature in MS, and destruction of 
myelin in MS leads to the disability and neurological decline observed in these patients. 
Demyelination in the CNS occurs as a consequence of a direct injury to the OL	 [7]; in 
the context of MS this is due to inflammatory damage [7]. With the loss of myelin, the 
axon loses both trophic support and the fidelity of the excitable signal.  
 Remyelination is the process of restoring myelin sheaths to unmyelinated areas of 
axons and restoring saltatary conduction and functional deficits by newly matured OLs	
[7, 27]; however, the newly formed myelin has shorter segments along the axon and is 
thinner [7]. Limited remyelination is observed in MS. However, these areas of 
remyelination or shadow plaques have limited efficiency and eventually, in part due to 
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reoccurring inflammation, ultimately fail [28, 29]. This leads to chronically demyelinated 
lesions [28, 29]. While OLs can participate in remyelination, most OPCs are found to 
migrate to an area of injury to fix the damage, but they do not mature [27]. Potential 
explanations for this failure of OPC differentiation include the pathological expression of 
inhibitory signals, the lack of pro-differentiating signals, or an innate deficit in the ability 
to efficiently differentiate. Additional studies have found that although OPCs are able to 
migrate to areas of injury, there is also a depletion of these OPCs under chronic distress 
[7]. Early life experiences, as stated in a recent paper, would suggest that depletion of 
OPCs in juveniles has the effect of developing chronic demyelination when they mature 
to adulthood. In this study, it was found that depletion of OPC cells during early 
postnatal days (P5-7), after myelin injury, had limited remyelination in adults [30]. 
Therefore, understanding which cues inhibit the OPC maturation and defining how 
trophic factors may be used to promote OPC differentiation in MS is an area of intense 
study. Also, one factor related to the regulation of myelinating potential in MS is the role 
of the extracellular environment, which will be addressed in later chapters.  
2. Oligodendrocytes (OLs) 
OLs are the myelinating glial cell of the CNS. One OL is able to myelinate up to 
40 different axons [3]. An individual OL can extend many processes, which contact and 
repeatedly circles a segment of an axon; this is known as an internode. Myelin is a 
multilamellar membrane, which allows for rapid salutatory nerve conduction by acting as 
an electrical insulator and physically organizes the clustering of sodium channels to the 
unmyelinated regions between the internodes, called the Nodes of Ranvier [31, 32].  
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OLs differentiate from migratory and mitotic precursor cells known as 
oligodendrocyte progenitors cells (OPCs) [32, 33]. The mechanism(s) for OPC 
differentiation into OLs is highly regulated spatially and temporally; specifically, 
differentiation begins with OPCs from the subventricular zone (SVZ). OPCs are bipolar, 
migratory, and proliferative, and present in the adult CNS, therefore, OPCs provide a 
potential target for MS regenerative medicine to promote remyelination because not all 
OPCs are terminally differentiated into OLs  
 OLs differentiation occurs in stages over time that can be identified by 1. 
expression of specific proteins, 2. morphology, or 3. the loss of other surface 
intracellular antigens [6, 32, 34] (Figure 1-3).  Specifically, Platelet-derived growth 
factor alpha-receptor (PDGFR-α), NG2 proteoglycan and A2B5 are used to detect the 
early stages of OL differentiation, specifically at the OPC stage [32, 34-36]. The antigen 
O4 is used differentiate between early OPCs and late OPCs, OL lineage cells will 
remain O4 positive even as mature, myelinating OLs. A variety of markers are used to 
identify immature OLs and mature myelinating OLs. These include: galactosylceramides 
(GALC) and 2’,3’-Cyclic nucleotide-3’-phophohydrolase (CNP). Where immature OLs 
will express these markers, they will not express other myelin component antigens such 
as MBP, proteolipid protein (PLP), myelin-associated glycoprotein (MAG) or 
myelin/oligodendrocyte glycoprotein (MOG) [32, 37, 38]. OLs will become positive for 
these markers once they are mature and competent to form compact myelin.  
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Figure 1-3: Stages of OPC differentiation. Representative images of the stages of 
Oligodendrocyte differentiation and stage-specific markers (60x Magnification). The top panels 
depict the morphology of the four main stages of OPC differentiation: Early OPC, Late OPC, 
Immature OL, and Mature OL. The bottom panel depicts the markers that each stage of OPC/OL 
differentiation are positive or negative for. Adapted from [6]. 
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There are many factors that are known to promote and/or inhibit the migration 
and differentiation of OPCs. These factors would ultimately affect myelination (Figure 1-
4) [39-47]. CNS myelination is a tightly regulated process that has stage specific 
requirements that are temporally regulated [39, 40, 43, 45, 46, 48]. For example, 
tenascin-c, an extracellular matrix molecule (ECM), has been shown to inhibit the 
migration of OPCs, specifically to retinal ganglion cell axons [49].  
There are many growth factors that have been shown to be important for the 
proliferation and/or differentiation of OPCs. Many of the factors that are important for the 
proliferation of OPCs can also inhibit the differentiation of OPCs. Several of these 
factors are described in the following section. 
3. Oligodendrocyte Cell Biology 
From work initially performed by Raff and Noble, it was found that there were 
factors in calf serum that prevented the differentiation of OPCs into OLs [50, 51]. This 
observation led to intense research into understanding the factors that both promote 
and inhibit the differentiation of OPCs. Many research groups have identified a variety of 
factors that influence OPC differentiation. Briefly, I will describe some of the main 
factors studied with regards to OPC differentiation. 
Bone morphogenic protein (BMP) has been shown to inhibit OPC differentiation 
[52]. The mechanism of inhibition of differentiation is in part due to maintaining the 
OPCs in the proliferative and immature phase but in part through promoting the 
progenitor cells into different CNS cell type lineage [52]. 
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PDGF is made by both astrocytes and neurons in the developing CNS and it is 
necessary for the survival and proliferation of OPCs; it signals through PDGFR-alpha [3, 
32, 53]. In addition, it keeps the OPCs in a proliferative and immature state.  
Fibroblast Growth Factor (FGF)-2 is also a necessary mitogen for OPCs; 
however, it is also inhibits the differentiation of OPCs into OLs [3, 32, 54]. FGF-2 
promotes proliferation and specification of OPCs through the interaction with FGF 
receptor 1 or2 and by activation and phosphorylation of extracellular signal-regulated 
protein kinases (ERK) [3, 55].  
Triiodothyronine/thyroid hormone 3 (T3) plays an important role in the 
production of myelin and OPC differentiation into OLs and can actually override the 
signaling from mitogens such as PDGF and FGF to remain in the proliferative state [3, 
56, 57]. T3 has been demonstrated to be in important for myelination using hypothyroid 
mice; hypothyroidism is a well-known cause of hypomyelination, meaning that the 
presence of thyroid hormones is important for myelination [57].  
Insulin- like growth factor (IGF)- I stimulates the proliferation of OPCs and 
increase survival by activating the PI3K/Akt pathway through the IGF-1 receptor and 
ultimately by preventing the phosphorylation and degradation of cyclin D1 and ultimately 
preventing apoptosis [3, 32, 58]. It has also been shown to be important for myelin 
formation and thickness; in IGF-I transgenics, there are significantly more myelinated 
axons as well as increase thickness of myelin [3, 32]. In addition, IGF-1 may also target 
OLs directly to promote remyelination, which has been shown using an animal model of 
MS, where remyelination occurs concordant with upregulation of IGF-1 [58]. 
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Wnt/β-catenin is heavily researched signaling pathway with regards to OPC 
differentiation and myelination due to conflicting reports about the necessity of Wnt/β-
catenin. Initially it was observed that there are elevated levels of Wnt3a and Wnt7a 
present in the MS lesions that sparked the initial interest in studying the Wnt/β-catenin 
pathway and its influence on OPC differentiation	 [59]. Wnt/β-catenin signaling has been 
shown to both inhibit and promote OL differentiation [60]. The canonical Wnt pathway 
acts through the Frizzled receptor and leads to the nuclear localization of β-catenin. 
Studies using Wnt3a have shown to inhibit the differentiation of OPCs [61]. A recent 
study has found that Wnt/β-catenin signaling has differing roles depending on the stage 
of OPC differentiation; activation of β-catenin in NPCs inhibits the generation of OPCs; 
however, β-catenin activation is necessary for OL differentiation and myelination [62]. 
This phenomenon is further explored in Chapter 6 of my thesis. The canonical signaling 
pathway of WNt/β-catenin is described in Figure 1-6. 
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Figure 1-4. Inhibitory and Stimulatory factors that affect OPCs differentiation into 
OLs at various stages of OPC differentiation. The middle panel depicts cartoon 
images of the different stages of OPC/OL differentiation: Progenitor/Early OPC, Pro-
oligodendrocyte/Late OPC, OL/ Immature OL, Myelinating OL/ Mature OL. The top 
panels details factors that inhibit OPC differentiation at the various stages of 
differentiation. The bottom panel details factors that promote OPC differentiation at the 
various stages of differentiation.  Adapted from [3, 4] 
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Figure 1-5. Pathway of canonical Wnt/β-catenin signaling (A.) Without Wnt ligand, 
the β-catenin pathway is inactive state. Without Wnt ligand, β-catenin interacts with the 
destruction complex, which consistens of the proteins Axin/APC/GSK3β. β-catenin 
interacts with the destruction complex and is phosphorylated and binds to β-Trcp, 
where it is targeted for degradation. This results in a downregulation of β-catenin 
mediated gene transcription. (B.) In the presence of Wnt ligand, β-catenin signaling is 
active. There is an upreglation of β-catenin mediated gene transcription, for example C-
myc. Wnt binds to its Frizzled receptor and LRP5/6 co-receptor thus activating Dvl. Dvl 
then interacts and inhibits the degradation complex thus leading to free β-catenin. β-
catenin is then able to translocate into the cell nucleus and stabilize with the 
transcriptional complex, Lef//Tcf promoting gene transcription. Additionally, ? signify 
areas where additional signals may influence β-catenin signaling. We hypothesize that 
TIMP-1 is one of the other signals that mediate β-catenin. Adapted from [5]. 
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4. Myelin 
 Myelin is a multilamellar extension of the plasma membrane of OLs. Compact 
myelination of axons allows for electrical insulation that promotes rapid salutatory nerve 
conduction and provides fidelity of neural signaling [32, 63, 64]. OLs are also though to 
provide trophic support to the axons [32, 63, 64]. Myelin is able to ensure these 
functions, at least in part, due to its structure, thickness, low water content, and lipid 
richness [3, 32 ]. Myelin sheath segments, or internodes, are typically 15-200um long 
and separated by myelin free spaces called nodes of Ranvier [31, 32]. It is within the 
nodes that sodium channels are clustered, which allow for salutatory conduction [31, 32]. 
The structure of myelin is composed of 40% water; the dry weight is 70% lipids and 
30% protein [32, 65].  
 Myelin is composed primarily of distinct lipids and proteins. Myelin contains 
cholesterol, phospholipids, and glycolipids at a ratio range from 4:3:2 to 4:4:2 [32, 65]. 
GalC is a major component of myelin and comprises 20% of the dry weight of myelin 
[32, 65]. The major proteins in myelin within the CNS are PLP[66-69], MBP[67-69], 
MAG[69, 70], MOG[69, 70], and CNP[68, 71]; these genes are temporally regulated to 
develop myelin.  
 Myelination occurs from the caudal region to the rostral region in the brain and 
from the rostral region to the caudal region in the spinal cord [3, 32, 72]. The timing of 
myelination depends on species: in the mouse, myelination starts at birth in the spinal 
cord, and is complete around p45-60, whereas, in humans, myelination begins during 
the second trimester, peaks in during the first year of life, and continues until 20 years of 
age [32, 73]. Recent studies have found that myelin formation is actually a lifelong 
process in the CNS and is necessary for mastering new complex motor skills [74]. 
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McKenzie et al. found that in the healthy adult brain, myelinating OLs were continually 
being formed [74]. An inability of mice to acquire new complex motor skills occurred 
when myelination was blocked, suggesting an important role for myelination in the adult 
CNS [74].  
 It is recognized that the process of myelination is very complex. Our understanding 
on the specific mechanisms and signals that control myelin formation and maintenance 
in health and disease is constantly emerging. Early notions suggested that axon surface 
ligands, secreted molecules, and axonal activity are critical for compact myelin [60]. 
However, recent studies have redefined the requirement for this as OLs can myelinate 
inert carbon fibers [75]. Additionally, experiments in culture have shown that OLs will 
myelinate inherently without signaling from the axons, suggesting additional 
mechanisms to promote myelination [60, 75]. The process of myelination requires the 
formation of the membrane with the specific composition described above that allows 
for the compaction and formation of the dense lamellar sheaths. The three main steps 
that are required for myelination include: the migration of OLs to axons, not dendrites, 
that need to be myelinated; the adhesion of the plasma membrane processes of the 
OLs to the axons; the actual engulfment and wrapping of the axons to a fixed space and 
number of wraps.  
 The reason why some axons are myelinated but not others are myelinated is not 
fully understood. In general an axon must have a diameter of at least 1μm to be 
myelinated [76]. Axonal signaling can influence OLs to promote myelination. Ligand 
dependent axonal regulation of myelination mechanisms discovered have largely been 
inhibitory including: Jagged, which inhibits Notch pathway [77]; PSA-NCAM[78]; LINGO-
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1[79]; all of which inhibit OPC differentiation and myelination [3, 60]. In addition, 
integrins have been shown to play an important role with regards to the initiation of 
myelination. Specifically, pre-myelinated axons produce laminin-α 2 which interacts with 
β1 integrin receptors on the immature OLs to promote the initial interaction of its 
cytoplasm to the axon [3, 80]. This receptor-ligand meeting activates integrin-linked 
kinase to initiate myelination (ILK) [3, 80]. 
   There is also evidence that neuronal activity plays an important role with regards 
to myelination. Specifically, using myelinating cultures and blocking action potentials 
using tetrodotoxin, Na+ channel blocker, prevented the initiation of myelination	 [81]. 
Additionally, using α-scorpion toxin, which induces electrical activity, there was 
increased myelination	 [81]. This data suggests a role of electrical activity in regulation 
myelination.  
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Figure 1-6: Compact Myelin.  Representative electron microscopy (EM) images of 
the corpus collosum of control mice (A) and mice treated with cuprizone (B). Dark 
circles in A show proper myelination and the loss of myelin when fed cuprizone as 
depicted in B with minimal black circles or myelin sheets. Scale bar=2um. Images 
courtesy of Alex Nicaise.   
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V. Animal models of CNS Demyelination 
 Animal models have provided tremendous benefits to an understanding of myelin 
and treatment of demyelinating diseases like MS.  Currently, there are a number of 
widely used animal models, but three main animal models of CNS demyelination are 
used to study distinct and different aspects of myelin biology and autoimmune-induced 
demyelination: experimental autoimmune encephalomyelitis (EAE), Lysolecithin, and 
dietary cuprizone intoxication.  
1. EAE 
 EAE was first identified in the 1930s when researchers were trying to understand 
the phenomenon of paralysis that occurred with vaccinations in children	 [82]. EAE is the 
most commonly used animal model to study MS and has great value as a model of the 
inflammatory components involved on MS. EAE is characterized by inflammation and 
demyelination that is induced by injection of myelin peptides such as: MOG peptide, 
residues 35-55;PLP; MBP, residues 1-37, emulsified with completes Freud’s adjuvant 
as well as an injection of pertussis toxin, to allow for a permeable BBB and the 
sensitization of the immune system to the self-antigens [83-86]. EAE in C57B6 mice 
using MOG peptide, is a well-characterized and highly reproducible model; however, it 
is monophasic, meaning there are no relapses in addition the immune component is 
predominately an autoreactive T cell response that results in demyelination within the 
CNS, mostly in the spinal cord [84, 85]. However, areas of demyelination in this model 
are random, allowing for complications in studying this model. EAE in SJL mice develop 
a relapsing and remitting form of EAE using MBP peptide or spinal cord emulsifant, 
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where there are periods of acute recovery	 [87-89]. Additionally, EAE mimics MS by 
primarily affecting the white matter, however, it is not a perfect model and lacks some of 
the complexity seen in MS, such as disease progression, difficulty in studying 
remyelination due to the spontaneity of lesion formation, and the regional specificity to 
the spinal cord, where as MS effects the brain as well [85]. EAE has proven useful for 
treating MS. It has resulted in three of the six currently approved MS therapeutics after 
showing promising results in this model including: glatiramer acetate, mitoxantrone, and 
natalizumab [90].  
2. Toxin-Induced Demyelination  
 Microinjection of lysophospatidylcholine (lysolecithin) into the white matter of mice 
induces demyelination, and is a good model to study remyelination [85]. This model is 
very useful in studying the molecular and cellular components with regards to 
remyelination. This model has a focal lesion and therefore is a useful model to study 
remyelination, unlike EAE where the lesion formation is random. Unfortunately, there is 
no immune component in this model of demyelination and, therefore, is a major 
weakness of the model.  
 Cuprizone is another toxic model of demyelination used to study the 
remyelination events. Cuprizone is a copper chelator, administered orally to rodents that 
reproducibly evoke robust and predictable CNS demyelination, most noticeable in the 
corpus callosum where there is spontaneous remyelination events [91]. The site of 
injury is both reliable and consistent and provides a useful tool in studying the 
remyelination events. It is also easily administered due to the oral consumption of 
cuprizone through chow by the mice. Additionally, it also causes global demyelination, 
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making it an easy model to study demyelination and thus remyelination. However, the 
exact mechanism of demyelination is not fully understood, but results in apoptosis of 
OLs [85]. Similar to lysolecithin model of demyelination, a weakness of this model is the 
lack of an immune component of demyelination.  
VI. Emerging Remyelinating Therapies for MS 
Current mainstream therapies have been shown to improve the quality of life for 
most patients, but unfortunately most do not promote remyelination in the MS brain. 
Considerable research is now focused on the discovery of such agents that may target 
OLs to promote remyelination. It is known that OPCs are present in the MS lesion	 [27], 
so targeting these stem cells to differentiate into myelinating OLs provides an interesting 
therapeutic intervention. One recently identified example is in phase 3 trials: an antibody 
targeting Lingo [92]. This antibody blocks the effect of LINGO-1, a protein that prevents 
OLs to myelinate. Leucine-rich repeat and immunoglobulin-like domain-containing 
protein (LINGO)-1 is a transmembrane protein that has been shown to inhibit OPC 
differentiation through decreasing activity of Fyn kinase and ultimately increasing RhoA 
signaling, a pathway involved in OPC differentiation [3, 79]. In addition, treatment of 
anti-LINGO in the lysolecithin model of demyelination and cuprizone model of 
demyelination induces robust remyelination, suggesting an important role of LINGO-1 in 
inhibition of OPC differentiation and a potential therapeutic measure in treating MS [93]. 
Recently a new high throughput-screening platform has been developed using 
micropillar arrays [75]. Using this array, compounds to promote remyelnation can be 
screened in order to determine if they promote myelination by determining the formation 
of myelin rings around the micropillars [75]. Interestingly, with the use of this new 
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technology, a cluster of antimuscarnic compounds were found to promote OL 
differentiation among which, benztropine and clemastine were found to cross the BBB in 
animal studies [75]. Clemastine was found to also promote remyelination in vivo using a 
demyelinating animal model, lysolecithin injection [75]. Interestingly, this study has lead 
to advances in potential remyelination therapies for MS patients. Around the same time, 
another group found similar results of anti-muscarinic components, specifically 
benzatropine, promoting OPC differentiation in vitro, as well as promoting remyelination 
in the EAE model [94].  
Another recent study by Najm et al. identified additional compounds that promoted 
OL differentiation in vitro, organotypic slice cultures, and in vivo in early postnatal 
mouse pups: miconazole and clobetasol [95]. These new potential therapeutics were 
identified using a stem-cell based screening platform, where OPCs derived from ES cell 
lines from mouse pups were tested for enhanced OPC differentiation and myelin 
formation in vitro.  This study also confirmed the potential of these agents to promote 
remyelination in vivo using the lysolecithin model of demyelination in adult mice, where 
they found that the drugs were also able to promote remyelination in the slice culture as 
compared to controls [95]. These recent studies are both promising and exciting for the 
merging field of remyelinating therapies for treating MS.  
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Chapter 2. Astrocytes and CNS Myelination  
Historically, astrocytes had been defined as the “glue” that holds together the 
CNS, however, emerging active roles of astrocytes have been discovered recently. For 
the purpose of my thesis, I will be focusing on the emerging role of astrocytes promoting 
myelination, however, briefly I will describe additional functions of astrocytes in the CNS.  
Astrocytes are a prominent type of glial cell, and the most abundant cell type in 
the CNS. Astrocytes can be identified by star-like morphology and expression of a 
range of markers including: S100B [96], vimentin [97], and glial fibrillary acidic protein 
(GFAP) [98, 99]. They are organized in distinct, non-overlapping domains, without 
interdigitation and exhibit cell contact inhibition of proliferation [100].  
Astrocytes are heterogeneous. This is not unexpected given the range of diverse 
functions attributed to these cells. Grossly, astrocytes can be divided into two main 
types of astrocytes that are defined by the areas of the CNS in which they are located: 
Protoplasmic or, grey matter astrocytes; Fibrous or, white matter astrocytes [50]. It has 
been speculated that each type has developmentally distinct origins, which will be 
discussed further in the following section [50, 101]. The origins and nature of astrocyte 
heterogeneity is an area of growing interesting, with limited consensus.  
In the following sections I will outline the basic questions pertaining to a 
fundamental understanding of astrocytes in the CNS. In particular, I will relate how the 
basic understanding of astrocyte biology is expected to further the understanding in a 
variety of CNS diseases. Specifically, how astrocyte dysfunction may be an underlying 
etiology during injury and inflammation. 
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I. Origins and Functions of Astrocytes 
Developmental biology of Astrocytes 
a. During development (as depicted in Figure 2-1)  
 In this chapter, I will discuss astrocyte differentiation in the brain and the spinal 
cord during development and adulthood astrocyte differentiation. It is important to 
understand the developmental origins of astrocytes because it is believed that injury 
induced proliferation and differentiation of astrocytes reactivates important 
developmental mechanisms.  
 In the developing mammalian CNS, neural progenitor cells (NPCs) generate 
neurons and glial cells, originating from the embryonic germ layer, the neuroectoderm 
[102]. Astrocytes are thought to progress in a step-wise fashion through four stages: (1) 
a radial glial progenitor, (2) a proliferating intermediate progenitor, (3) a maturing 
postnatal astrocyte, (4) an adult astrocyte [101, 103, 104]. The mechanism(s) in 
regulating this switch from neuronal fate towards glial cells is not fully understood [100, 
104]. Additionally, studies have also found another type of multipotent cell, NG2 cells, 
that can give rise to astrocytes during development [105, 106]. 
There is no current consensus on the morphologically or genetically distinct 
stages of astrocyte differentiation. Radial glia can actively divide and are believed to be 
a common progenitor to neurons and astrocytes in different regions within the CNS 
[104]. Radial glia can divide both symmetrically, producing two identical daughter cells 
(radial glial or NPCs), or asymmetrically, producing two different daughter cells (NPC 
and a radial glial cell) [104]. At varying times, radial glia will migrate to different regions 
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within the CNS and differentiate. Radial glia can give rise to both grey matter and white 
matter astrocytes in development in the brain and in the spinal cord.  
Promotion of astrocytic fate is due in part to promotion of JAK-STAT signaling 
and activation of Notch signaling [100, 104]. In addition, the diversity of astrocytes is 
due, in part by location and cues form neurons and not believed to have a homogenous 
stepwise differentiation; however, this is a somewhat controversial topic that has been 
debated among many groups [100, 101, 104].  
The current views with regard to terminal differentiation of astrocytes involve 
patterning, specification, migration, and local cell-cell contact [101]. Neural tube 
patterning is a process that generates large diversity within cell populations, wherein, 
cell-extrinsic patterning signals, when secreted factors such as sonic hedge hog (SHH) 
and Wnts, are converted to cell-intrinsic differences in transcription factor expression, 
creating distinct domains of transcription factor expression [101, 107, 108]. However, 
cell patterning, as of yet, has not been observed in cortical astrocytes, only in the spinal 
cord astrocytes.  
 A variety of transcription factors have been implicated in regulating astrocyte 
generation. Specifically, nuclear receptor corepressor for multiple transcription factors 
(N-CoR) has been shown to repress the generation of astrocytes by forming a complex 
with neuregulin receptor Erb4 and binding and repressing astrocytic genes [101, 109]. 
Another example of a transcription factor regulation astrocytic specification is 
neurogenin (ngn1-3), which have been shown to block astrocyte specification [101, 110]. 
There are also a variety of transcription factors that promote the generation of 
astrocytes. NFIA is a member of a family of transcription factors that bind to CAATT 
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boxes and control gliogensis in the embryonic spinal cord; NFIA also promotes 
differentiation of astrocytes [101, 111]. Sox9 is expressed in NSCs in the spinal cord 
and has been shown to be important for the generation of grey matter astrocytes [101, 
112]. 
1. Grey Matter Astrocytes 
Both grey matter and white matter astrocytes can be found in the brain and 
differentiate from a common glial progenitor cell. Glial progenitor cells can differentiate 
into two types of immature cells, what is commonly known as OPCs and also a form of 
an immature protoplasmic astrocyte (grey matter astrocyte). OPCs are commonly 
shown to differentiate into OLs; however, it is now believed that they can also give rise 
to Fibrous or white matter astrocytes [51]. In a study by Raff et al., they found that when 
they cultured this glial progenitor cell, later termed OPC, that not only could it give rise 
to OLs, but also to fibrous astrocytes, depending on the media it was cultured in, 
suggesting that extrinsic signaling to these OPCs determined the fate in which they 
differentiate [51]. However, protoplasmic astrocytes could not be generated from this 
cell population, suggesting a bifurcation, or additional lineage step from glial progenitor 
cells into proteoplasmic astrocytes (Figure 2-1). To complicate the matter, Nishiyama’s 
group found another type of multi-potent cell, NG2 cell, which was originally thought to 
give rise only to OLs, however, using transgenic line of mice that expressed DsRed in 
NG2-expressing cells, found that a portion of the NG2 cells differentiate into 
protoplasmic astrocytes in the forebrain but not to white matter astrocytes, however, 
NG2 cells can only differentiate into astrocytes during development [105, 106]. These 
conflicting studies further show the importance into the study of astrogliogensis and the 
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heterogeneity of this cell type.  
2.  White Matter Astrocytes 
During development, astrocytes in the spinal cord develop and differentiate 
similarly to astrocytes in the cortex. Astrocytes originate from radial glia in the spinal 
cord, [113]. Again, this data suggests a common progenitor to OLs and fibrous 
astrocytes, potentially OPCs, as depicted in Figure 2-1. Essentially, during 
development, the generation of spinal cord astrocytes is similar to that of cortical white 
matter astrocytes, derived from radial glial cells. Neural tube patterning has been shown 
to be important for astrocytic specification in the spinal cord, specifically that a basic 
helix-loop-helix (bHLH) code is required for astrocytic development [108]. Three types of 
ventral white matter astrocytes (VA1, VA2, VA3) have been shown to arise due to 
combinational patterning of Pax6 and Nkx6.1[107]. However, it has not been 
determined whether this patterning is critical for astrocytic specification in all regions of 
the CNS, especially with grey matter astrocytes. 
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Figure 2-1: Astrocytic differentiation during development. Adapted from [50, 51, 105, 113]. 
Briefly, glial progenitor cells originate from radial glial cells that divide into asymmetric daughter 
cells. Glial progenitor cells can differentiate into two distinct progenitor cell populations, OPCs or 
immature protoplasmic astrocytes. OPCs are able to differentiate into fibrous astrocytes and 
immature protoplasmic astrocytes can differentiate into protoplasmic astrocytes. 
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b. Astrocytes in the mature, adult CNS 
Development of new astrocytes is not a limited process throughout a lifespan, 
since astrocytes can continue to develop during adulthood. Astrocytes can arise from 
resident stem cell populations within the adult CNS. Although there are man similarities 
to the developmental process of astrocyte generation, astrocyte differentiation in the 
adult CNS is a less understood potential mechanism of astrocyte proliferation and 
resident astrocytes in the adult brain and spinal cord. I will describe the steps of 
differentiation of astrocytes in adulthood. 
Postnatally, astrocytes can arise from neural stem cell populations in the 
subventricular zone (SVZ) [103, 104, 114, 115]. In response to injury, astrocytes can 
arise from the NSCs in the SVZ [115]. Additionally, injury stimulates an expansion of 
postnatal astrocytes that is not fully understood, but believed to be due to proliferation of 
the astrocytes and not from migration of progenitor cells from the SVZ [103]. This data 
suggests that astrocytes are also able to generate locally. These studies show multiple 
mechanisms to allow for adult generation of astrocytes in the CNS.  
Astrocytes additionally arise from adult stem cell population in the spinal cord and 
the entire ventricular neuroaxis contains multi-potent stem cell population that can 
differentiate into astrocytes, among other CNS cell types [116]. Dissociated spinal cord 
cultures were used and were shown to be able to differentiate into astrocytes, 
additionally discovering an adult stem cell population within the spinal cord [116]. 
Additionally, it was found that both protoplasmic and fibrous astrocytes can arise in the 
adult spinal cord, from distinct intermediate cell types, suggesting a mechanism similar 
to that seen during development [117]. 
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Figure 2-2: Astrocyte differentiation in the adult CNS. Adapted from [50, 51, 114, 116, 117]. 
Briefly, in the adult CNS, glial progenitor cells originate from an adult population of neural stem 
cells. Glial progenitor cells can differentiate into two distinct progenitor cell populations, OPCs or 
immature protoplasmic astrocytes. OPCs are able to differentiate into fibrous astrocytes and 
immature protoplasmic astrocytes can differentiate into protoplasmic astrocytes. 
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Astrocyte functions and CNS Myelin 
 Astrocytes fulfill essential functions that promote proper CNS development and 
maintain CNS homeostasis. Key functions of astrocytes include: ion and water 
homeostasis, energy metabolism, blood flow regulation, release of trophic factors, and 
synaptic signaling [118]. Astrocytes are known to have 3 main functions in maintaining a 
healthy CNS: 1. Synapase regulation 2. BBB maintanence 3. Trophic support for 
myelination. In the following sections, as the focus of my thesis studies, I will 
concentrate on how astrocyte regulation allows for he trophic support of myelination.  
 a. Astrocytes and Myelination 
 The temporal relationship between the development of astrocytes and 
oligodendrocytes point to an import role for astrocytes in myelination [101]. Recent work 
has determined the role of astrocytes in promoting myelination carries into adulthood, 
and astrocytes may be critical determinants of remyelinating potential in the adult CNS	
[119]. Work from our lab has shown that astrocytes promote remyelination in the EAE 
model [46]. In this study, it was determined that the protein tissue inhibitor of 
metalloproteinase (TIMP)-1 is important for remyelination [46]. TIMP-1 is predominately 
produced by astrocytes in the CNS, and thus, these data suggest that TIMP-1 is 
involved in the astrocytic functions necessary for timely and correct myelination 
following injury [46]. In addition, TIMP-1 was shown to be important for developmental 
myelination, which supports the earlier stated notion that through studying 
developmental processes, we may better understand how to restore myelin in diseases 
like MS [46]. Astrocytes secrete a variety of trophic factors that promote myelination and 
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control OL proliferation. Examples of these factors include: PDGF [32], FGF-2 [54], LIF 
[120], CNTF [121], IGF-1 [58], and BMP [3, 52, 122]. OPC cultures grown in TIMP-1KO 
astrocyte conditioned media did not support OL differentiation, suggesting an important 
role of TIMP-1 as an astrocytic secreted factors in promoting myelination [46]. 
 One emerging important aspect of astrocyte biology is the plastic nature of 
astrocytes and determining what controls how astrocytes function. Nash et al found that 
active astrocytes are able to promote myelination, where as quiescent astrocytes do not 
support it, suggesting a fundamental role of astrocytes in supporting myelination, in part 
through secretion of inhibitory and trophic factors onto OLs [123]. They found that the 
activity of astrocytes directly depended on the extracellular matrix (ECM) [123]. 
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Figure 2-3:  Astrocytic functions in the healthy CNS. Astrocytes are known to promote a 
healthy CNS environment through a variety of ways including secretion of trophic factors as well 
as direct cell contact. This diagram depicts some of the major functions of the astrocytes and 
how the astrocytes promote these functions in the healthy CNS.   
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II. Reactive Astrogliosis 
Under normal, healthy, basal conditions, astrocytes are though to be 
homeostatically active, but after injury or inflammation astrocytes undergo major 
phenotypic changes, known as “reactive gliosis” [123]. The mechanisms that control 
astrogliosis are not fully understood, but it is known to be a major hallmark feature 
accompanying a variety of CNS traumas. Specifically, a staple of reactive astrocytes is 
the upregulation of intermediate filament proteins, in particular GFAP, as well as 
vimentin and reexpression of nestin, a marker for early development [124]. Indeed, a 
prominent feature of many neurological diseases and focal injuries is “reactive 
astrogliosis”. Reactive astrogliosis is characterized by a significant change in astrocytic 
phenotype, specifically, changes in their morphology (i.e. hypotrophy) and chronic 
changes gene expression [124, 125]. Reactive astrogliosis is a CNS response to an 
injury or disease that is thought to be a means of “sealing off” the injured tissue and 
restricting inflammation. However, glial scarring can also lead to enhanced neuronal 
death, inhibit axonal regeneration and prevent remyelination [126]. The latter effect of 
astrogliosis is thought to be mediated by the production of several classes of growth-
inhibitory molecules including CSPGs [126].  
 It is now accepted that astrocytes can undergo a spectrum of activation states or 
phenotypes ranging from “quiescent” to active or reactive [123]. This spectrum of 
astrocyte phenotypes is an area of intense research. It has been shown that areas 
farther from the injured site in the CNS, the astrocytes are activated and not reactive. 
Factors known to induce activated phenotype include: transforming growth factor (TGF)-
alpha [127], ciliary neurotrophic factor (CNTF) [128], interleukin (IL)-6 [129], LIF [130], 
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and oncostatin [130, 131]. Active astrocytes become hypertrophic and secrete a variety 
of enzymes, growth factors, trophic factors, and antioxidants [123]. Active astrocytes 
have been shown to support recovery after injury, like promoting remyelination, unlike 
the reactive astrocytes, which inhibit remyelination and axonal regrowth [123].  
A long-term effect of reactive gliosis is the formation of what is called a glial scar. 
Glial scars are most often found around lesions focally, injured site, or foci of infections 
[124]. The glial scar is comprised primarily of astrocytes, but may also contain microglia, 
OPCs, and immune cells [124]. It is thought that the purpose of the glial scar is to 
restrict spread of inflammatory cells and limit damage emanating from a focused area, 
thus protecting the CNS from further immune-mediated injury, as well as encapsulating 
infections and areas of tissue necrosis [123]. However, glial scars may also be 
detrimental to CNS recovery and regeneration. For instance, it is well recognized that 
the environment of the glial scar prevents axonal regeneration following spinal cord 
injury, and reactive astrocytes circumscribe chronic myelin lesions in MS [123, 124].  
Unfortunately, the mechanisms of glial scar formation are not fully understood. 
Recent work provided mechanistic insight to better understand how the of glial scar 
formation is controlled [132]. In this study the response to CNS injury was reported to be 
associated with increased Wnts [132]. Since Wnts regulate β-catenin, Rodriguez et. al 
used a β-catenin conditional knock out to eliminate β-catenin from OPCs, and they 
reported reduced glial scaring in response to a spinal cord injury in the mice [132]. This 
work supports the idea that a glial scar engages many CNS cells types that interacting 
within the injured site to regulate the formation of the scar [132]. Interestingly, OPCs are 
known to be the first cells to infiltrate areas of damage and thought to mold the 
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astrocyte responses [133], therefore, these studies provide further evidence of OPCs 
orchestrating CNS cellular responses in the context of the glial scar.  
Reactive astrocytes undergo profound phenotypic changes associated that are 
associated with changes in gene expression [123, 125]. Using laser capture 
microdissection in mouse brain, has found that TIMP-1 is one of the most upregulated 
genes during reactive astrogliosis; however, the significance of this increased 
expression is not fully understood (Figure 2-4) [125]. The function of TIMP-1 in the 
context of astrocytic function is covered in a later section of this chapter.  
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Figure 2-4. Spectrum of Astrocytic phenotypes. Astrocytes undergo a spectrum of 
phenotypes ranging from quiescent to reactive. In addition, phenotypic different astrocytes 
secrete different factors. Recent work has tried to determine differences in secreted factors 
between quiescent and reactive astrocytes, specifically quiescent astrocytes have been shown 
to secrete CXCL10 and reactive astrocytes have been shown to secrete a variety of factors, 
including TIMP-1. Adapted from [123, 125]. 
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Astrocyte functions in neurodegenerative diseases 
 Not only are astrocytes reactive to acute injury, but dysfunction of astrocytes is 
now recognized as an underlying cause of a variety of CNS disorders. It is thought that 
a better understanding of the how astrocytes develop and function may lead to a better 
understanding of their role(s) in these neurodegenerative conditions. In the following 
sections I will focus on the relationship between astrocytic dysfunction in a variety of 
CNS disorders.  
 Amyloid lateral sclerosis (ALS) is an adult motor neuron disease characterized by 
death of upper and lower motor neurons and gliosis. A mutation in the gene that 
encodes superoxide dismutase 1 (SOD1), an enzyme that converts superoxide into 
oxygen and hydrogen peroxide, is a known cause of ALS in twenty percent of inherited 
cases by causing toxicity in the neural cells [134]. SOD1 mutated astrocytes when co-
cultured with motor neurons have been shown to induce apoptosis of the motor neurons 
[134, 135]. With this mutation, astrocytic functions are impaired, specifically secretion of 
toxic molecules to motor neurons [134, 135]. This suggests that astrocytes play a 
fundamental role in the degeneration of motor neurons in ALS.  
 Alexander’s disease is a disease caused by a mutation in GFAP; it is clinically 
described by macrocephaly, abnormal white matter, and developmental delay [101]. 
The exact mechanism that leads to the dysfunction of astrocytes in unclear, but is due 
in part through aggregation of GFAP in the cytoplasm of the astrocytes, which leads to 
white matter injury, suggesting a potential pathological role on oligodendrocytes and 
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their ability to myelinate [101].  
 MS is an autoimmune disease of the CNS that is characterized by focal areas of 
demyelination. The contribution of astrocytes to demyelination is not fully understood, 
but they are thought to determine whether the MS lesion/plaques are able to 
remyelinate [99]. Astrocytes secrete a variety of factors that may either promote 
myelination; such as, ciliary neurotrophic factor (CNTF) [136, 137], TIMP-1	 [46], BDNF	
[138], and leukemia inhibitory factor (LIF) [99, 122] or they may produce factors that can 
block OPC differentiation such as CXCL10 [123], platelet derived growth factor (PDGF) 
[139], fibroblast growth factor (FGF)-2 [139], LINGO-1	 [140], and fibronectin [119]. 
Dysfunction of the astrocytes leads to differential protein secretion and thus determining 
what factors control astrocyte activation would be expected to help resolve how 
astrocytes contribute to limited remyelination in MS. It has been recognized that reactive 
astrocytes surround the plaque in the MS brain, and astrocytes can exert control on 
OPCS and remyelination. Together these findings suggest an important role of 
astrocytes in the pathology of MS [99].  
 Additionally, astrocytes have recently been shown to play a fundamental role in 
ischemic stroke pathology. The infarct of strokes has shown to not only have severe 
neuronal death but also reactive gliosis; it is now appreciated that the astrocytes have a 
primary role in stroke pathology. First, astrocytes are known to support neuronal 
survival; in response to ischemic stroke, astrocytes can take up oxygen free radicals, a 
major cause of ischemic brain injury [141], and protect neurons from further injury [142].. 
Additionally, reactive astrocytes, particularly after stroke release a variety of cytokines 
tumor necrosis factors (TNFs), interleukins (IL1,6,10), and interferons; these cytokines 
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can be both harmful and supportive in response to ischemic stroke [143]. In addition, 
astrocytes form glial scaring surrounding the infarct that again can be harmful and 
detrimental for recovery, suggesting an important area of research in understanding 
glial scar formation with regards to stroke [144]. Barres group further explored the 
reactive astrocyte in a mouse model of stroke, by occluding the middle cerebral artery 
(MCAO), and using micro laser capture dissection, and determined the most 
upregulated genes in reactive astrocytes using this stroke model as robust model of 
inducing astrogliosis [125]. From their results, TIMP-1 was one of the most upregulated 
genes in response to stroke injury in reactive astrocytes [125]. In chapters 5,6, and 7 of 
this thesis, I will delve further in the subsequent sections into the role of TIMP-1 in 
reactive astrocytes and in particular how TIMP-1 controls astrogliosis and OPC 
maturation. 
III.  TIMP-1 and the CNS  
TIMP-1 is a member of the tissue inhibitors of metalloproteinase (TIMPS), a 
family of four secreted proteins (named TIMP-1 to -4) that range in size from 21-29kDa. 
TIMPs, as their name implies, inhibit matrix metalloproteinases (MMPs), a family of 
extracellular proteases. TIMPs bind MMPs through a non-covalent bond between the N-
terminal domain of the TIMP and the catalytic domain of the MMP in a 1:1 
stoichoiometry, as depicted in Figure 2-5 [145, 146].  TIMPs are 180 amino acids that 
are constructed by two functional domains: an amino-terminal (N) and a carboxy-
terminal (C) domain. Structurally, these two domains are folded into beta-barrels that 
are held together by six disulfide bonds [147]. Although the TIMPs are somewhat 
redundant, they are found to mostly have differing biological functions and have 
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different affinities for the MMPs [148]. The C-terminal domain, which is less well 
characterized, can mediate some protein-protein interactions, for example, TIMP-1 
binds to pro-MMP-9, and TIMPs -2 and -4 bind to pro-MMP-2[146, 147, 149-152]. 
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Table 2-1:  CNS TIMPs and what they inhibit and CNS cell source. Adapted from [153-156] 
TIMP MMPs Inhibited ADAMs inhibited CNS cell source 
-1 -1,-2,-3,-7,-8,-9,-11,-
14,-15,-16,-19-,24 
-10 Astrocytes, Neurons 
-2 -1,-2,-3,-7,-8,-9,-11,-
13,-14,-16,-24 
-12,-17 Neurons 
-3 -1,-2,-3,-7,-8,-9,-13,-
14,-16, 
-10,-12,-17,-19,-28 Neurons 
-4 -1,-2,-3,-7,-8,-9,-14,  
--26 
-17,-28 Dorsal Root Ganglia 
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TIMP-1  
TIMP-1 was first described in 1975 as a small molecular weight serum protein, 
found to inhibit human collagenase activity by fractionating serum and finding the factor 
that blocked collagenase activity; it was later termed TIMP-1 [157]. Interestingly, TIMP-1 
has undergone the least evolutionary changes of all the TIMPs suggesting it may have 
conserved function and importance [148]. From early studies on TIMP-1, it was 
recognized that TIMP-1 may have dual functions as an enzyme inhibitor and a trophic 
factor. However, only recently have these separate functions become well characterized 
in a variety of systems.  
The most studied function of TIMP-1 is its role in regulation of MMP activity. 
TIMP-1 forms a specific complex with proMMP-9, which is believed to actually activate 
MMP-9 [148]. TIMP-1 is known to also interact and inhibit all MMPs except for MT1-
MMP and ADAM-10 [147, 148] As stated, the N-terminal domain of TIMP-1 is crucial for 
its MMP inhibition; through use of NMR, it was found specifically that TIMP-1 interacts 
with the catalytic domain of MMP-3 [148]. Six sections of the TIMP-1 amino acid 
sequence interact with MMP-3; specifically the alpha-amino and carbonyl groups of the 
N-terminal TIMP-1 portion interact with the Zn of MMP-3 to displace a water molecule 
that is important for catalysis [148]. Because of TIMP-1’s ability to block MMPs, TIMPs 
play important roles in tissue remodeling and homeostasis. TIMP-1 has also been 
shown to be important in homeostasis in the CNS, specifically through secretion by 
astrocytes [152]. MMPs are crucial for remodeling the ECM and thus TIMPs are able to 
modulate remodeling and control tissue homeostasis in the CNS microenvironment.  A 
balance between MMPs and TIMPs is crucial for preventing pathogenic conditions in 
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the CNS [152], since dysregulated MMP activities are associated with pathogenesis. 
For instance, TIMP-1’s interaction with MMPs can prevent breakdown of the BBB and 
maintain the integrity of the BBB [152].  
 All of the TIMPs have unique expression within the mammalian system. For 
example, TIMP-1 is high enriched in the reproductive organs, but minimally expressed 
in CNS tissue [147]. During development of the CNS, TIMP-1 was found to be 
expressed within the soma of Bergmann glia in the external granular layer and in 
neurons within the Purkinje cell layer in the developing cerebellum [147]. There is a 
specific pattern of TIMP-1 expression during development; during embryogenesis, 
TIMP-1 levels are very low, increase right before birth in the telencephalic and 
mesencephalic ventricular zones and rapidly declines where it is minimally expressed 
only in the cerebellum, and eventually decrease postnatally [152]. In the healthy adult 
CNS, TIMP-1 is undetectable [147, 158]. Proinflammatory cytokines have been found to 
induce the expression of TIMP-1 in the CNS, namely, IL-1β, tumor necrosis factor-alpha 
(TNF-alpha), IFN-gamma, and IL-6, but in astrocytes, IL-1β signaling is primarily 
responsible for inducing TIMP-1 expression [147]. 
TIMPs 2, 3 and 4 are abundantly expressed in the CNS, while TIMP-1 
expression is undetectable under basal conditions [147, 159]. Interestingly, TIMP-1 is 
dramatically upregulated in a variety of CNS diseases, whereas the other TIMP levels 
often remain constant and unchanged [45]. The rapid and robust induction of TIMP-1 in 
neurological diseases suggests a role for TIMP-1 in neuropathology [45]. Clinical and 
experimental data support a positive correlation between elevated expression of TIMP-1 
in the CNS and remyelination. For example, with acute demyelinating encephalomyelitis 
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(ADEM), a temporary condition with complete remyelination, TIMP-1 expression is 
dramatically elevated[160]; however, TIMP-1 expression is not increased in patients 
with MS, which is marked by minimal remyelination [161]. The levels of the other TIMP 
proteins remain unchanged under diseases conditions, suggesting a selective 
responsive role for TIMP-1 to neuropathology [45].  
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Figure 2-5 : Functional domains of TIMP-1 and interactions with MMP. A. As described, 
TIMP-1 has two function domains: N-terminal domain which mediates MMP inhibition, amino 
acids (1-126) and C-terminal domain which mediates growth factor functions, amino acids (127-
184). B. Structural depiction of TIMP-1 interacting and inhibiting MMP-3 in a 1:1 stoichiometric 
ratio.  Adapted from [147, 162, 163]. 
 
 
 
 
TIMP%1:MMP%3,*1:1*Ra-o*
BACKGROUND 
 
Astrocytes and Remyelination in Multiple Sclerosis (MS). MS is a chronic inflammatory disease of the 
central nervous system (CNS). The cause(s) of MS are unknown. In the majority of MS cases autoreactive T 
cell responses drive clinical relapses and immune-mediated pathology, characterized by demyelinated lesions, 
perivascular inflammation and gliosis1. Current immunomodulatory therapies can manage severity in early 
stages of disease2, however relapses with continued demyelination and limited remyelination represents a 
major impediment to long-term success of treatment. Failure to fully remyelinate white matter lesions is a 
cardinal feature of MS, which contribute to interrupted axon conductance and axon degeneration. These are 
strongly correlated with disease progression and clinical disability in MS3, 4. Oligodendrocyte progenitor cells 
(OPCs) that are arrested in the earlier stages of OL differentiation are present in demyelinated lesions in MS5-7. 
The identification of OPCs in and around myelin lesion in MS reflects a failed regenerative response8. 
Emerging data now indicate that dysregulation of astrocytes may contribute to limited remyelination in MS. 
Strategies to restore astrocytic trophism for OLs provide new therapeutic potential to invigorate endogenous 
remyelination in MS.   
 Astrocytes have become a focus of intensive research in MS for several important reasons. Reactive 
astrogliosis is a prominent pathological feature of demyelinated lesions in MS. Many studies also implicate 
astrocytes as deleterious for CNS remyelination. For instance, astrocytes can form physical barriers to 
progenitor cells and impair remyelination9. Astrocytes are also sources of factors that facilitate autoreactive T 
cell recruitment during EAE10, and astrocytes can promote virus-induced demyelination through production of 
chemokines11. Astrocytes can also produce BMP4, which represses OL differentiation12, 13, and astrocytic 
endothelin-1 impairs OL differentiation and CNS remyelination14, 15. However, astrocytes have also been shown 
to promote homeostasis and CNS repair. For instance, astrocytes are a source of secreted factors that can 
either promote or impair OL differentiation16, including platelet derived growth factor ! (PDGF!) which 
stimulates OPC proliferation 17 and may promote CNS remyelination18. These disparate and often physiological 
antagonists functions of astrocytes on OLs and CNS myelination support astroglial heterogeneity as a potential 
feature of myelin pathology in MS. Moreover, heterogeneity among astrocytes implies that extrinsic factor(s) 
during disease may influence the phenotype and function of astrocytes to either support or impair OL 
differentiation. Identification of factors that promote the beneficial functions of astrocytes toward OLs may 
establish a new mode to foster endogenous remyelination in MS. Herein, we provide data to indicate that 
TIMP-1 is an extracellular signal that promotes astrocytic support for OL differentiation and CNS myelination. 
 Tissue inhibitor of metalloproteinases (TIMP)-1. TIMP-1 is a 28 kDa secreted protein and well 
characterized regulator of matrix metalloproteinase (MMP) activity19. Matrix metalloproteinases (MMPs) are a 
family of extracellular endopeptidases that mediate extracellular matrix (ECM) remodeling. Remodeling of the 
ECM is a fundamental process involved in tissue development, plasticity and regeneration. MMPs are 
regulated in part by TIMPs, a family of four (4) proteins which share largely redundant properties of broadly 
blocking MMP proteolysis by non-covalently binding to the MMP active site in a 1:1 stoichiometric ratio20, 21. 
Tissue homeostasis is thus achieved by a tight balance of MMP proteolysis to TIMP expression. However, an 
imbalance in TIMP:MMP ratios resulting in deregulated MMP activities that have been associated with many 
CNS diseases, including MS22-25.  
 TIMP-1 protein is highly conserved among species and is 
encoded from six exons that can be physically and functionally 
defined as an N-terminal domain [amino acids 1-126; TIMP-1(N)] 
that is sufficient to retain MMP inhibitory function of the full length 
protein26; and a C-terminal domain [amino acids 127-184; TIMP-
1(C)] has recently been shown to mediate protein-protein 
interactions27 (Figure 1). This latter function of TIMP-1 has garnered 
attention as TIMP-1 can elicit biological functions independently of 
MMP inhibition that receptor-mediated signaling28 that has been 
reported to  mediate growth factor-like functions in non-neuronal cell 
types29, 30. The C-terminal domain of TIMP-1 can bind MMPs with low 
affinity: this interaction enhances the overall MMP inhibitory function of the full length protein27. Hence, TIMP-1 
has dual functions as an MMP inhibitor and growth factor19, 31. Herein, we provide data to support a new 
function for TIMP-1 as a regulator of astrocytes to promote OL differentiation and CNS myelination.  
 
Figure 1. Schematic of TIMP-1 depicting the 
functional domains. Number indicate the 
amino acids separating these two domains. 
A. B. 
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Table 2-2: Currently Known Functions of TIMP-1 in the CNS. 
Inhibitory Functions Trophic Function 
MMP activity [155] Tissue Remodeling [164] 
Apoptosis[148, 165] Changes in cell morphology 
Glioma malignancy[148, 166] Glioma malignancy[148, 167] 
Angiogenesis [164] Myelination [46] 
 Astrocyte activity [46] 
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1. TIMP-1 expression in neurodegenerative diseases 
As stated, TIMP-1 levels under basal conditions in the healthy, adult CNS are 
below detectable limits, however, in a variety of CNS diseases, TIMP-1 is dramatically 
upregulated. In the CNS, TIMP-1 is predominately produced by astrocytes [147, 154]. 
TIMP-1 expression in human CNS disorders can be measured in the CSF, but studies 
using post mortem brain tissues have also identified elevated TIMP-1 expression. For 
example, higher levels of TIMP-1 are found in patients with AD, Parkinson’s disease, 
Huntington’s disease, viral meningoencephalitis and ALS [147]. Additionally, reactive 
astrocytes have also been shown to produce increasing amounts of TIMP-1 in response 
to HIV-1 associated dementia (HAD), which is thought to represent an attempt to repair 
and protect the CNS [152]. TIMP-1 has also been found to be induced after seizures, 
which can be produced by neurons and astrocytes [154]. In general, TIMP-1 is 
increased in a variety of neurological disorders and has been proposed as a biomarker 
of CNS injury.  
Of particular interest to our research is the observation that TIMP-1 is not 
increased in select neurodegenerative diseases. In particular, the absence of elevated 
TIMP-1 expression in HIV-encephalomyelitis and MS warrant further discussion for their 
remarkable parallels between human disease and TIMP-KO mouse studies	 [46, 160, 
168].  TIMP-1 levels are not elevated in MS, a neurological disorder with minimal repair. 
Specifically, MMP-9 to TIMP-1 ratio in serum has been studied as a potential marker for 
MS [169]. In MS, there is increased expression of MMP-9 in serum, without subsequent 
expression of its inhibitor, TIMP-1, suggesting a potential pathogenic role linked to the 
lack of TIMP-1. In the mouse model of MS, EAE, TIMP-1 is found to be increased in Wt 
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mice, where it is expressed by astrocytes surrounding demyelinated lesions [155]. This 
was initially thought to represent a protective role for TIMP-1 balancing elevated MMPs 
in this condition [155]. Unlike MS, EAE is associated with significant myelin repair, again 
suggesting a potential role of TIMP-1 for repair. In addition, from work previously done 
in our lab, we have shown that mice lacking TIMP-1 in the EAE model have limited 
remyelination as compared to Wt mice	 [46]. This lead to our hypothesis that TIMP-1 
from astrocytes is important for remyelination, and that understanding astrocyte 
dysfunction and what astrocytes make in response to inflammation and injury is 
important for a variety of CNS disorders, including MS. Chronic inflammation is a 
feature in HIV encephalomyelitis and MS, which is potentially important for the 
regulation of TIMP-1 expression in these diseases [158]. Ghorpade et al have proposed 
multiple mechanisms including loss of mRNA stabilizations and changes in transcription 
factors to explain the loss or absence of TIMP-1 expression with chronic inflammation 
[158]. What is interesting about this idea is that TIMP-1 is known to be induced by injury 
or inflammation, yet, in chronic inflammation TIMP-1 expression is no longer induced. 
The lack of TIMP-1 contributes to a neuropathology through a failure of tissue recovery 
or repair. This lead to the understanding that diseases like MS, where there is chronic 
inflammation could lead to the downregulation of TIMP-1 and thus the inability to repair.  
This data show an importance of TIMP-1 with regards to remyelination and has 
lead to interesting studies in the mechanisms. TIMP-1 has been   studied extensively 
using the mouse model of MS, EAE in both knockout conditions and overexpressing 
conditions. First, work done previously in our lab that TIMP-1 is necessary for 
remyelination to occur in chronic EAE [46]. In chronic EAE, Wt mice are able to fully 
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recover and remyelinate in the lesioned area, where as TIMP-1 KO did not have 
remyenation, suggesting an important role of TIMP-1 in remyelination [46]. This was 
further shown to be a direct effect of TIMP-1 onto the OLs to promote differentiation and 
remyelination [46]. Additionally, over-expressing TIMP-1 by astrocytes ameliorated EAE 
disease course in part through inhibition the migration of lymphocytes into the CNS 
[170].  
We hypothesize that TIMP-1 stimulates OPC differentiation through a receptor-
mediated signal transduction pathway to regulate Wnt/β-catenin signaling. Additionally, 
we propose that study of the trophic functions of TIMP-1 to promote OPC differentiation 
is expected to identify important mechanisms controlling OPC differentiation that could 
be important to foster for remyelination, which will be further described in Chapter 6.  
TIMP-1 as a trophic factor 
TIMP-1 has predominately been studied for its role in regulating the proteolytic 
activity of MMP. Recent work has shown that is has potentially many other non MMP-
inhibitory effects. TIMP-1 was first discovered to have potential growth factor functions 
by Gasson et al. where they found that TIMP-1 was able to stimulate the growth of 
erthyroid progenitors by a mechanism of direct cell binding [171]. They also suggested 
homology between TIMP-1 and a growth factor called Erythoid potentiating activity 
(EPA) [172]. This was the first reported case of trophic factor functions of TIMP-1. Since 
that time multiple groups, including our lab have shown trophic factor functions of TIMP-
1 in a variety of cellular systems, including the CNS.  
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TIMP-1 expression by astrocytes is highly inducible. In the CNS, this 
extracellular protein is produced predominately by astrocytes in response to infection, 
inflammation, or injury [46, 147]. TIMP-1, while being made by astrocytes, is also known 
to activate astrocytes; TIMP-1KO mice exhibited attenuated astrocytic responses, which 
have been associated with differences in astrocytic-mediated support for OL 
differentiation [46, 147]. Previous work using TIMP-1KO mice has shown that TIMP-
1KO mice develop worsened myelin injury when compared to wildtype (wt) in a model of 
inflammatory demyelination [46], conversely transgenic mice that overexpress TIMP-1 
from astrocytes are more resistant to demyelinating injury [170]. Thus, TIMP-1 may be 
an important molecule involved in regulating myelination in the CNS.  
Although previously believed to be working through MMP inhibition, recently we 
have shown that this effect is due, in part, through trophic function. Our experiments 
have determined that the primary action of TIMP-1 as a novel non-MMP mediated 
signaling effect of TIMP-1 to promote oligodendrocyte progenitor cell (OPC) 
differentiation. This work is presented in Chapter 6 of this thesis. 
TIMP-1 receptor and its intracellular signaling pathway 
The identification of a receptor for TIMP-1 has provided renewed interest in the 
non-MMP-related functions of TIMP-1 and a means to explain and study its signaling 
mechanism. Initial work on breast epithelial cells identified a TIMP-1 receptor, a 
tetraspanin protein called CD63 [173]. Specifically, CD63, β1 integrin and TIMP-1 were 
found to form a complex on the membrane of breast epithelial cells[173]. Knocking 
down CD63 reduced TIMP-1 localization to on the cell membrane, suggesting this 
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interaction with TIMP-1 was required for the CD63/ β1 integrin complex to form [173] 
Co-immunoprecipitation of CD63 with TIMP-1 confirmed this interaction [173].  
CD63 is a cell surface tetraspanin that contains four transmembrane α-helices, 
two extracellular loops, and a cytoplasmic tail [173, 174]. Like other tetraspanins, CD63 
interacts with cell adhesion molecules such as integrins, specifically β1-integrins, 
regulating intracellular signal transduction pathways [173, 175]. β1-integrin is a member 
of a larger family of cell surface glycoproteins that mediate the interaction between a 
cell and the extracellular environment [176, 177]. Integrins regulate many cellular 
behaviors, specifically differentiation [176, 177].  Together, the CD63- β1-integrin- 
TIMP-1 complex has been confirmed in several systems	[173, 174, 176, 178].  
Upon TIMP-1 binding to CD63, CD63 is activated and its cofactor, β1 integrin, 
then activates PI3k/Akt signaling. This PI3K/Akt pathway has been shown to be 
important for many functions associated with TIMP-1, such as cell adhesion, motility, 
survival, and proliferation [173, 174, 179, 180]. Several pathways have been implicated 
in being regulated by TIMP-1 including MAPK and cyclic adenosine 3’,5’-
monophosphate (cAMP)-protein kinase a pathway [179]. Akt is phosphorylated by PI3k 
at threonine 308 and serine 473 sites	 [181]. Akt then phosphorylates and inactivates 
glycogen synthase 3β (GSK3β) at serine 9 [182, 183]. GSK3β is a serine/threonine 
kinase that plays an important role in canonical Wnt signaling by phosphorylating β-
catenin, along with the protein axin and another factor called adenomatous polyposis 
coli (APC) [183, 184]. When GSK3β is phosphorylated, β-catenin to target it for 
degradation. When GSK3β is phosphorylated, β-catenin is released and then able to 
translocate into the nucleus where it promotes gene transcription by interacting with 
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LEF-1/TCF factors. This pathway has been implicated in not only astrogliosis but also in 
promoting OL differentiation, suggesting a potential mechanism of trophic TIMP-1 action 
[62, 185-189]. This potential mechanism is the focus of Chapter 6 of this thesis. These 
are the core elements downstream of β1/CD63 that I have been studying in the context 
of TIMP-1 signaling in glial cell. 
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Chapter 3. The Extracellular Matrix and Glial Cells 
I. ECM and the CNS 
 The extracellular matrix (ECM) is a complex network of both structural and trophic 
support for cells and tissues that can modulate the behavior of cells [190]. The ECM 
plays important roles in regulating cell migration, cell division, cell fates, differentiation 
and cell survival[191, 192]. In the CNS, the ECM is defined as any secreted molecules 
that are immobilized outside of a cell [191, 192].  
 The ECM provides a dynamic medium through which cells may interact with other 
cells and respond to changes in the environment. Cell express receptor molecules, such 
as integrins that recognize ECM ligands. All cell types in the CNS express receptors in 
order to facilitate interactions with the ECM. These interactions mediate a multitude of 
cellular behaviors, and can promote production and secretion of a large amount of 
additional ECM molecules [191].  
  In the CNS, the ECM is composed primarily of hyaluronan and chondroitin sulfate 
proteoglycans [193]. For my studies, I focused on some of the more predominately 
expressed ECM molecules that have been implicated in neurological disease states 
including: Laminin (Ln), Tenascin (TnC), Fibronectin (Fn), and Vitronectin (Vn) [194]. In 
the adult CNS, specific ECM molecules are localized to specific regions, which will be 
discussed in the following sections; however, this transition is from profuse and broad 
ECM expression to more localized specific localization not truly understood [192]. In 
addition, under disease conditions the make up of the ECM drastically changes. 
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Laminins 
 Laminins (Lns) are a major component of the basal lamina, which surrounds the 
brain and blood vessels throughout the CNS. Ln is also present in the ventricular zone 
(VZ), and through out the developing neocortex [194]. Ln is present in the ventral 
longitudinal pathway from embryonic days 8-17, suggesting an important role of Ln in 
growth cone development [195]. 
  Lns are composed of 3 separate chains, α (5 variants, ranging from 200 to 
440kDa), β (four variants, ranging from 120 to 200kDa), and γ (3 variants, ranging from 
120 to 200kDa), which allows for a lot of diversity (16 known isoforms) in structure and 
function [196]. Ln α-chain gene is located on chromosome 18, β chain gene location 
can be located on either chromosome 1 or 8, and γ chain gene is located on 
chromosome 1 [197, 198]. Ln 14 and Ln 15 are found in the CNS and produced by 
astrocytes [199, 200]. 
  Ln α5 chain is present in essentially all basal lamina. Null mice for Ln α5 chain die 
during development, and therefore Ln is required for embryogensis [201]. These null 
mice have been found to have many developmental defects including: failure of anterior 
neural tube closure[201].  This phenotype relates to the promotion of NPC migration 
and differentiation by Ln[194]. Lns are important for the development of neural cells and 
in directing them to correct location within the CNS[194].  
 Ln has been shown to also play important roles in OL physiology. Ln is important 
for OL survival, as shown by blocking integrins associated with Ln interactions can 
induce OL cell death [202]. Expression of Ln correlates with the onset of CNS 
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myelination, and Ln expression reappears in MS lesions in areas that remyelinate [192]. 
When the integrin receptors to Ln are blocked (α6 β1), oligodendrocytes don’t 
differentiate properly and do not form proper myelin sheaths [192]. In addition, Ln-
deficient mice have delayed OL differentiation and there is an accumulation of 
undifferentiated OPCs in the adult mouse brain [203]. Previous studies have found that 
Ln promotes the differentiation of OPCs through its activation of the Src family kinase, 
Fyn [203].  
  Ln expression has also been shown to be important for astrocyte biology. Ln 
promotes migration and differentiation of astrocytes, which was shown through deletion 
of chains β2 and γ3 [204]. Interestingly, Ln is also shown to be upregulated and 
secreted by reactive astrocytes in response to injury [205].  
Tenascins 
 Tenascins (Tns) are large multimeric glycoproteins present in the ECM of the brain. 
There are two main Tns in the CNS, TnC and TnR. TnC is expressed in regions of 
active neurogenesis and is upregulated during embryogenesis and wound healing [194, 
206]. TnC is a hexamer that can range from 220-320kDa[207]. The gene that encodes 
TnC is located on chromosome 9q32-34 [208]. In addition, reactive astrocytes 
predominately produce TnC [191, 206]. TnC expression is also regulated spatially and 
temporally, and is only expressed during development and repair [209]. TnC has long 
been shown to be important for the quiescent phenotype of astrocytes and has been 
shown to prevent proliferation [210]. TnC has also been shown to play an important role 
in astrocytic phenotype and myelination [123]. Interestingly, TnC induced a quiescent 
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phenotype in astrocytes, accompanied by a suppression of astrocytic support for 
myelination by regulating the factors that astrocytes were secreting, namely CXCL10 
[123]. TnC has also been shown to have direct effects on OLs as well [211]. TnC was 
shown to inhibit MBP expression in cultured OLs by preventing the activation of the 
tyrosine kinase, Fyn, showing an important role of TnC on OL differentiation [211]. TnC-
defcient mice also had earlier MBP expression, suggesting that TnC in part blocks the 
maturation of OPCs into myelinating OLs [211].  
 Interestingly, TnC null mice have shown no overt developmental phenotype, 
changes in lifespan, or ability to reproduce. This suggests potential redundant 
developmental functions to correct for the loss of TnC with the other TnS [212]. 
However, more recent research done with TnC knockouts has been shown to have 
subtle CNS abnormalities.  A major finding using TnC knockouts has shown that TnC is 
important for the migration of cells, specifically the myelinating cells of the CNS, OPCs 
[213]. Specifically, OPCs migrated earlier to specific areas in the CNS such as the optic 
nerve [213]. Although there is normal myelination seen in these mice, again suggesting 
potential redundant and conserved mechanisms [213]. 
Fibronectin 
 Fibronectin (Fn) is a high molecular weight (HMW) glycoprotein that exists in two 
identical dimer of ~250kDa each that has been shown to be produced by astrocytes, 
hepatocytes, fibroblasts, endothelial cells and macrophages [119, 191, 214]. The gene 
encoding Fn is located on chromosome 2q34, but due to alternative splicing can result 
in up to 20 isoforms [214, 215]. The alternative splicing can occur at 3 sites: EDA, EDB, 
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and IIICS [216]. Fn has two major variants in the body: (1.) Plasma fibronectin, which is 
secreted into the blood as as a dimer by hepatocytes, and (2.) Cellular fibronectin, 
which is made by resident cells and found in tissue [119]. Under normal basal 
conditions, Fn is expressed in the adventitia of parenchymal and leptomenigeal blood 
vessels of the choroid plexus [191, 217]. However, the expression of Fn is transient and 
expressed during development at major migratory pathways, such as the initial 
migration of cells into the external granule layer, suggesting an important role for cell 
migration[218, 219]. Fn has been shown to induce the migration of OPCs to lesion sites, 
but prevents OPCs to differentiate as well as preventing OLs to extend processes and 
branches, thus blocking remyelination [191, 192, 220].  
 Fn has also been shown to being essential for development through use of 
knockout mice, specifically, Fn knockouts are embryonic lethal at day 8.5 and therefore 
essential for development and survival [221]. In Fn knockout mice defects are noted in 
the mesodermally derived tissue, such as head and trunk deficiencies [221]. However, 
many conditional Fn knockouts have been generated in order to study specific roles of 
Fn in development and disease. In an inducible knockout of Fn, (knockout of Fn after 
2months of age), using an ischemic stroke model, it was shown that Fn is essential for 
neuron survival and reduced the infarct size [222]. More recently, conditional deletion of 
Fn from astrocytes have been shown to be essential for the recruitment of OPCs after 
lesion [223]. Using a toxin model of demyelination, lysolecithin, it was found that when 
astrocytic Fn was conditional knocked out, there was less recruitment of OPCs to the 
lesioned area; however, there were no differences in the ability to remyelinate [223]. 
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Figure 3-1. Functional Domains of Fibronectin. Yellow sections represent Type I 
domain, where Fn can interact with Fibrin, and the extracellular matrix.  Blue sections 
represent the Type II domain, where Fn can interact with Collagen. Red sections 
represent the Type III domain where Fn can interact with integrin receptors. Adapted 
from	[119].   
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Vitronectin 
 Vitronectin (Vn) is a multifunctional 75 kDa ECM glycoprotein [224]. The gene that 
encodes Vn is located on chromosome 17q11[225]. Vn plays an important role during 
neurite outgrowth during CNS development. Under normal conditions, there are small 
amounts of Vn expressed, specifically localized to blood vessels [191]. However, there 
is much higher expression of Vn in the developing CNS, specifically from E10-18, that is 
quickly downregulated in the early postnatal period [226]. The specific role of Vn in 
inflammatory conditions such as MS is not known [191]. Vn has been shown to promote 
microglia activation though integrin signaling, specifically αvβ5 [227]. Vn is 
predominately made in the liver, and the source of Vn in the CNS is not known [228].  
 Vn has also been shown to not being essential for normal mouse development 
using Vn knockout mice, and have no overt phenotype including normal survival and 
fertility [229]. Interestingly, Vn has been shown to be important for activation of microglia, 
however, there is no necessity of Vn in order for microglial activation, suggesting 
potential redundancies and conserved processes [230]. 
Integrins 
 Interactions between the extracellular matrix and cells are mediated through 
transmembrane cell surface adhesion receptors known as integrins. Integrins are αβ 
heterodimers consisting of 18 different α subunits and 8 different β subunits to generate 
potentially 24 different heterodimers (Figure 3-2) [231]. Integrins transduce signaling 
from the extracellular matrix to influence cellular behavior including, proliferation, 
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migration, differentiation, and cell death [232]. All cells express integrins, including the 
cells of the central nervous system. Integrins have been shown to be important for man 
physiological functions such as development and repair. 
 Integrins have been shown to be important in the CNS, as well. Specifically, mice 
lacking β1 integrin in the CNS have been shown to have deficits in myelination including 
decreased myelin thickness, however, there were no differences in the amount of OLs 
[233]. Additionally, Barros et al. showed that β1 integrin was essential for promoting Akt 
for efficient myelination, suggesting the importance of integrin signaling with regards to 
correct functions in the CNS [233]. Additionally, αV integrin has been shown to be 
important for the migration, proliferation, and differentiation of OPCs, specifically by 
blocking αV integrins in OPC cultures [234]. In general, integrins have been shown to be 
extremely important in the correct and timely development of the mammalian CNS 
through interactions with their respective extracellular ligands.  
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ECM Molecule CNS cell 
expressed 
Expression in 
Development 
Expression in 
Adult 
Integrin 
Receptors 
Laminin Astrocytes Widely 
expressed 
Basement 
membranes 
α3β1, α6β1, 
αvβ3 
Tenascin C Astrocytes Highly 
expressed in 
areas of active 
neurogenesis 
Undetectable αvβ3, α8β1, 
αvβ6, α9β1, 
αvβ1 
Fibronectin Astrocytes, 
endothelial 
cells, 
macrophages 
In areas of 
migratory 
pathways 
Near blood 
vessels 
α3β1, α4β1, 
α5β1, α8β1, 
αvβ1, αvβ3, 
αIIβ3, αvβ6, 
α4β7,  
Vitronectin Unknown Highly and 
diffusely 
expressed 
Minimally 
expressed near 
blood vessels 
αvβ5, α8β1, 
αIIβ3, αvβ1, 
αvβ3, αvβ8 
 
 
 
 
 
 
Table 3-1: ECM expression changes during development and in the adult CNS. Adapted 
from [1, 2] 
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Figure 3-2. ECM and their Integrin Receptors. Integrin receptor network depicting 
some of the important heterodimeric matchings of the α and β subunits and the 
respective ECM molecules that interact with said integrins. Adapted form [232] 
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II. Proteolytic regulation of the ECM in the CNS 
Degradation of the ECM in the CNS is an important process in development, tissue 
repair, homeostasis, and remodeling that is highly regulated [235]. Among the proteins 
implicated in the breakdown and turnover of the ECM, matrix metalloproteinases 
(MMPS) are the major protease modifiers of ECM degradation [235].  
MMPs are a family of 23 extracellular zinc-dependent proteolytic enzymes that 
predominately degrade and regulate the remodeling of the ECM [227, 235]. MMPs also 
have other physiological functions including: development, plasticity, cellular growth, 
survival, apoptosis, migration and signaling [236]. The structure of MMPs is conserved 
among the whole family: the pro-peptide domain contains a cysteine residue that binds 
Zinc at its active site, which keeps MMPs in the inactive state, a catalytic domain, a 
haemopexin-like domain, which is involved in anchoring to the ECM and is important for 
substrate recognition, and many have a transmembrane domain (Figure 3-3) [237]. 
MMPs can be divided into four subfamilies including: gelatinases, collagenases, 
stromelysins, and membrane type (MT)-MMPs, depending on the their substrate affinity 
[237, 238]. MMPs are secreted as latent or inactive enzymes that require activation 
through cleavage of the pro-peptide domain [237].  
Regulation of MMPs occurs in multiple levels: transcription, activation of 
zymogen, and/or inactivation by specific inhibitors [239]. Specifically, for my thesis 
studies, I focused on the regulation of MMPs through their inhibitors tissue inhibitors of 
metalloproteinases (TIMPs). TIMPs inhibit MMP activity by binding to the catalytic site of 
MMPs, as discussed in Chapter 2.  
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Figure 3-3: General structure of MMPs. Adapted from [240]. The general structure remains 
consistent amongst the various MMPs including the pro-peptide domain that contains a cysteine 
residue that binds zinc in the active site; catalytic domain; haemopexin-like domain, which is 
involved in anchoring to the ECM and is important for substrate recognition; transmembrane 
domain. 
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MMPs, CNS Development, and Myelin  
MMPs play crucial and beneficial roles in the development of the CNS [241, 242]. 
MMP protein production during development is believed to facilitate the migration of 
cells through a more dynamic and fluid environment. For instance, MMP-9 null mice 
have been shown to accumulate granule cells in the external granule cell layer as a 
result of inappropriate cell migration [239]. Also, MMPs have been shown to facilitate 
axon migration during development, by producing a dynamic and fluid ECM [239, 243, 
244]. MMP inhibitors that showed reduced neurite outgrowth, where MMP-3 specifically 
has been shown to be important for the migration of cells through the basement 
membrane [239, 243, 244].  
 MMP-9 has been found to be elevated during development in areas specific for 
myelination including the corpus callosum [245]. MMPs -9 and -12 also play an 
important role in myelination and OL extension; null mice for these MMPs were found to 
have reduced myelination and less mature OLs in the corpus callosum [239, 246]. 
Interestingly, MMP-9 was also shown to be essential for the process of remyelination. 
MMP-9 KO mice, treated with lysolecithin were shown to have deficits in remyelination 
due to a build up of NG2 proteglycan, suggesting an important role for MMP activity in 
remyelination [247]. Specifically, OLs express MMP-12 during development and 
differentiation and is necessary for OL process extension and myelination [248]. In 
MMP-12 KO mice, OPCs had delayed differentiation and differences in morphology as 
compared to wildtype [248]. In summary, MMP-9 and MMP-12 have been shown to be 
important for OLs and myelination, however, in directly though regulation of the ECM.  
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MMPs and the adult CNS 
Some studies have investigated the presence of MMPs in the adult CNS with the 
belief that MMPs are important for ECM turnover, myelin turnover, and decreased 
angiogenesis in the adult CNS [249]. Studies have found that astrocytes, microglia, and 
neurons produce MMP-2 and -9, while microglia produce MMP-7 [249]. Additionally, 
using real-time polymerase chain reaction, MMP-2, -11, and 14 mRNA has been found 
to be highly and constitutively expressed in all regions of the CNS, however, the 
function of these well characterized enzymes in the CNS remains elusive [155]. Also, 
MMPs have been shown to be important for synaptic plasticity, specifically in the 
hippocampus, where it has been shown the MMP-3 and -9 are contribute to long-term 
potentiation (LTP), the electrical manifestation of memory [250]. In MMP-9 KO 
hippocampal slices, LTP is impaired, but can be restored with the application of 
recombinant MMP-9 to the slice preparation [251].  
MMPs have also been shown to be important under diseased conditions within the 
CNS. In the adult CNS abundant and incorrect expression of MMPs can be harmful and 
may result in tissue damage, suggesting a potentially pathogenic contribution of MMPs, 
in diseases such as MS, which will be addressed further in the following section [236]. 
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Table 3-2: Important MMPs in CNS, cell source, and substrates they degrade. Adapted 
from [241].  
MMP Type of MMP Substrate Degraded CNS Cell source 
MMP-1 Collagenase Collagens I, II, III, VII, 
VIII, X, XI, gelatin, 
tenascin, 
aggrecan,fibronectin, 
vitronectin 
Astrocytes, monocytes, 
macrophages, microglia 
MMP-2 Gelatinase A CollagenI, III, IV, V, VII, 
X, gelatin, fibronectin, 
laminin, aggrecan, 
elastin, vitronectin, 
tenascin 
Astrocytes, monocytes, 
macrophages, 
microglia, endothelial 
cells 
MMP-3 Stromelysin Collagen II, III, IV, IX, X, 
proteoglycans, 
fibronectin, laminin, 
elastin, vitronectin, 
tenascin 
Astrocytes, monocytes, 
macrophages, 
microglia, endothelial 
cells 
MMP-7 Matrilysin Casein, gelatins I, II, IV, 
V, fibronectin, 
proteoglycans, Collagen 
IV, aggrecan, elastin, 
vitronectin tenascin, 
laminin 
Microglia, monocytes, 
macrophages 
MMP-9 Gelatinase B  Collagens IV, V, XI, XIV, 
elastin, aggrecan, 
laminin, casein 
Astrocytes, monocytes, 
macrophages, 
microglia, endothelial 
cells, neurons, 
neutrophils, 
CCR2+CCR5+ T cells 
MMP-12 Metalloelastase Elastin, collage IV, 
gelatin, fibronectin, 
vitronectin, laminin, 
aggracan 
Macrophages, 
microglia, astrocytes 
MMP-14 MT-MMP Pro-MMP-2, Collage I, 
II, II, gelatin, fibronectin, 
vitronectin, laminin, 
aggrecan 
Monocytes 
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 III. ECM and CNS myelin 
The ECM in the MS lesion varies between the type/stage of lesion as well as 
from the normal appearing white matter or the healthy brain. There are significant 
changes in the ECM makeup in the MS brain when compared to the healthy brain [252]. 
The role of MMPs in demyelinating diseases are many, but 3 have been described for 
MS: (1.) Breakdown of the BBB, (2.) Facilitating extravasation of brain parenchyma by 
immune cells, and (3.) direct proteolysis of myelin proteins [238]. 
Expression of MMPs is altered in response to a demyelinating injury. For 
instance, in MS, MMP-9 and -7 have been shown to be elevated in cerebral spinal fluid 
(CSF) and serum in patients with MS [238, 241]. In particular, patients with higher levels 
of MMP-9 in their serum were found to have higher expanded disability status scale 
(EDSS) scores [253], which is a measure of increasing disability used to described MS 
patients that ranges from 1 (no disability) to 10 (death due to MS). Also, increased 
MMP-9 levels in serum was also shown to have a higher number of MRI Gd-TD active 
lesions [169]. Additionally, MMP-3 has been shown to correlate with disease activity, 
and is increased in serum during relapses in patients with RRMS [254].  
In EAE MMP-2, -3,-8, -9, -10, -11, -12, -13, -14, and -25 were found to be 
elevated [238, 242].  Additionally, MMP-2, -7, and -9 have also been shown to be 
expressed in macrophages/microglia and lymphoctyes around perivascular cuffs [242]. 
It is believed that MMPs may promote migration of leukocytes into the CNS, 
exacerbating the disease [241]. Interestingly, treatment with MMP inhibitors has been 
shown to ameliorate the clinical course of EAE in mice and limits immune cell infiltration 
into the CNS in EAE [255]. Studies on MMP-9 null mice have shown that these 
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knockout mice do not develop EAE [256]. In contrast, MMP-12 null mice have a 
worsened disease phenotype in EAE, suggesting a potentially important role for repair 
[241, 242, 257].  
MMP-2 is upregulated in a variety of diseases, specifically ones related to 
inflammation and immunity, however, the precise role of MMP-2 in MS is not fully 
understood [241]. MMP-2 is predominately made by monocytes, but has also been 
shown to be made by astrocytes, microglia, and macrophages, and is believed to 
promote immune cell migration into the CNS through disruption of the BBB [241, 258]. 
Additionally, there is conflicting data on the role of MMP-2 with regards to MS, some 
groups have found it is upregulated in serum, others have found the opposite [258].  
MMP-3 is an activator of other MMPs including MMP-1, -7, and -9 [241]. MMP-3 
is also upregulated in MS, and corresponds with disease activity in RRMS, possibly 
contributing to further BBB breakdown [241]. The precise role of MMP-3 is MS is not 
fully appreciated, but is believed to promote remyelination. Studies using the cuprizone 
model of MS have shown that during remyelination in the corpus callosum, MMP-3 was 
highly expressed in astrocytes suggesting a potential benefit of MMP-3, specifically 
through removing myelin debris to promote remyelination [236, 241]. Additionally, MMP-
3 in a known activator of microglia and plays an important role in the pathology of a 
variety of neurodegenerative diseases [259]. 
MMP-9 is secreted by astrocytes, endothelial cells macrophages/microglia, and 
circulating immune cells in the CNS [260]. MMP-9 is believed to influence the integrity of 
the BBB and promote infiltration of immune cells in to the CNS [241, 261]. Patients 
treated with IFN-β were shown to have reduced amounts of MMP-9 in serum samples 
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that correspond with stabilization of the disease [262].  MMP-9 is involved in a variety of 
inflammatory processes, specifically MS where there is increased expression of MMP-9 
in serum and CSF [169, 241, 253].  
MMP-12 is widely expressed in various stages of MS lesions by macrophages, 
but most intensely in the active demyelinating lesions [263]. However, most studies 
regarding MMP-12 are involving mouse models of MS. Specifically, in Theiler’s virus 
model, MMP-12 is the highest transcriptional upregulated gene, and MMP-12 KO mice 
had reduced demyelination and infiltration of immune cells in response to Theiler’s virus 
infection, a viral model of CNS demyelination, suggesting a pathogenic role of MMP-12 
by harming OLs [264]. However, MMP-12 has also been shown to be important for 
myelin formation and OL differentiation, as described previously during CNS 
development. These studies show the complex role of MMP-12 may be context 
dependent with respect to studying demyelination and interpreting its possible role(s) in 
MS.  
Inhibitory ECM environments may play a crucial role in determining remyelination 
and thus functional improvement. The plaques are the area of much interest, especially 
in promoting remyelination. There are four main types of lesions or plaques: reactive, 
active demyelinating lesions, chronic active and chronic inactive lesions [265]. A lot of 
interest and research has been focused on the differences between the types of lesions 
as well as the extracellular environment of said lesions. 
ECM expression in lesions, as described in Table 3-3, is a well-studied and 
interesting area of research. In the active plaques, there is little expression of TnC, 
however, there is a significant increase in Vn expression, compared to healthy tissue, 
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near blood vessel walls, the border of the lesion and by demyelinated axons and 
reactive astrocytes [191, 228, 266]. Fn accumulation in the form of HMW aggregates 
have also been detected in active lesions and shown to play an important role in 
regulating OLs (see above) [119, 191, 228, 267]. In chronic inactive lesions, there is 
similar expression of TnC that is seen in the normal healthy CNS [191, 238, 266]. Vn 
levels are also undetectable in the chronic plaques [228, 267]. Ln is upregulated in all 
active areas of demyelination [268]. Chapter 4 focuses on my thesis work with regards 
to the role of the ECM, in particular the ECM changes seen in MS, in regulating 
astrocytic behavior.  
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Table 3-3: ECM changes in MS lesion types. Adapted from [191, 228, 266, 267, 269] 
 
ECM Reactive 
Lesion 
Expression 
Active 
demyelinating 
lesion 
expression 
Chronic active 
lesion 
expression 
Inactive lesion 
expression 
Laminin Upregulated Upregulated Upregulated Similar to 
NAWM 
Tenascin C Downregulated Downregulated Downregulated Similar to 
NAWM 
Fibronectin Upregulated Upregulated Upregulated Similar to 
NAWM 
Vitronecin  Upregulated Upregulated Undetectable Undetectable 
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Abstract 
Astrocytes perform critical homeostatic physiological functions in the central nervous 
system (CNS) and are robustly responsive to injury, inflammation, or infection. We 
hypothesized that the components of the extracellular matrix (ECM), which are known to 
vary during development and in response to disease, determine astrocytic responses to 
injury and inflammation. We examined the response of primary astrocyte cultures grown 
on different ECM proteins to a mechanical wound (i.e. scratch). ECM substrates 
selected were laminin (Ln), vitronectin (Vn), fibronectin (Fn) or Tenascin C (TnC). We 
found that regrowth of the scratch wound was ECM dependent: recovery was arrested 
on fibronectin (Fn), almost complete on either Vn, Ln, or TnC. To determine whether 
ECM responses were also influenced by inflammation, we treated ECM plated cultures 
with interleukin-1β (IL-1β). We found that IL-1β arrested astrocyte growth on Ln, 
accelerated astrocyte growth on Fn and had no significant effect on astrocyte growth on 
TnC or Vn. We also determined that blocking β1integrins, the major class of receptors 
for all ECM proteins tested, prevented the robust response of astrocytes exposed to 
TnC, Ln and Vn, and also inhibited the robust effect of IL-1β to stimulate astrocyte 
growth on Fn. In addition, we evaluated downstream targets of integrin signaling, 
specifically the mammalian target of rapamycin (mTOR), and determined that activation 
of this pathway contributed to the response of astrocytes grown on TnC, but not on Ln, 
Vn or Fn. These findings provide new insights into the role of ECM as a source of 
heterogeneity of glial responses that may have important implications for 
neuropathological sequelae.  
 
Keywords: Astrocyte, Extracellular Matrix (ECM), Integrins, mTOR 
Abbreviations: ECM, extracellular matrix; Ln, Laminin; Vn, Vitronectin; Fn, Fibronectin; 
TnC, Tenascin C; IL-1β. Interleukin-1β; mTOR, mamalliam target of rapamycin. 
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1. Introduction 
 The extracellular microenvironment provides fundamental cues that guide cellular 
responses. The protein composition of the extracellular matrix (ECM) exhibits regional 
variation and dynamic changes related to age, injury or disease [270]. These changes in 
the ECM play an important role in molding central nervous system (CNS) development 
and influence cellular responses within the adult CNS [271]. For instance, tenascin C 
(TnC) is a secreted ECM glycoprotein that is expressed prominently during 
development and down-regulated in the mature CNS. However, TnC levels are up-
regulated during neuroinflammation, specifically in response to pro-inflammatory 
cytokines [272]. Laminins (Ln) and fibronectins (Fn) are highly expressed during 
regeneration and have been shown to promote regeneration [41]. Specific changes in 
ECM protein expression, such as the accumulation of Fn or TnC in demyelinated 
plaques in multiple sclerosis, have also been shown to impede remyelination in this 
disease [119, 266]. Similarly, up-regulation of TnC in plaques of Alzheimer’s mouse 
brain has lead to a suggested role of TnC as an integral part of the inflammatory 
pathology in this disease [273]. Studies on how ECM influences the function of cells 
within the CNS have revealed a prominent role for ECM regulation of astrocytic 
functions [123, 274].  
Astrocytes are the most abundant cell type in the CNS and provide homeostatic 
and sentinel functions when they become activated in response to CNS injury, 
inflammation or disease [123]. Astrocytes have a spectrum of resting and activation 
states that are influenced by the extracellular environment [123]. This extracellular 
influence on the activation of astrocytes likely underlies whether astrocytes contribute to 
CNS pathology or promote CNS recovery [275].ECM molecules activate intracellular 
signaling cascades through interactions with transmembrane protein receptors called 
integrins. Integrins are members of a family of glycoproteins that regulate many cellular 
behaviors, including proliferation and differentiation [177]. Integrin α and β subunits form 
heterodimers that endows a range receptor diversity and specificity for ECM proteins. 
Study on how different ECM molecules influence the behavior of astrocytes is expected 
to enable a better understanding on the role(s) of astrocytes in pathological settings. 
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 Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and 
mTOR signaling has been implicated in regulation of cell growth, proliferation, motility, 
survival, as well as promoting protein synthesis, and transcriptional activation [276-278]. 
mTOR has two distinct complexes, mTORC1 and mTORC2, that regulate distinct signal 
transduction pathways. In the CNS, mTOR has been shown to enhance protein 
synthesis and promote neural cell differentiation, therefore, promoting an importance of 
mTOR signaling in the health CNS. Rapamycin is an inhibitor of mTOR activation, 
specifically mTORC1, and has been shown to attenuate glial cell activation [279]. 
Integrin signaling has been reported to engage a variety of downstream targets in the 
mTOR pathway. Given that astrocytes can exhibit disparate reactions to specific ECM 
proteins [280], we reasoned that activation of mTOR signaling may be one mechanism 
underlying these differences  
 In this study, we hypothesized that the ECM substrate would impact the 
response of astrocytes to a mechanical injury and an inflammatory stimulus. For these 
experiments we used the canonical pro-inflammatory cytokine, interleukin-1β (IL-1β) 
because it is known to activate astrocytes and is prominently produced in a variety of 
neural injury settings [281]. We report that astrocytic behavior was dramatically 
influenced by the ECM protein substrate and that this determined the activation and 
contribution of mTOR signaling to these astrocytic responses. Together, these finding 
provide new information on the regulation of astrocytes that may serve to define the 
extracellular cues that contribute to astrocytic heterogeneity in responses to CNS injury 
and inflammation.  
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2. Material and Methods: 
2.1 Primary Glial Cultures. Cultures were generated from cerebral cortices of neonatal 
C57BL/6 mouse pups (P0-P3), using a neural tissue dissociation kit (Miltenyi Biotec) 
[282]. Cells were plated into T175 flasks for up to 2 weeks before detachment using 
trypsin (Sigma) and then re-plated onto coverglass coated with Ln (10μg/μL; Sigma 
Aldrich), TnC, (100μg/μL; EMD Millipore), Fn (10μg/μL; Sigma Aldrich), or Vn (25μg/μL; 
Sigma Aldrich) in 24-well plates. .The purity of each culture system was consistent with 
previous reports of 90-97% GFAP+ cells [46], as verified by immunocytochemistry (ICC) 
for GFAP for astrocytes (1:1000, Chemicon), and, Iba-1  for microglia (1:1000, WAKO). 
 
2.2 Scratch Injury model. Confluent astrocyte monolayers were scratched once across 
the diameter of the coverglass using a sterile P200 pipette tip to produce an injury 
~600μm in diameter [283]. Cells were fixed at different time points and ICC performed.  
IL-1β (10 ng/ml; Peprotech) was added to the cultures as a prototypic inflammatory 
stimulus, as previously described [284]. The role of β1integrin was tested using a 
function blocking antisera (Ha2/5; 5μg/mL) and compared with control, isotype-matched, 
IgG (both from BD Pharmigen). Effects of mTOR were assessed using rapamycin (5 µg; 
Santa Cruz Biotech) dissolved in DMSO (10 nM, Sigma). Scratch injuries were 
measured perpendicular to the longitudinal axis of the scratch at a minimum of three 
points spanning from the edges of the scratch using image analysis software (Northern 
Eclipse software; Empix Imaging). Western blotting was performed on cultures grown in 
6 well plates coated with Ln, TnC, Fn, or Vn, and scratched 4 times per well using a 
sterile P200 pipette tip as described above. 
 
2.3 Immunocytochemistry (ICC). ICC was performed as previously described [46]. 
Cultures were fixed in 4% paraformaldehyde, washed and then incubated with primary 
fluorescent conjugated antisera for Glial Fibrillary Acidic Protein (GFAP-Cy3; 1:1000, 
Sigma). 4',6-diamidino-2-phenylindole (DAPI) was added after incubation to identify 
nuclei. Immunoreactivity was visualized using a fluorescent microscope (Olympus, 
IX71) and image analysis software (Empix Imaging). 
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2.4 Western Blot Analysis. Lysates from primary cultures grown on Ln, TnC, Fn, or Vn 
were prepared as previously described [46]. Cells were scraped into PBS, after 0, 4, or 
24hrs after treatment, centrifuged (6000xg), the pellet was resuspended in RIPA buffer 
[Triton X-100, NaCl, Tris-HCl base, Deoxycholic Acid, SDS, H2O] and mechanically 
dissociated using a motorized pellet pestle (Fisher Scientific). Each sample was 
prepared with 2x loading buffer [Tris-HCl, Glycerol, SDS, H2O, BPB, DTT] and 15μg of 
total protein was loaded into a graduated 5-15% acrylamide gel (Biorad). After PAGE, 
protein was transferred onto PVDF membrane (Thermo Scientific). Blots were blocked 
and then incubated overnight in primary antisera. Primary antisera included pAktS473 
(1:1000, Cell Signaling), panAkt (1:1000, Cell Signaling) S6KpThr389 (1:1000, Cell 
Signaling), p70S6Kinase (1:1000, Cell Signaling), and β-actin (1:2000, Sigma). 
Secondary antisera were HRP-conjugated anti-mouse (1:10,000, Vector Labs), or HRP-
conjugated anti-rabbit (1:10,000, Vector Labs) for detection using ECL reagent (GE 
Biosciences). Exposed films were developed and quantified relative to β-actin loading 
for each sample [46].  
 
2.5 Statistics: 
Experiments were performed in quadruplicate replicates and repeated in triplicate. 
Comparisons between treatments on the same substrate were made using t-tests, or 
one-way ANOVA to evaluate changes over time. Inter-group comparisons for 
differences on each ECM over time, or treatment were made two-way ANOVA. Data are 
presented as mean±SEM. The null hypothesis for all experiments was P<0.05.  
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3. Results 
3.1 Astrocyte response to scratch is ECM dependent 
 We hypothesized that the composition of the ECM may influence the behavior of 
astrocytes and their ability to recover from a scratch injury. This idea was based on 
previous studies that have demonstrated the utility of the scratch assay to explore the 
behavior of astrocytes [206, 284], and additional studies that explored the impact of 
ECM on astrocyte phenotype [123]. We examined the response of astrocyte cultures to 
a scratch injury by assessing rate and extent of recovery. Primary murine glial cultures 
were grown on cover-slips that had been coated with one of the following ECM proteins 
(Ln, TnC, Vn, or Fn), grown to confluence, scratched and then recovery assessed 4 or 
24 hours later. Over the 24 hours incubation, astrocytes grown on Ln, TnC or Vn 
exhibited significant recovery (Figure 1). In contrast, astrocytes grown on Fn exhibited 
only minimal wound closure that was significantly less than all other ECM substrates 
tested (P<0.0001; Figure 1B).  
 
3.2 Astrocyte response to IL-1β is ECM dependent 
 Previous work suggests that exposure to IL-1β impairs the response of human 
astrocytes to wound recovery [284]. To determine whether the ECM composition 
influenced the effect of IL-1β, we treated cultures with IL-1β and assessed recovery on 
the different substrates. Consistent with previous work, treatment with IL-1β arrested the 
recovery of astrocytes grown on Ln (P>0.05 vs. 0 hr), which differed significantly from 
the robust recovery seen on Ln under control conditions (P<0.001 vs. 24 hr control; 
Figure 1). When treated with IL-1β, astrocytes grown on Vn. exhibited a trend of 
reduced recovery but the magnitude of this effect was not statistically significant 
(P<0.07 vs. 24hr control; P<0.5 vs. 0hr control). In contrast, cultures grown on TnC, 
maintained their strong response in the presence of IL-1β. Most interestingly, astrocytes 
on Fn exhibited a minimal growth response under control conditions, but IL-1β treatment, 
induced a robust and significant recovery response (P<0.001 vs. Cntl 24 hr.). 
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3.3 ECM-specific β1integrin-mediated astrocyte responses   
 To identify potential mediators of the astrocyte responses to ECM substrates, we 
first examined β1integrins as the principal class of ECM receptors. To evaluate the 
contribution of β1integrin to astrocyte wound healing responses, we used a function-
blocking antibody, Ha2/5. Astrocytes grown on TnC, Ln, or Vn exhibited an impaired 
scratch repair response when β1integrin was blocked, compared to IgM control-treated 
cultures on the same substrates (P<0.001, TnC; P<0.005, Ln; P<0.04, Vn) (Figure 2A). 
The contribution of β1integrin to astrocyte responses to Fn were difficult to assess as 
astrocytes grown on Fn exhibited only a minimal wound repair response that was not 
altered by treatment with Ha2/5 (Figure 2A). However, when astrocytes grown on Fn 
were treated with IL-1β, which evoked a robust recovery, this IL-1β effect was 
completely blocked by Ha2/5 (P<0.0001 vs. control antibody; Figure 2B). In addition, 
Ha2/5 also inhibited astrocyte growth on TnC in the presence of IL-1β, (P<0.007; Figure 
2B).  
 
3.4 ECM selective activation of mTOR signaling 
We next examined how the ECM affects putative downstream signaling of 
integrin receptors, specifically mTOR as an effector of cellular responses [177, 276]. To 
determine whether mTOR activity contributed to the astrocytic wound response on 
different ECM substrates, we assayed astrocyte cultures by western blotting for 
differential activation of mTOR, specifically, phosphorylation of S6 kinase (S6k; Thr389), 
which is preferentially activated by mTORC1, and phosphorylation of PKB (Akt; 
Ser473), which is preferentially activated by mTORC2 [181].  
Analysis of S6k activation in astrocytes grown on each different ECM substrate 
revealed a differential in response to scratch or IL-1β that depended on the substrate 
(Figure 3, A-D). Astrocytes grown on TnC revealed significant mTORC1 activation, in 
contrast, astrocytes grown on Ln, Vn, or Fn exhibited no significant change. 
Interestingly, the pattern of S6k activation was affected by IL-1β treatment in astrocytes 
grown on TnC (P<0.006; 4hr IL-1β vs. 4 hr control). We also found that S6k activation in 
astrocytes grown on Ln, Vn or Fn was not significantly modified by IL-1β treatment. 
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There were no significant differences in levels of S6kinase in response to scratch on 
any substrate tested (Figure 3A-D). 
We then examined whether the activity of mTORC2 was also differentially 
regulated by ECM substrate, scratch injury, and inflammatory stimulation, using 
phosphorylation of Akt (ser473) [276] (Figure 3, E-H) . Astrocytes grown on TnC 
showed significant Akt activation over time after the scratch (P<0.02), but this effect was 
absent following treatment with IL-1β. Akt was also activated in astrocytes grown on Ln 
after scratch (P=0.02); however, IL-1β did not modify Akt activation. Astrocytes grown 
on Vn or Fn also exhibited robust Akt activation in response to scratch injury (Vn, 
P<0.04; Fn, P=0.005), and IL-1β did not significantly modify this activation. We also 
looked at overall Akt levels, and saw no significant difference. There were no significant 
differences in overall Akt expression in response to scratch on any substrate tested 
(pan-Akt;, Figure 3,E-H). 
 
3.5 ECM specific effects of rapamycin on astrocyte scratch wound response  
To determine whether these changes in mTOR activation on different ECM 
substrates functionally contributed to the differential wound responses we observed, we 
next examined how the ECM affects mTOR as an effector of cellular responses [177, 
276]. mTOR has two different complexes: mTORC1, which is inhibited by rapamycin; 
and mTORC2, which is not inhibited by rapamycin [276]. To determine whether mTOR 
activity contributed to the astrocytic wound response on ECM substrates, we treated 
cultures grown on different ECM substrates with rapamycin. Analysis of scratch wound 
recovery revealed that rapamycin blocked the response of astrocytes grown on TnC 
(P<0.05) but had no effect on astrocytes grown on Vn, Fn or Ln (Figure 4).  
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4. Discussion  
 In this study, we established the following hierarchical relationship towards 
improved wound regrowth on ECM substrates: TnC>Vn>Ln>Fn. Previous work has 
shown that the pro-inflammatory cytokine, IL-1β, can inhibit the proliferative and 
migratory responses of astrocytes in an in vitro scratch wound assay [284]. We also 
determined that the response of astrocytes to IL-1β was context dependent: wound-
healing responses varied with the ECM substrate and ECM also impacted the response 
to IL-1β. Stimulation by IL-1b, also altered the following hierarchical relationship of ECM 
on wound regrowth: Fn>TnC>Ln>Vn. We also discovered that IL-1β arrested the 
astrocyte wound healing response on Ln, but markedly promoted the response on Fn. 
These findings complement previous observations [284, 285] on ECM effects on 
astrocyte responses to other cytokines, including TNF [280]. Together, these data point 
to ECM as factors influencing the heterogeneity of astrocyte responses.  
 As integrins are the major class of ECM receptors, we next examined the role of 
β1integrins in mediating ECM dependent effects of astrocytes [41]. Interestingly, 
β1integrin blockade inhibited the recovery of astrocytes grown on Ln, TnC, and Vn 
suggesting an important role in astrocyte responses on these substrates. In addition, 
β1integrin blockade also inhibited the recovery of astrocyte grown on Fn when 
stimulated with IL-1β. 
 mTOR signaling has been implicated in a variety of important pathways, 
including autophagy, cell proliferation, cell survival, and cytokine production by 
astrocytes [41]. We found that mTOR played an important part in the ECM specific 
effects as evidenced by western blot analyses and the scratch injury response of 
astrocytes grown on TnC to rapamycin. These data suggest mTORC1 signaling 
pathway mediated the enhanced activity of astrocytes grown on TnC; but had little effect 
on astrocytes grown on Ln, Vn, or Fn, suggesting signaling through mTORC2, the 
rapamycin-independent complex. These results indicate that the failure of rapamycin to 
affect astrocytes grown on Ln or Vn may have been due to a specific bias toward 
mTORC2 signaling. While all substrates had significant activation of pAKTs473. This 
differential signaling resulting from the ECM suggests important differences in regulation 
of astrocytic responsiveness. Astrocytes grown on TnC, but not Vn, Ln, or Fn exhibited 
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significant S6k activation over time, suggesting ECM-dependent differential regulation of 
mTORC1 signaling. Our data indicate a propensity of reactive astrocytes to respond to 
specific inflammatory signals that is directly regulated by the ECM. Future studies 
exploring the potential hierarchy among these ECM substrates may further define how 
ECM regulated heterogeneity impacts astrocyte function and reactivity and the 
production of factors that contributes to neuroinflammation and pathology [286, 287]. 
We propose that the disparate reactions of astrocytes on different ECM 
substrates, reveals important new information about the roles of astrocytes in the CNS. 
In this study, we chose the ECM substrates on account of their highly dynamic 
expression levels during neurological diseases. For instance, the ECM composition in 
and around demyelinated lesions in multiple sclerosis (MS) varies with the stage of the 
lesion [119]: where TnC is down-regulated in active lesions; Ln, Fn and Vn are up-
regulated in active lesions [266]. These ECM components have been reported to impair 
oligodendrocyte progenitor differentiation, and thus are considered impediments to 
remyelination in MS [288]. However, the presence of reactive astrocytes in all myelin 
lesions in MS suggests that differences in ECM content would also impact the role of 
astrocytes in these settings. Future studies addressing this issue may reveal how ECM 
regulates astrocyte functions to impact other neural cell types, including 
oligodendrocytes [46, 123] microglia or neurons [289], and expand our growing 
understanding of astrocytes as active participants in neuropathology [123]  
 
5. Conclusions  
These findings complement the growing awareness that astrocyte diversity may be 
strongly influenced by external stimuli, including the ECM. They also provide a new 
perspective on the roles of the microenvironment as a significant factor influencing the 
diversity of astrocyte functions in CNS physiology and neuropathology. 
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8. Figures 
 
Figure 4-1. Astrocytic Response to Scratch Response and IL-1β is determined by ECM 
substrate. (A) Mixed glial cultures grown on cover-slips were coated with Ln, TnC, Vn, or Fn 
and then scratched. Scratch widths were measured after initial scratch, 4 hours, and 24 hours. 
Pictures of immunocytostaining are depicted after the initial scratch and 24 hours with or without 
IL1β by staining for the astrocytic marker, GFAP and DAPI. (B) The wound recovery was 
quantified to compare astrocyte wound recovery on different ECM substrates with and without 
the addition of IL-1β. Data are presented as box-and-whisker plots depicting the treatment 
median value and the interquartile range of outcomes for each treatment combination, 
representing n=4/treatment repeated in triplicate. (**, P < 0.01; ****, P < 0.0001). 
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Figure 4-2. Inhibition of Astrocyte Scratch Response to ECM substrates by β1 integrin 
blockade.  (A) Quantification of 24 hour wound recovery of mixed glial cultures were grow on 
cover-slips coated with Ln, TnC, Vn, or Fn and stimulated with a mechanical scratch with either 
with â1 integrin blocking antibody Ha2/5 or control IgM. Analysis of variance was used to 
determine whether Ha2/5 affected wound injury responses on the different ECM substrates. (B) 
Primary cultures were treated with Ha2/5 or Ha2/5 and IL-1β and 24 hour scratch wound 
recovery measured on different ECM substrates, as indicated. Following each treatment, wound 
recovery was measured following each treatment relative to initial wound diameter (at 0 hour) 
and comparisons made to controls for each treatment. (*, P<0.05; **, P<0.01; ***, P<0.005; ; 
****, P<0.001). (C) Representative photomicrographs of GFAP+ astrocytes from each culture 
condition, as indicated, showing comparable gross morphology on each substrate with or 
without Ha2/5 treatment. Scale bar = 30 µm. 
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Figure 4-3. The influence of ECM substrate on mTORC activation after scratch. Time 
course analysis of S6 Kinase activation (pThr389; A-D) and Akt (pS473; E-H) following scratch 
wound in astrocytes grown on TnC (A,E), Ln (B,F), Vn (C,G), or Fn (D,H) with or without 
treatment with IL-1β. Representative immunoblots for activated S6 Kinase (pThr389) from each 
time point (as listed on the abscissa above each column) for Control (upper row) and IL-1β 
(lower row) for each ECM substrate, as indicated. Representative western blots for S6kinase 
from each time point show no significant change in overall levels of enzyme expression. (E-H) 
Representative western blots of time course analysis for pAkt activation (pS473) after scratch 
wound with or without treatment with IL-1β in primary astrocyte cultures. Immunoblotting for 
pan-Akt from each time point show no significant change in overall expression Akt expression 
over this time course. Quantification of western blots bands were corrected for sample loading 
relative to β-actin labeling of same blots (data presented as arbitrary units, a.u.) S6 Kinase data 
represent n=8/ treatment/time point.( *, P=0.006) and pAkt data represent n=8/ treatment/time 
point. ( *, P<0.02, TnC, Ln; P<0.04, Vn; **, P<0.005, Fn). 
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Figure 4-4. Differential Modulation of Astrocyte Scratch Responses by Rapamycin is ECM 
Dependent. Astrocytes grown on different ECM substrates were scratched and treated with 
either rapamycin (5 μg/mL) or vehicle. Measurements of scratch wound recovery after 24 hours 
were compared with control-treated cultures on the same ECM substrate. Rapamycin was found 
to only impair scratch wound recovery of astrocytes grown on TnC ( *, P < 0.005). 
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Abstract 
Interleukin-1β (IL-1β) is a pleotropic cytokine known to influence the central nervous 
system (CNS) responses to injury or infection. IL-1β also directly induces astrocytic 
expression of tissue inhibitor of metalloproteinases (TIMP)-1, a potent trophic factor and 
regulator of matrix metalloproteinase activity. In this study we examined the functional 
relationship between IL-1β and TIMP-1 and determined that the behavior of astrocytes 
in response to IL-1β is determined by TIMP-1 expression. Using primary astrocytes from 
C57Bl/6 mice, we found astrocytes from wildtype (Wt) mice exhibited a robust wound 
healing response to a scratch wound that was arrested in response to IL-1β. In contrast, 
TIMP-1 knockout (TIMP-1KO) astrocytes, exhibited minimal response to the scratch 
wound but an accelerated response following IL-1β-treatment. We also determined that 
the scratch wound effect in Wt cultures was attenuated by inhibition of Rho kinase but 
amplified in the TIMP-1KO cultures. We propose that the specific induction of TIMP-1 
from astrocytes in response to IL-1β reflects a previously unrecognized physiological 
relationship where the directionality of astrocytic behavior is determined by the actions 
of TIMP-1. These findings may provide additional insight into glial responses in the 
context of neuropathology where expression of TIMP-1 may vary and astrocytic 
responses may be impacted by the inflammatory milieu of the CNS.  
 
Keywords: Astrocyte, TIMP-1, IL-1β, ROCK, MMP 
Abbreviations: IL-1β: Interleukin-1β; TIMP-1: Tissue Inhibitor of Metalloproteinase-1; 
ROCK: Rho Kinase; MMP: Matrix Metalloproteinase. 
  
	 96	
1. Introduction 
Astrocytes are known to promote cellular differentiation, regulate synapse 
function, and promote axonal regeneration[46, 102, 290]. A prominent feature of many 
neurological diseases and injuries is 'reactive astrogliosis', which is defined by 
proliferation, astrocytic phenotype changes, changes in morphology and gene 
expression that is believed to reflect pathological changes in astrocytic functions[124, 
125]. The mechanisms regulating astrogliosis are not fully understood. 
Reactive gliosis can be modeled in vitro by stimulating astrocytes with pro-
inflammatory factors, such as interleukin 1 beta (IL-1β). IL-1β replicates features 
observed with reactive gliosis in vivo, including upregulated glial fibrillary acidic protein 
(GFAP) gene expression and cellular hypotrophy[291, 292]. Importantly, IL-1β induction 
of reactive astrogliosis has been shown to be due to deactivation of the Rho kinase 
(ROCK) signaling pathway; constitutively active ROCK was found to eliminate the 
impaired astrocytic response induced by IL-1β[284]. In addition, it has been shown that 
this IL-1β effect is partially due to the effect of the extracellular matrix and cross talk 
between additional signaling cascades such as ERK1/2, leaving an area of interest with 
regard to regulation of IL-1β effects on astrocytes[293]. Interestingly, the ROCK 
pathway has been implicated in a variety of CNS diseases including stroke and 
Alzheimer’s disease (AD) where ROCK inhibitors are potential therapeutic agents[294]. 
Astrogliosis is also a hallmark feature of these diseases, suggesting that pathological 
changes in ROCK pathway regulation may affect astrocyte functions in disease. 
IL-1β is also known to modify the behavioral response of astrocytes to injury[295], 
in part, through altering the astrocyte secretome [296]. Tissue Inhibitor of 
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Metalloproteinase (TIMP)-1 is a highly inducible secreted protein produced by 
astrocytes after CNS infection, inflammation, or injury [124, 125, 147].  TIMP-1 
expression is also directly regulated by IL-1β [45, 146, 297]. We have recently 
determined that reactive gliosis is greatly diminished in the absence of TIMP-1 [46], and 
that TIMP-1 is a potent activator of astrocytes [46]. Given the ubiquitous induction of 
TIMP-1 with acute brain injuries in association with astrogliosis [147], and the pleiotropic 
nature of TIMP-1 function [46], we hypothesized that TIMP-1 may impart physiological 
responses to astrocytes resulting from IL-1β exposure. 
Herein, we report that the astrocyte responses to IL-1β are determined by the 
production of TIMP-1 as it regulates the functional effect of by modulating injury-induced 
activation of ROCK pathway. These findings provide new information on the functions of 
astrocytes that relate to pathology in many CNS diseases. 
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2. Materials and Methods: 
2.1 Primary Astrocyte Cultures. Cultures were developed from cerebral cortices of 
neonatal C57BL/6 wildtype or TIMP-1 deficient (KO) mouse pups (P0-P3) using a 
neural tissue dissociation kit (Miltenyi Biotec)[282, 295]. Cells were plated in T175 flasks 
for 2 weeks before detachment using trypsin (Sigma) and re-plating into 24-well plates 
onto laminin-coated coverglass (Ln, 10 μg/μL; Sigma Aldrich) The purity of each culture 
system (GFAP+ cells) was consistent with previous reports[46, 230], as verified by 
immunocytochemistry (ICC) for GFAP (1:1000, Chemicon), and, Iba-1 to identify 
microglia (1:1000, WAKO). 
 
2.2 Scratch Injury model. A scratch injury ~600μm in diameter across a confluent 
astrocyte monolayer was made using a sterile P200 pipette tip[283, 295]. At varying 
times after injury, cells were fixed and ICC performed. Treatments included: IL-1β (10 
ng/ml; Peprotech)[284, 295]; rm-TIMP-1 (10ng/mL; R&D) or the TIMP-1 C-terminal 
domain peptide (amino acids 126-184; Anaspec Inc.)[46]; GM6001 (12.5 µmol/L; 
Calbiochem)[298]; ROCK-inhibitor, Y-27632 (10 µM; Fisher)[284]. Scratch injuries were 
measured perpendicular to the longitudinal axis of the scratch at a minimum of three 
points spanning the width of the scratch. Measurements were then used to determine 
the amount of recovery relative to baseline (i.e. wound diameter at time of the scratch, 
or t=0) for each sample and treatment. The average of each technical replicate was 
then compared across biological replicates to assess variability, though all data points 
were included in the final analyses.  
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2.3 ELISA:  A TIMP-1 ELISA (Duoset; R&D Systems) was performed on conditioned 
media samples according to manufacturer’s protocol, as previously described[46].  
 
2.4 Immunocytochemistry (ICC). ICC was performed as previously described[46]. 
Cultures were fixed in 4% paraformaldehyde, washed and incubated with primary 
fluorescent conjugated antisera for Glial Fibrillary Acidic Protein (GFAP-Cy3; 1:1000, 
Sigma). 4',6-diamidino-2-phenylindole (DAPI) was added after incubation to 
counterstain nuclei. Immunoreactivity was visualized by fluorescence microscopy 
(Olympus, IX71) and representative images acquired using image analysis software 
(Empix Imaging). 
 
2.5 Rho-associated Kinase (ROCK) Activity Assay: was performed according to 
manufacturer’s protocol (Cell Biolabs, Inc.). Briefly, protein lysates were collected from 
astrocyte cultures and placed in MYPT-1 coated wells; the level of ROCK activity was 
measured by optical density to quantify Thr696 phosphorylation of MYPT-1[299]. 
 
2.6 Statistics: Experiments were performed in quadruplicate replicates and then 
repeated in triplicate. Comparisons between treatments were made using t-tests, or, 
where appropriate, a two-way ANOVA with Bonferroni post-hoc tests was used to 
evaluate response differences between genotypes with treatments using GraphPad 
Prism software (La Jolla, CA). Data are presented as mean±SEM. The null hypothesis 
for all experiments was P<0.05.  
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3. Results: 
To understand the dynamics of TIMP-1 expression in culture and to determine 
whether its expression was altered by a mechanical wound in vitro, we measured levels 
of TIMP-1 in conditioned media from Wt cultures either at the time of the scratch (t0), 4 
or 24 hours later. We found that production of TIMP-1 was induced over time by the 
scratch wound without any additional stimulus, where TIMP-1 levels were significantly 
elevated by 4 hours post injury, and subsequently returned to baseline levels by 24 
hours (Figure 1). No significant changes in TIMP-1 production was found in untreated, 
unscratched cultures over the same 24 hr time course (Figure 1). Consistent with 
previous findings we found IL-1β induced a significant increase in TIMP-1 protein levels 
in the conditioned media from Wt cultures (Figure 1). We next determined what effect 
mechanical wound stress would have on induction of TIMP-1 in response to IL-1β 
treatment. Interestingly, when compared with either scratched or IL-1β treatment alone, 
TIMP-1 production in the scratched astrocyte cultures was delayed and significantly 
lessened in scratched cultures that were also treated with IL-1β (Figure 1). These data 
pointed to a previously unrecognized complexity in the relationship between IL-1β, 
TIMP-1 and mechanical wound stress in astrocytes.  
Our previous studies had determined that TIMP-1 can directly activate 
astrocytes[46], but the functional implications of this activation had not been previously 
addressed. To examine how TIMP-1 influences the behavior of primary astrocytes in 
culture, we compared confluent primary Wt and TIMP-1KO astrocyte cultures and 
assessed their response to a scratch wound[295]. We found significant recovery in Wt 
astrocytes by 24 hours after the scratch (Figure 2), however, TIMP-1KO astrocytes 
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exhibited minimal recovery (Figure 2). Since (a) IL-1β induces TIMP-1 expression, (b) 
IL-1β treatment attenuated the production of TIMP-1 when the culture was scratched, 
and (c) IL-1β treatment is also known to arrest scratch recovery in astrocyte 
cultures[284, 295], we next examined the effect IL-1β on scratch recovery in TIMP-1KO 
astrocytes. Consistent with previous work[284, 295], we found that administration of IL-
1β (10ng/mL) was sufficient to arrest recovery in Wt glial cells, whereas application of 
IL-1β was found to increase the rate of scratch wound recovery in TIMP-1KO cultures 
(Figure 2). Thus, the physiological response of astrocytes to IL-1B was inverted in the 
absence of TIMP-1. 
 To confirm that TIMP-1 was responsible for these differences in the astrocytic 
response to the scratch injury, we examined whether we could recover a "wildtype" 
phenotype by introducing TIMP-1 to the TIMP-1KO astrocytes. Application of 
recombinant murine (rm)-TIMP-1 protein was found to significantly improve wound 
recovery (P=0.0017, Figure 3A). TIMP-1 is well-characterized as a dual function protein, 
with both metalloproteinase-inhibitory function and a receptor-mediated growth factor 
function. To determine what function of TIMP-1 mediated the scratch recovery, we then 
applied a recombinant peptide of TIMP-1 which encompassed only the trophic factor 
domain and found that it significantly improved scratch wound recovery (Figure 3B). 
When we applied GM6001 (12.5uM), a non-selective broad spectrum MMP inhibitor 
compound, to either TIMP-1KO cultures (Figure 3C) or Wt cultures (Figure 3D) and 
measured the scratch response, we found that GM6001 did not significantly alter the 
scratch wound response of either genotype (P=0.3369; Figure 3C,D). This result 
indicated that deficit in scratch wound response in TIMP-1KO astrocyte cultures was a 
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result of a trophic factor action of TIMP-1 and not via inhibition of MMPs.  
 To determine why the physiological response of astrocytes to IL-1β is inverted in 
TIMP-1KO astrocytes, we examined how TIMP-1 may influence IL-1β regulation of Rho 
GTPases[284]. The ROCK pathway is important for cell shape, motility, and 
migration[300]. ROCK activity was measured in cell lysates from Wt and TIMP-1KO 
cultures that had been either treated with IL-1β, or vehicle, and either a ROCK inhibitor 
(ROCKi, Y-27632; 10 µM), or vehicle control. Basal ROCK activity in TIMP-1KO 
astrocytes was significantly lower than basal levels measured in Wt cultures (P<0.01, 
Figure 4A). Treatment with IL-1β increased ROCK activity in both Wt and TIMP-1 KO 
cultures (Figure 4A), with the increase in IL-1β induced ROCK activity in TIMP-1 KO 
cultures equal to levels in untreated Wt cultures (P>0.05).  
 To evaluate the functional impact of these differences in ROCK activity, we 
performed the scratch assay on Wt and TIMP-1KO astrocyte cultures using ROCKi and 
IL-1β (Figure 4B). Addition of ROCKi to Wt cultures dropped ROCK activity to levels 
equal to basal levels in TIMP-1KO cultures (not shown), and there was a significant 
decrease in the ability of the wt astrocytes to recover from the injury (Figure 4B). 
Addition of IL-1β to ROCKi treated Wt cultures significantly impaired wound healing 
resulting in negative recovery (i.e. wound widening). In contrast, application of the 
ROCKi to TIMP-1KO astrocyte improved the scratch wound response compared to 
baseline scratch response in these cultures (ANOVA, P<0.005; Figure 4B), and, there 
was no measurable effect of IL-1β over that of ROCKi treatment in the knockout 
cultures (Figure 4B)   
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4. Discussion:  
 Our data confirm previous findings that ROCK activation is important for recovery 
from a scratch injury in Wt astrocytes[284]. However, our data also indicate that 
inhibition of ROCK in TIMP-1KO astrocytes elicited an opposite response to Wt cultures. 
These data imply that the physiological impact of IL-1β on astrocytes may be 
determined, in part, by the production and ability of astrocytes to express TIMP-1. 
TIMP-1 is a top candidate gene upregulated in two models of astrogliosis[125], and we 
have previously shown that TIMP-1 is important for astrocyte activity in vivo[46]. There 
is also an emerging understanding that TIMP-1 is dynamically regulated and that 
dysregulation of TIMP-1 expression by astrocytes may contribute to context under 
which astrocytes respond in a variety of neurological diseases. We postulate that many 
of the actions of TIMP-1 in this context are not MMP-mediated but rather through a 
receptor-mediated signaling mechanism. Previous studies have reported TIMP-1 
activation of PI3K and Akt signaling in non-neural cells[179], though these process have 
not yet been directly confirmed in CNS cell types[178]. Future studies on the trophic 
actions of TIMP-1 may provide important insights into the acute effect of inflammation 
on astrocytes in disease, where a rapid elevation in TIMP-1 have been associated with 
CNS repair. In contrast, elevated expression of TIMP-1 is not always observed in 
several chronic inflammatory neurodegenerative diseases, including HIV-
encephalomyelitis and multiple sclerosis (MS)[158, 160, 169], suggesting that a reduced 
propensity of astrocytes to express TIMP-1 may result from chronic inflammation and 
then significantly impact how astrocytes function/respond  in these chronic disease 
states.  
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 In this study, we wanted to further elucidate the contribution and function of 
astrocytes in response to IL-1β, which has been shown to be important for the formation 
of the glial scar because the mechanism that generates the astroglial phenotype of the 
reactive astrocytes is still not fully understood. A better understanding of the regulation 
of astrocyte reactivity could provide a beneficial insight into astroglial heterogeneity in 
function and phenotype in disease. In particular, the role of TIMP-1 and the ability of 
astrocytes to react to external stimulation. These previous observations have lead to our 
study to understand a potential mechanism for TIMP1 regulation of astrocyte activity. 
On a cellular level, our data are also consistent with primary human astrocyte cultures 
from MS lesion biopsies, which have been reported to exhibit increased proliferation 
and migratory capacity when compared with cultures derived from non-diseased brain 
or spinal cord regions[301]. Although measurement of TIMP-1 produced in the context 
of human disease-specific astrocyte cultures has not yet been reported, our findings 
would suggest that the behavior of astrocytes may strongly influenced by TIMP-1 
expression and this would change over time as a result of the chronic inflammation 
during disease.  
 We have found that the astrocyte response to IL-1β is linked to the presence of 
TIMP-1, and that this response is coupled to the activity of the ROCK pathway. The 
ROCK pathway has been implicated in many cell functions including migration. It is 
important to highlight that the cellular response to a scratch wound is complex and is 
known to engage many signaling pathways related to cell proliferation, migration and 
cell death [302]. For instance, cdc42, another GTPase shown to impact astrocyte 
behavior in the scratch assay [283], also interacts with ROCK signaling[303]. Based on 
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our scratch assay data (Figure 4), the absence of TIMP-1 dramatically influenced the 
magnitude of scratch wound recovery by regulating ROCK activity in response to IL-1β. 
It is possible that a mechanism for TIMP-1 regulation of astrocyte responses to IL-1β 
may involve signaling molecules such as cdc42. Interestingly, another upregulated gene 
in response to astrogliosis, is lipocalin 2 (lcn2)[125], which also has been previously 
shown to play an important role in astrocytic reactivity is also positively regulated by 
ROCK pathway signaling[304]. Previous studies have found that stimulating lcn2 can 
act to polarize the function of astrocytes[305] by activating the ROCK pathway and 
stimulating reactive gliosis[304]. If TIMP-1 is found to regulate lcn2 expression, future 
studies may provide a plausible ROCK-mediated mechanism by which astrocytic 
reactivity, astrogliosis, and wound healing may be managed TIMP-1. 
Dysfunction of astrocytes is recognized as an underlying etiology of a number of 
neurological diseases including: MS, AD, and amyotrophic lateral sclerosis (ALS)[46, 
118, 122, 134, 135, 145, 147]. Reactive astrocytes surround MS plaques and are 
thought to impair remyelination[99], which suggests an important role for astrocytes in 
the pathology of MS. In AD, activated astrocytes have been shown to release pro-
inflammatory factors that promote inflammation and foster Aβ deposition[118]. 
Astrocytes are thought to cause of motor neuron degeneration in ALS[134, 306]. TIMP-
1 has been implicated in all of these, and other, neurodegenerative diseases. Therefore, 
our findings may have broad implications for understanding astrocytic functions in a 
variety of neurodegenerative diseases[147].  
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5. Conclusions. Astrocyte responses to IL-1β are profoundly influenced by the 
production of TIMP-1 through modulation of the ROCK pathway. These findings provide 
new information on how TIMP-1 may control astrocyte function and impact astrocyte 
function(s) in a variety of CNS diseases. 
 
6. Acknowledgments: 
We thank Sophie Gysling and Cory Willis for technical assistance. This work was 
supported by grants (to S.J.C.) from National Institutes of Health (NS078392), National 
Multiple Sclerosis Society (RG5001-A-3), and CT Innovations (SCA-06-011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 107	
 
 
 
 
7. Figures 
 
 
 
 
Figure 5-1: TIMP-1 induction in response to mechanical injury and inflammation. Analysis 
of TIMP-1 production in primary cultures 0, 4, and 24 hrs in response to control (squares)  or IL-
1β treatment (triangles) and scratch wound (red lines).  2-way ANOVA, P<0.0002; where ****, 
P<0.0001 Cntl w/ IL-1β vs. Cntl; **P<0.01 Scratch w/ IL-1β vs. Cntl w/ IL-1β, and * P<0.05, 
Scratch w/ IL-1β or Scratch vs Cntl. 
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Figure 5-2: The physiological effect of IL-1β on astrocytes is inverted in TIMP-1KO 
cultures. 
(A). Representative images of WT and TIMP-1KO astrocytes treated with vehicle or IL-1β. (B). 
Quantitative analysis of scratch recovery (in percent) from baseline scratch wound in confluent 
Wt and TIMP-1KO astrocyte cultures treated with vehicle or IL-1β (10 ng/ml).ANOVA, P<0.0001;  
**, P<0.01 TIMP-1KO Cntl vs. Wt Cntl; ***, P<0.001, Wt Cntl vs TIMP-1KO Cntl or Wt IL-1β, and 
P<0.002 TIMP-1KO IL-1β vs. TIMP-1KO Cntl. Scale bar = 800um. 
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Figure 5-3: Introduction of 
recombinant TIMP-1 restores Wt-
like phenotype response to 
TIMP-1KO cultures. (A) 
Quantification of scratch recovery 
(in percent from baseline) in TIMP-
1KO astrocyte cultures treated with 
either vehicle or rm-TIMP-1 (10 
ng/ml). (B). Quantification of 
scratch recovery in TIMP-1 KO 
astrocyte cultures treated with a C-
terminal peptide of TIMP-1 [TIMP-
1(C); 10 ng/ml]. (C,D) 
Quantification of scratch recovery in 
TIMP-1KO and wildtype astrocyte 
cultures treated broad spectrum 
MMP-inhibitor, GM6001, or vehicle 
(control). Student's t test:; ***, 
P=0.001. 
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Figure 5-4: Diminished astrocytic Rho kinase activity in absence of TIMP-1. (A). ROCK 
activity measured in Wt and TIMP-1KO astrocytes treated with either IL-1β or vehicle (control). 
Two-way ANOVA; **, P=0.007 for genotype, P<0.018 for treatment effect. (B). Quantification of 
scratch recovery in Wt and TIMP-1KO astrocyte cultures (in percent from baseline scratch) 
when treated with either IL-1β or IL-1β and Rho kinase (ROCK) inhibitor. Two-way ANOVA, ** 
P<0.0009 for genotype interaction, and P<0.01 for IL-1β treatment. (C) Hypothesized IL-1β 
pathway regulation of RhoK and the influence of TIMP-1 where the absence of receptor-
mediated signaling via TIMP-1 (i.e. TIMP-1KO) modifies the physiological response of 
astrocytes to IL-1β. 
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Abstract 
The extracellular protein tissue inhibitor of metalloproteinase (TIMP)-1 is both a matrix 
metalloproteinase (MMP) inhibitor and a trophic factor for oligodendrocytes. In this report we 
provide a characterization of the signaling mechanism by which TIMP-1 stimulates 
oligodendrocyte progenitor cells (OPCs) differentiation into mature myelinating oligodendrocytes. 
We show that trophic action of TIMP-1 to promote OPC differentiation is a function independent 
of its ability to regulate MMPs. We also report that TIMP-1 trophic functions on oligodendrocytes 
are mediated by β1 integrin and CD63, which together represent a putative receptor complex. 
Downstream of CD63/β1 integrin, we found that TIMP-1 regulates the activity of β-catenin. This 
non-canonical β-catenin regulation was counteracted by Wnts 3a and 7a to regulate OPC 
differentiation. Taken together, these data support a novel function for TIMP-1 in the temporal 
and spatial regulation of OPC maturation via β1/CD63-Akt-β-catenin signaling. These data 
contribute to an emerging understanding on the role of TIMP-1 in CNS myelination and repair.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	 113	
Introduction 
  
 Oligodendrocyte progenitor cells (OPCs) are a population of resident stem cells within 
the CNS. OPCs mediate myelination, which plays important roles in learning and brain recovery. 
OPCs have been identified within demyelinated lesions in the MS brain, yet these progenitor 
cells do not differentiate into myelinating OLs [27]. Multiple Sclerosis (MS) is a chronic 
inflammatory demyelinating disease of the central nervous system (CNS) characterized by 
lesions or plaques of demyelinated axons. Demyelination is the process where myelin is lost 
from axons, usually from a direct insult to the OL in the CNS [7, 8]. Demyelination strongly 
correlates with disease progression and clinical disability in MS patients [11, 12]. Thus 
understanding why OPCs are arrested in MS and how we may coax OPCs to foster 
remyelination in the MS brain early therapeutic strategies to promote remyelination may provide 
long-term benefit in MS.  
 Tissue inhibitors of metalloproteinase (TIMP)-1is a recently identified trophic factor that 
promotes OPC differentiation and CNS myelination	 [46, 146]. TIMPs are a family of secreted 
proteins that are best known as regulators of matrix metalloproteinases (MMPs) protease 
activity [145, 146]. Specifically, using an animal model of MS, EAE, in Wt and TIMP-1KO mice, 
we showed that there was significant recovery in the chronic stages of EAE in Wt, and minimal 
in TIMP-1KO, suggesting an important role for TIMP-1 in myelin biology	 [46]. TIMPs exhibit 
other biological functions independent of their MMP inhibition. The C-terminal domain, which is 
less well characterized, can mediate some protein-protein interactions [147, 152]. TIMP-1 has 
been widely studied for its MMP-inhibitory functions, however, TIMP-1 has also been reported to 
evoke cellular signaling mechanisms independently of MMPs. [173, 174, 179].  
Recently, CD63, a tetraspanin protein, was identified as a putative receptor for TIMP-1, 
providing a possible signaling mechanism for the MMP- independent effect of TIMP-1, although 
a role for CD63 as receptor for TIMP-1 in the CNS has not been not been previously reported.  
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 CD63 interacts with cell adhesion molecules such as integrins, specifically β1-integrins, 
regulating intracellular signal transduction pathways [173, 175]. β1-integrin is a member of a 
larger family of cell surface glycoproteins that mediate the interaction between a cell and the 
extracellular environment [176, 177]. Previous work has shown that β1-integrin is crucial for 
OPC migration [220]and is also important for the activation of Akt to promote OL differentiation 
for CNS myelination [233]. In transgenic mice that over-express a constitutively active Akt, the 
mice have hypermyelinated axons, suggesting an important role for Akt activation in the 
regulation of CNS myelination [307]. These data suggest a potential role for this β1-
integrins/CD63 pathway in OPCs in response to TIMP-1. 
An additional target of Akt signaling is the transcription factor β-catenin through the 
regulation of Glycogen synthase kinase 3β (GSK3β), a serine/threonine kinase, is a 
downstream substrate of Akt that when phosphorylated becomes inactivated [126, 170]. When 
GSK3β is phosphorylated by Akt, β-catenin is not degraded and then able to translocate into the 
nucleus where it promotes gene transcription by interacting with LEF-1/TCF factors. Inhibition of 
GSK3β can also promote β-catenin translocation into the nucleus to promote differentiation of 
oligodendrocytes [187]. Though, there are conflicting data on whether β-catenin mediated 
transcription promotes or inhibits OL differentiation because β-catenin can be regulated by 
many different processes ( as depicted in Figure 1-5 of this thesis) [185].  
 In this study, we explored the mechanism by which TIMP-1 stimulates OPC 
differentiation and determined that TIMP-1 regulates β-catenin signaling that requires 
β1integrin/CD63 signaling. These data provide new information on how TIMP-1 may stimulate 
OPC differentiation and how a loss of TIMP-1 trophic activity in patients with MS may contribute 
to chronic demyelination and remyelination failure in MS. 
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Materials and Methods 
Primary Oligodendrocyte Precursor Cell (OPC) Cultures.  
OPC cultures were developed from the cortices of neonatal Sprague-Dawley rat pups (P0-2; 
Harlan). Cortices were denuded of meninges and hippocampi, and were then mechanically 
minced and manually homogenized with a flame polished Pasteur pipet into a single cell 
suspension in culture medium (DMEM/F12;Gibco) containing 10% fetal bovine serum (FBS; 
Denville Scientific). The cell suspension was spun for 9 min (1800 rpm@ room temp/RT) and 
the pellet was resuspended culture media for plating into flasks coated with poly-l-lysine (PLL 
0.3mg/mL; Sigma Aldrich). Once a confluent cell monolayer formed, flasks were shaken for 1 
hour (55 rpm @ 37˚C), media exchanged with fresh culture media to remove any cellular debris 
and microglia and then returned to the incubator for 2-4 hours (37°C). Cultures were then 
shaken overnight (255 rpm) to lift OPCs. Supernatant from shaken flasks was spun down at 
1800 rpm for 10 minutes and pellet was resuspended in before mentioned media and incubated 
for 3-4 hrs at 37°C in non-tissue treated petri dishes. The media was collected spun down at 
1800 rpm and resuspended in media and plated onto the coated coverslips for more than 1 hr 
[for PLL coating: glass coverslips were washed in sterile 1N HCl (30 min/RT), washed with 
sterile water (3 time) and then incubated with poly-l-ornithine (0.05mg/mL; Sigma) 3 hrs/37°C]. 
Once plated onto coverglass, media was exchanged for differentiation media [Neurobasal 
media (Gibco) with 2% B27 serum-free supplement (Gibco), 2mM L-glutamine (Gibco), and 
10ng/mL T3 (Sigma) for up to 4 days and then OL maturation was assessed. For experimental 
treatments, where indicated, OPCs were treated with specific peptides or inhibitors daily for 4 
consecutive days and their impact on OL differentiation was assessed by immunocytochemistry 
for markers for each stage of OL differentiation.   
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Peptides, Function Blocking Antisera and Chemical Inhibitor Treatments. 
Peptides. All peptides used were purchased from commercial sources. These included full 
length recombinant murine (rm)TIMP-1 (10ng/mL; R&D Systems), C-terminal domain of TIMP-1 
(amino acids 126-184 of TIMP-1, referred to as "TIMP-1(C)"; 100ng/mL, Anaspec), and Wnt3a 
and Wnt7a (both 5ng/mL; from R&D Systems). Inhibitors used included the broad spectrum 
MMP inhibitor, GM6001 (12.5 µM; selleckchem), the Akt inhibitor, MK-2206 (5µM; Selleckchem). 
Function Blocking Antibodies. anti-β1 integrin (5uM; Ha2/5, BD Pharmingen) and its serotype 
matched Hamster IgM2 control (Sigma), and anti-CD63 (5µM; Santa Cruz) its serotype matched 
IgG control (Santa Cruz).  
 
Analysis of OPC Differentiation.  
The number of mature OL was evaluated by immunocytochemistry using stage-specific markers 
CNPase and myelin basic protein (MBP) to establish efficiency of differentiation. The number of 
cells per field (20x magnification) in 4 fields per coverslip using n=4 samples per treatment 
group will be used for analysis, in triplicate. Using higher magnification (i.e. 40-63x) parameters 
of process length and square area (μm2) of processes and Sholl analysis was used to determine 
the complexity of individual cells by counting the number of independent processes that cross a 
concentric circle twice the soma diameter [308].  
 
Immunochemistry.  
Immunochemistry was performed as previously described [46]. Cultures were fixed in 4% 
paraformaldehyde, washed and then incubated with primary fluorescent conjugated antisera for 
MBP (1:500; Millipore, Billerica, MA), A2B5 (1:500; Millipore, Billerica, MA), Olig2(1:500, 
Millipore), CNPase (1:500; Sigma-Aldrich), BIII tubulin (1:500;abcam). 4',6-diamidino-2-
phenylindole (DAPI) was added after incubation to identify nuclei. Immunoreactivity was 
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visualized using a fluorescent microscope (Olympus, IX71) and image analysis software (Empix 
Imaging). 
 
Lysoletchin and Cerebellar Slice cultures 
 P7 TIMP-1 KO mouse pup cerebellum were used for slice cultures, in accordance with 
establish animal protocol, according to previously established protocols [309]. Demyelination 
was induced by addition of .5mg/ml lyphosphatidylcholine (lysolecithin, Sigma), to the medium 
for 18 hours, and then normal medium was replaced into the culture. Cultures were maintained 
for up to 12 days after demyelination induction and were processed for immunolabeling.  
 
Western Blot Analysis.  
Lysates from OPC cultures grown on poly-ornithine were prepared as previously described [46]. 
Cells were scraped into PBS, after 0, 4, or 24hrs after treatment, centrifuged (6000xg), the pellet 
was resuspended in RIPA buffer [Triton X-100, NaCl, Tris-HCl base, Deoxycholic Acid, SDS, 
H2O] and mechanically dissociated using a motorized pellet pestle (Fisher Scientific). Each 
sample was prepared with 2x loading buffer [Tris-HCl, Glycerol, SDS, H2O, BPB, DTT] and 
100μg of total protein was loaded into a  5-15% gradient acrylamide gel (Biorad). After PAGE, 
protein was transferred onto PVDF membrane (Thermo Scientific). Blots were blocked and then 
incubated overnight in primary antisera. Primary antisera for  Active β-catenin (1:1000, Cell 
Signaling) and β-actin (1:2000, Sigma). Secondary antisera were HRP-conjugated anti-mouse 
(1:10,000, Vector Labs), or HRP-conjugated anti-rabbit (1:10,000, Vector Labs) for detection 
using ECL reagent (GE Biosciences). Exposed films were developed and quantified relative to 
β-actin loading for each sample [46].  
 
Image Analysis. All immunostaining was visualized using fluorescent non-overlapping Alexa-
fluorophore-conjugated secondary antisera directed against the species of the primary 
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antibodies (1:500; Invitrogen, Carlsbad, CA). For computer assisted image analysis of 
immunolabeling we used Northern Eclipse software (Empix Imaging, Cheektowaga, NY) on an 
Olympus IX71 inverted microscope. All comparative analyses were made using coded samples 
prepared with the same reagents and processed at the same time.  
 
Statistics. Experiments were performed as quadruplicate technical replicates and repeated 
three times with biological. Comparisons between treatments were made using student t test to 
evaluate changes between treatments or one-way ANOVA to evaluate changes at different 
differentiation stages. Data are presented as mean±SEM. The null hypothesis for all 
experiments was P<0.05.  
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Results 
TIMP-1 promotes OPC differentiation via its trophic factor domain 
We had previously determined that TIMP-1 is a potent trophic factor for OPC differentiation	 [46]. 
To define the mechanism of action by which TIMP-1 fosters OL maturation, we tested the 
functional contribution the well-characterized N-terminal MMP-inhibitory domain or TIMP-1 and 
its trophic factor domain. To test the possibility that TIMP-1 acts via MMP inhibition to promote 
OPC differentiation, we treated OPCs daily for 4 days with full length recombinant murine (rm)-
TIMP-1, or the broad spectrum MMP-inhibitor, GM6001, and then quantified the proportion of 
mature OLs relative to maturation in control-treated cultures. Whereas we found that GM6001 
completely blocked OPC differentiation, we found that administration of full length recombinant 
murine (rm)TIMP-1 significantly increased the number of CNPase+/Olig2+ OLs in culture 
(Figure 1). To test the trophic action of TIMP-1 separately from its MMP inhibitory function, we 
treated OPCs daily with TIMP-1(C) and measured OL maturation after 4 days. Consistent with 
the trophic effect of rmTIMP-1 (full length), we found that TIMP-1(C) also significantly increased 
the number of CNPase+/Olig2+ OLs when compared with control-treated cultures (Figure 1). 
Importantly, there was no significant difference between the proportion of mature OLs in OPC 
cultures treated with either rmTIMP-1 or TIMP-1 (C) (Figure 1). These results suggested that 
the trophic function of TIMP-1 was sufficient to promote OPC differentiation and the MMP-
inhibitory actions of TIMP-1 in the assay did not explain the increased OL maturation in 
response to treatment with rmTIMP-1.  
 
The trophic function of TIMP-1 is receptor-mediated 
In breast epithelial cells, CD63, a member of the tetraspanin family, was found to be a 
cell surface receptor for TIMP-1 [173]. Several previous studies have implicated a putative role 
TIMP-1 trophic signaling in the CNS the implied a receptor-mediated mechanism, although one 
has not been previously characterized for the CNS. To address this absence in our knowledge, 
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we next sought to characterize the potential for CD63 as a receptor for the effects of TIMP-1 on 
glial cells.  
 We tested several commercially available antibodies against CD63 and identified one 
that served as a function-blocking antibody for CD63. From this, we administered the αCD63 
antisera daily, in conjunction with rmTIMP-1, to OPC cultures and assessed the OL maturation. 
Co-application of αCD63 antisera to OPCs cultures treated with rmTIMP-1 significantly 
diminished the number of Olig2+/MBP+ OLs when compared with rmTIMP-1 and serotype 
matched IgG control antisera (Figure 2).  These results indicated that rmTIMP-1 may require 
the CD63 signaling complex to initiate its trophic actions on OPCs in cultures. To fully evaluate 
the CD63 receptor complex, we next tested the requirement of β1 integrin for TIMP-1 trophic 
signaling. It had been previously determined that (a) OPCs express β1-integrin [220] and (b) β1-
integrin is required for CD63 signaling to form a TIMP-1 receptor complex	 [173]. To test whether 
rmTIMP-1 requires β1-integrin, we administered the well-characterized Ha2/5, β1-integrin 
function-blocking antibody to OPCs cultures treated with rmTIMP-1. Blocking β1-integrin using 
Ha2/5 was found to significantly reduced the number of Olig2+/MBP+ OLs in response to 
rmTIMP-1 treatment when compared with a serotype-matched antibody control (Figure 2). 
Together, these data suggest the CD63/β1-integrin receptor complex participate in the trophic 
signaling of TIMP-1 on OPCs to promote their maturation.  
 
TIMP-1 promotes OL maturation in Cerebellar slice cultures  
We next tested whether the findings of rm-TIMP-1, would be recapitulated in an 
organotypic slice culture of demyelination. To this end, we applied lysoletchin to cerebellar slice 
culture of TIMP-1 KO mice. We found that application rm-TIMP-1 (10ng/mL) was sufficient to 
promote remyelination following lysoletchin-induced demyelination in this slice culture system 
(Figure 3). Cultures treated with rm-TIMP-1 when compared with controls treated cultures 
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exhibited significantly more MBP expression 12 days after lysoletchin treatment. Importantly, 
this effect was blocked when treated with rm-TIMP-1 and the β1-integrin integrin blocker, Ha2/5 
(Figure 3). This suggested that the increased MBP expression was mediated through a TIMP-1 
receptor mediated signaling pathway involving β1-integrin. 
 
TIMP-1 activates Akt to promote OPC differentiation 
Previous work had determined that TIMP-1 can activate protein kinase B, or Akt, 
downstream of the CD63/β1 integrin receptor complex [174]. Akt has also been shown to have 
importance for promoting OPC differentiation and CNS myelination [307]. To determine whether 
TIMP-1 activated Akt signaling and whether this was required for the trophic action of TIMP-1 on 
OPC maturation, we applied the Akt specific inhibitor, MK2206, to OPC cultures treated with 
rmTIMP-1. Analysis of Olig2+/MBP+ OLs following treatment determined that MK2206 
significantly attenuated the trophic effect of TIMP-1 (Figure 4). To confirm that this effect was 
not mediated through cell death, we determined that there was no difference between the 
amounts of Olig2 positive cells between all treatment groups (Figure 4). Thus, inhibition of Akt 
prevents the trophic action of TIMP-1 on OPCs, which suggested that PKB/Akt may be 
downstream effector, or at the very least a regulator, TIMP-1 activation of the CD63/β1 integrin 
receptor complex. 
 
TIMP-1 induces β-catenin activation in OPCs 
β-catenin is a transcriptional regulator that can be controlled by Akt activity. β-catenin is 
constitutively held in the cytoplasm where it is targeted for degradation by the proteasome, until 
activation of Akt releases β-catenin which then translocates to the nucleus where it promote the 
transcription of target genes. β-catenin signaling has been implicated as a control signal over 
OPC maturation to myelination OLs [62, 187]. Since we had determined that Akt was activated 
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by TIMP-1, we next sought to determine whether this activation had any impact on the 
regulation of β-catenin within OPCs. We determined that rm-TIMP-1 promoted the translocation 
of β-catenin into the nucleus as compared to control treated OPCs, suggesting that TIMP-1 
mediates β-catenin [310].  Additionally, we found that rm-TIMP-1 significantly increased active 
β-catenin in OPCs 24 hrs after treatment (Figure 4).   
 
Canonical Wnt signaling physiological antagonizes trophic actions of TIMP-1  
 Wnt3a and Wnt7a are known regulators of β-catenin signaling also recognized for 
impairing OPC differentiation [311, 312]. The elevated expression of both Wtn3a and Wnt7a in 
demyelinated lesions of patients with MS also points a potentially important pathological role for 
β-catenin regulation in the failure of remyelination in MS [59, 311, 313].  Elevated expression of 
Wnt/β-catenin regulated genes are found in the lesions of patients with MS, suggesting 
dysfunction of the Wnt/β-catenin leads to the lack of remyelination seen in MS [311]. To test 
whether the dual regulation of β-catenin by TIMP-1 and Wnts was competitive, we tested the 
physiological impact of Wnts with rmTIMP-1 on OPC differentiation. Consistent with previously 
published work, we found that Wnt3a significantly impaired the differentiation of OPCs to latter 
stages of maturity (CNPase+ or MBP+) stages when compared with control or rmTIMP-1 
treated cultures [39, 312]. When OPCs were treated with rmTIMP-1 in combination with Wnt3a 
we observed attenuated OPC differentiation (Figure 5). We tested the effect of Wnt7a on OPC 
differentiation and found that differentiation of OPCs to an mature stages (CNPase+ or MBP+) 
was not negatively affected. However, when Wnt7a was applied in combination with rm-TIMP-1, 
a significant block in the trophic actions of rmTIMP-1 on maturation was observed (Figure 5). 
These data may point to a possible physiological antagonism resulting from convergence on the 
same pathway.  
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Discussion 
 The results of this study on the influence of TIMP-1 on OPC differentiation may have 
implications for demyelinating diseases like multiple sclerosis. Multiple Sclerosis (MS) is a 
chronic demyelinating disease of the central nervous system (CNS) characterized by chronic 
white matter lesions exhibiting limited remyelination. Current immune-modulatory treatments 
that target the chronic autoimmunity associated with MS include treatment with β-Interferon, 
glateramir acetate and fingolimod. While these immunotherapies serve to manage the severity 
of relapses and their frequency, accumulating evidence suggest that do not reverse the 
demyelination or halt the progressive decline of function in MS patients. Therapeutic strategies 
to promote remyelination are now viewed for their potential to provide long-term benefits in MS 
by promoting brain lesion repair. In MS, it has been established that OPCs are recruited to 
demyelinated lesions but they fail to fully remyelinate [27, 314, 315], implying that OPCs in 
myelin lesions represent an endogenous regenerative response that fails as a result of a deficit 
in the environment [7]. We hypothesize that TIMP-1 is a factor missing from the myelin lesion 
environment in MS. Since we have shown that TIMP-1 promotes the maturation of OPCs, we 
studied the trophic functions of TIMP-1 to promote OPC differentiation through a previously 
unidentified and important mechanisms controlling OPC differentiation that could be important to 
foster remyelination in MS.  
 β-catenin is a transcriptional regulator that can either induce or repress gene expression. 
Future studies to understand how non-canonical β-catenin regulation by TIMP-1 when 
compared with canonical regulation by Wnts may serve to refine our understanding on 
functional roles of specific transcriptional targets of β-catenin. For instance, cyclin D1, a co-
factor involved in regulating cyclin dependent kinase activities and cell cycle progression, is 
transcriptionally induced by β-catenin activity. In this context, activated β-catenin, in conjunction 
with insulin-growth factor (IGF)-1, promotes cyclin D1 that has been shown to induce OPC 
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proliferation and enhance survival [316]. Additionally, c-myc, another target of β-catenin activity 
mediated transcription, has been shown to be important for OPC differentiation [317]. 
Specifically, c-myc activity was shown to be the switch between OPCs to remain in a 
proliferative and immature stage, to a mature OL [317]. Future studies to identify additional 
downstream targets of the TIMP-1-Akt-β-catenin signaling may shed light on the complex 
processes involved β-catenin regulation of OPC fate [59]. A recent study found that through 
non-canonical β-catenin signaling, through the Wnt effector transcription factor 7-like 2 (TF7L2) 
activation, there was a promotion of OPC differentiation [318], suggesting that there may be 
convergent roles of β-catenin depending on the interaction with differing transcription factors, 
which could be related to different factors, such as TIMP-1. Potentially, the TIMP-1 interaction 
with the β-catenin signaling pathway may result in differentiation gene regulation as compared 
to Wnt/β-catenin, thus leading differential outcomes of OPC differentiation.  
 β1-integrin has been shown to not only be important for the migration of OPCs, but also 
and more pertinently, in myelin development. With use of β1-integrin KO mice, it was shown that 
they had deficient myelination, but there was no different in the development of OPCs into OLs, 
specifically the myelin outgrowth process [233]. Even further, this deficiency was shown to be 
mediated by the inability to activate Akt to promote myelination [194]. However, this process has 
only been studied during development and would be an interesting phenomenon to study in a 
diseased model, such as EAE or lysolethcin. Interestingly, β1-integrin was has also been shown 
to be crucial for the migration of OPCs [220] and therefore, dysfunction of the TIMP-1/CD63:β1-
integrin complex and lack of remyelination could have a two problem two fold.  
 If TIMP-1 is a regulator of β-catenin, how might this pathway be implicated in multiple 
sclerosis? TIMP-1 is a highly inducible extracellular protein produced in the CNS predominately 
by astrocytes in response to infection, inflammation, or injury and is known to activate 
astrocytes [46, 147]. Previous work using TIMP-1KO mice has shown that TIMP-1KO mice 
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develop worsened myelin injury as compared to wildtype (Wt) in a model of inflammatory 
demyelination [46], whereas transgenic TIMP-1 overexpressing mice are more resistant to this 
form of myelin injury [170]. There exists a striking correlation between these animal studies 
where both clinical and experimental data support a positive correlation between elevated 
expression of TIMP-1 in the CNS and remyelination. For example, with acute demyelinating 
encephalomyelitis (ADEM), a temporary condition with complete remyelination, TIMP-1 
expression is dramatically elevated [160]; however, TIMP-1 expression is not increased in 
patients with MS, which is marked by minimal remyelination [161]. The levels of the other TIMP 
proteins remain unchanged under diseases conditions, suggesting a specific role for TIMP-1 in 
CNS myelin pathology [45]. Because of the lack of TIMP in the lesions, and the increased 
expression of Wnts, the sub sequential gene regulation from β-catenin can result in the 
impairment of OPC differentiation.  
 Many interesting questions remain to further elucidate how the TIMP-1 mediated 
activation of β-catenin pathway interacts with the Wnt signaling. More specifically, can TIMP-1 
modulate the activity of Wnt? A recent study on non-canonical Wnt signaling demonstrated that 
WNts regulate transcription factor 7-like 2 (tf7l2) signaling to increase differentiation of and 
enhance myelination [318]. This was previously unknown role non-canonical wnt signaling 
mechanism that can regulate OPC differentiation	 [318]. This data also suggests that modulation 
of the Wnt/β-catenin mechanism can have differing effects depending on downstream factors. 
This may shed light on why there are seemingly conflicting outcomes in studies examining Wnt 
signaling and OL/myelin.  
Our experiments add to a potential TIMP-1 mechanism of cross regulation of β-catenin 
signaling. To resolve how TIMP-1 vs Wnts both regulate β-catenin but have opposing effects on 
OL maturation, comparisons of differential gene regulation by Wnt/β-catenin transcription versus 
TIMP-/β-catenin mediated signaling would be warranted. Specifically, a comparative analysis of 
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OPCs treated with rm-TIMP-1 in the presence and absence of Wnts could serve to identify 
important differences that lead to key downstream regulators that promote OL differentiation 
and ultimately, remyelination. Also, there may be cross talk between the regulation of β-catenin 
by Akt activation since both Wnt and TIMP-1 can work through his proximal kinase. It is possible 
that differential activation of Akt, or downstream targets may also be differentially affect by 
TIMP-1 or Wnt. Ultimately results from studies on differential regulation of OPC differentiation 
via β-catenin I would help resolve the outstanding questions.    
 Work from our lab has shown that this phenotype may be accountable for a novel non-
MMP mediated signaling effect of TIMP-1 in the CNS in response to myelin injury [46]. 
Specifically, we have identified TIMP-1 as a trophic factor for OLs [46], and we have recently 
determined that TIMP-1 is a novel trophic factor for oligodendrocyte (OL) differentiation. Our 
experiments have determined that the primary action of TIMP-1 to promote oligodendrocyte 
progenitor cell (OPC) differentiation was independent of MMP inhibition, but rather through a 
novel signaling function. We hypothesize that TIMP-1 stimulates OPC differentiation through a 
receptor-mediated signal transduction pathway to regulate β-catenin-mediated gene 
transcription.  
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Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: TIMP-1 induces OPC differentiation through a previously unreported MMP-
independent mechanism. (A.) Representative images of CNP/Olig2+ oligodendrocytes (OL) 
following treatments as indicated (Vehicle, rm-TIMP-1, TIMP-1 (C), and GM6001). B. Graphical 
analysis of the percent of Olig2 positive cells that are also positive for CNPase to measure the 
amount of OLs (Immature and Mature) in each treatment group. Data are presented as mean 
SEMin each treatment, represent n=4/treatment repeated in triplicate. (**, P < 0.02). Scale bar= 
100μm. 
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Figure 6-2: CD63/β1 integrin mediates the trophic function of TIMP-1 on OPCs. (A-B; D-E.) 
Representative images of differentiated OLs with the following treatments, as indicated 
identified by Olig2 (green) and MBP (red) immunostaining. C, F. Graphical analysis of the 
percent of MBP+/Olig2+ cells in each treatment group. Data represent mean +/- SEM of OLs in 
each treatment, n=4/treatment repeated in triplicate. (**, P < 0.02;***,P<.005). Scale bar= 
100μm. 
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Figure 6-3: TIMP-1 increased MBP expression in organotypic slice cultures from TIMP-1KO 
mice. Representative images from  (A.) control, (B.) rm-TIMP-1, (C.) rm-TIMP-1 and Ha2/5 
treated TIMP-1 KO cerebellar slice cultures 12 days after lysoletchin induced demyelination 
Organtoypic slices were stained with MBP (red), βII tubulin (green), and DAPI (blue) Scale bar= 
100μm. (D.) Analysis of the mean fluorescence immunoreactivity of MBP in TIMP-1 KO slices, 
n=5. (*,P =0.012). Scale bar= 100μm. 
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Figure 6-4: TIMP-1 
mediates β-catenin 
signaling through Akt 
activation. (A-C.) 
Representative images of 
OLs Olig2+/MBP+ following 
rm-TIMP-1 and/or with 
MK2206 (Akt inhibitor) 
treatment (D.) Analysis of 
the Olig2+/MBP+ OL 
lineage cells in each 
treatment group. Data are 
presented as mean SEM +/- 
for each treatment, 
representing n=4/treatment 
that was repeated in 
triplicate (**, P < 0.02). (E.) 
Analysis of of Olig2+ cells 
per field for each treatment 
group determined no 
difference in the amount of 
Olig2+ cells with each 
treatment. Data are 
presented as mean SEM +/- 
for each treatment, 
representing n=4/treatment 
that was repeated in 
triplicate (**, P < 0.02). (F.) 
Representative images of 
OPCs with and without 
treatment of rm-TIMP-1 
showing the translocation of 
β-catenin to the cell nucleus 
of OPCs in culture. G. 
Representative western blot 
of active β-catenin (Cell 
signaling) in OPCs treated 
with rm-TIMP-1 or vehicle 
over 24 hrs (H.) Analysis of 
of β-catenin translocation 
into the nucleus over time 
both in control and rm-
TIMP-1 treated OPCs. (I.) 
Densitometric analysis of 
Rat OPCs treated with 
either vehicle or rm-TIMP-1 for 24 hrs. Data represent n=3 and expressed as arbitrary units. (*,P 
=0.013) 
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Figure 6-5: Canonical Wnt signaling physiological antagonizes trophic actions of TIMP-1 (A. 
Representative images of OLs treated wither rm-TIMP-1, in combination with Wnt3a or Wnt7a. 
OL lineage cells stained with Olig2 (green) and MBP (red) to identify mature OLs. (B.) Analysis 
of Olig2+/CNPase+ cells in each treatment group. Data are presented as mean +/- SEMof OLs 
in each treatment, n=4/treatment repeated in triplicate. (C.) Analysis of the Olig2+/MBP+ OL 
cells in each treatment group. Data represent mean +/- SEM in each treatment, representing 
n=4/treatment repeated in triplicate. (*,P<0.05, **,P<0.01). 
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Abstract 
The extracellular environment of demyelinated lesions in multiple sclerosis (MS) patients  
contributes to the limited remyelination observed in this disease. We had previously determined 
that astrocytic support of oligodendrocyte maturation is mediated via production of secreted 
factors regulated by tissue inhibitor of metalloproteinase-1 (TIMP-1). A comparative proteomic 
analysis of the astrocyte secretome identified a novel fragment of the first type III domain of 
fibronectin (Fn) which we have determined has functional homology with Anastellin and is 
negatively regulated by TIMP-1. This short homolog of Anastellin impairs OPC maturation. 
Anastellin fosters formation of high molecular weight Fn observed in MS lesions. These results 
provide a new mechanism through which astrocytes contribute to the non-permissive 
environment of a demyelinated lesion in the MS brain. 
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Introduction 
Astrocytes are dynamic cells unique to the central nervous system that provide critical 
homeostatic functions that adapt and respond to alterations in the extracellular environment. In 
the injured or inflamed CNS, astrocytes are often used to identify sites of pathology. In 
demyelinating diseases, such as multiple sclerosis (MS), astrocytes are considered important 
physiological regulators of remyelinating potential of oligodendrocytes [123]. We had previously 
determined that astrocytic production of tissue inhibitor of metalloproteinases-1 (TIMP-1), is 
closely linked to astrocytic support of oligodendrocytes; we had determined that TIMP-1 
regulation of the astrocyte secretome contributes to oligodendrocyte progenitor cell (OPC) 
differentiation [46].  
To explore the astrocyte secretome and its impact on OPCs, we performed a 
comparative proteomic analysis of the astrocyte secretome. We were able to discern the  
differences related to astrocytic regulation by TIMP-1. Herein, we report on the identification of a 
previously unrecognized posttranslational regulation of cellular fibronectin by TIMP-1. 
Interestingly, fibronectin (Fn) regulation of OPCs had been previously found reported [119]. 
Recent research has shown that Fn produced by astrocytes is increased at the demyelinating 
stages of MS [119]. Further, astrocytic Fn in these areas formed aggregates, believed to be the 
result of inefficient clearing of Fn following injury that prevented remyelination in an 
experimental model of demyelination by inhibiting the differentiation of OPCs [119]. We show 
that TIMP-1 regulates astrocytic Fn production, in part, through a post-translational mechanism 
and generation of Anastellin. 
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Results 
We had previously determined that conditioned media from primary TIMP-1KO astrocyte 
cultures failed to support the maturation of A2B5 OPCs, which was in contrast to conditioned 
media from wildtype (Wt) cultures that promoted OL differentiation [46]. We hypothesized that 
the failure of TIMP-1 KO ACM may have been accountable to the presence of an inhibitor of 
differentiation or the lack of a promoter of OPC differentiation [46]. To address these 
possibilities, proteins from serum-free ACM from TIMP-1KO and Wt primary astrocyte cultures 
was separated for analysis using an automated protein fractionation in 2D system [319]. Post 
separation analysis of protein abundance peaks using proteome lab software revealed unique 
differences from both Wt and TIMP-1KO ACM (Figure 1A). Mass spectrometry of 6 unique 
peaks from each genotype when compared with the mass spec of time constant matched 
samples provided a short list of potential candidates (Figure 1B). Among these uniquely 
expressed peptides was a proteolytic fragment of fibronectin (Fn). 
To determine whether Fn levels were directly transcriptionally regulated by TIMP-1 we 
assessed the expression of Fn in Wt and TIMP-1KO primary astrocyte cultures by quantitative 
PCR. To our surprise, we found no differences in Fn mRNA expression between Wt and TIMP-
1KO cultures, nor was Fn mRNA expression altered by application of recombinant murine 
TIMP-1 to TIMP-1KO cultures (Figure 1D). Thus, Fn was not transcriptionally regulated by 
TIMP-1. However, we found that TIMP-1 regulates the post-translational level of extracellular Fn 
from astrocytes (Figure 1D), where we saw significantly increased amount of Fn in our TIMP-
1KO cultures as compared to out Wt. Interestingly, this finding is consistent with human control 
and MS patients astrocytes (Figure 1E). Clinical and experimental data support a positive 
correlation between elevated expression of TIMP-1 in the CNS and remyelination. For example, 
with acute demyelinating encephalomyelitis (ADEM), a temporary condition with complete 
remyelination, TIMP-1 expression is dramatically elevated[160]; however, TIMP-1 expression is 
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not increased in patients with MS, which is marked by minimal remyelination[161]. To evaluate 
whether there is a cellular deficit in TIMP-1 expression from astrocytes in MS, we cultured 
astrocytes from human autopsy samples and assayed TIMP-1 and Fn expression. Consistent 
with previous studies, MS astrocytes produced higher levels of Fn than control astrocyte 
cultures [119]. Interestingly, there was also a significant difference in the production of TIMP-1 
relative to Fn in MS when compared with control samples. We found that human astrocytes 
from MS had a higher Fn to TIMP-1 ratio as compared to Control astrocytes, suggesting a 
pathological feature of TIMP-1 expression and Fn levels, in MS. Also, this too was found only to 
affect the protein level of Fn, not transcriptionally regulated. Thus, reduced expression of TIMP-
1 by astrocytes in MS may contribute to the elevated production of Fn and accumulation of high 
MW Fn in this disease. 
We next determined if Fn was sufficient to impair OPC differentiation by adding 
exogenous Fn (0-10 μg/mL) to our culture system (Figure 2A) to determine whether Fn 
contributed to reduced OPC differentiation. We found that 10μg of Fn was sufficient to block 
differentiation of OPCs into OL, by significantly decreased the amount of MBP+ cells in our 
culture. We next determined if Fn was the factor in our TIMP-1KO ACM preventing the 
differentiation of OPCs. We immunodepleted TIMP-1KO ACM with polyclonal antisera against 
Fn, or an IgM2 control antisera, and tested whether this affected the number of amount of 
differentiating OPCs grown in this media (Figure 2B). Analysis of MBP+ mature OLs in cultures 
treated with either native TIMP-1KO ACM or TIMP-1KO ACM treated with control IgM verified 
our previous findings that this media supported spurious differentiation. However, when anti-Fn 
antisera was added to the TIMP-1KO ACM, OL differentiation was increased to levels 
comparable with Wt ACM (Figure 2B).  
Anastellin, a proteolytic product of Fn breakdown, is known to be present in blood and its 
best-described function is as an antagonist of angiogenesis where it facilitates the formation of 
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high molecular weight aggregates of Fn	 [320]. Our determination that a Fn breakdown product 
was more abundant in TIMP-1KO ACM suggested a connection with Anastellin and Fn. Several 
recent studies have determined that astrocytes from MS cases produce copious amounts of 
higher molecular weight Fn, which impedes OPC differentiation. We tested if anastellin, in part, 
affected the differentiation by mediating the potency of Fn. We applied Anastellin either alone or 
in combination with Fn, and found that in combination with a sub-impairment level of Fn, OPC 
differentiation was significantly impaired (Figure 3A,B,C). Additionally, we confirmed this finding 
using our synthesized Fn proteolytic peptide found in the TIMP-1KO ACM, small homolog of 
anastellin we refer to as "shanestallin" (Figure 3D,E). Shanestallin did not significantly impair 
OPC differentiation when applied to OPC cultures alone. However, when applied in combination 
with a concentration of Fn that was also insufficient to affect OPC maturation, we found a 
significant impairment to OPC differentiation (Figure 3). Thus, the presence of a proteolytic 
fragment of Fn in TIMP-1 ACM can synergistically affect Fn-mediated impaired differentiation of 
OPCs in culture. 
Anastellin is known to block sphigosine-1-phophate (S1P)-1 signaling [321]. S1P-1 
signaling is also a therapeutic target for treatment of patients with MS [322]. Since the S1P1 
agonist, fingolimod (pFTY720), has been shown to directly stimulate OPC differentation [28], we 
next determined whether Anastellin could be a natural inhibitor of S1P signaling on 
oligodendrocytes. Application of pFTY720 to primary OPC cultures stimulated maturation of 
Olig2+/MBP+ OLs, whereas coincident treatment with recombinant Anastellin blocked the 
FTY720-induced increase in OPC maturation (Figure 4). Taken together, these data suggest 
that Anastellin, or an Anastellin-like peptide from Fn could be a naturally occurring, astrocyte-
derived regulator of OPC differentiation.  
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Discussion  
Failure of remyelination underlies the chronic demyelination in MS, which can lead to 
neurodegeneration and progressive clinical disability	 [29]. The presence of OPCs within 
demyelinated lesions in MS proffers potential for OL differentiation and remyelination [27]. 
However, this observation also points to disease-related perturbations in the lesion 
microenvironment in MS as a primary cause of diminished remyelination in this disease. 
Accumulating evidence also points to astrocytes as mediators of the MS lesion environment	
[119, 223]. 
Previous work in our lab determined that lack of TIMP-1 impairs differentiation of OPCs 
and remyelination [46]. We took this observation farther to understand what factor regulated by 
TIMP-1 could be impairing OPC differentiation utilizing proteomic techniques, identifying an 
anastellin-like peptide, shanestallin. We determined that both anastellin and shanestallin, in 
combination with Fn, were able to block OPC differentiation. Previously, anastellin has been 
shown to promote Fn aggregation	 [320] and HMW Fn aggregates are found in MS lesions	 [119]. 
We hypothesize that TIMP-1 mediates the proteolysis of Fn, which leads to Fn breakdown 
products such as shanestallin (or Anastellin), which may promote the formation or HMW 
aggregates reported within the MS lesion [119]. Our work confirms that there is a negative effect 
of Fn on OPC and extends our understanding by showing that Anastellin-like peptides can 
exacerbate OPC differentiation by enhancing the effect of Fn, but also potentially acting on 
OPCs directly. On this latter point, our data suggest that Anastellin may antagonize S1P1 
signaling and diminish the efficacy of FTY720 to promote OPC differentiation. Given the 
previously defined presence of HMW Fn in MS lesions, identification of Anastellin or Anastellin-
like peptides may represent a potential additional deleterious mechanism by which Fn may 
endogenously limit OPC fate in MS lesions. By extension, identification of Anastellin and 
addressing the means by which it is generated may also represent an approach to further 
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enhance the efficacy of an already approved therapy for treatment of MS (Fingolimod)	 [21, 25, 
28, 322]. We found that anastellin blocked the trophic effect of Fingolimod on OPCs.  
TIMP-1 is a highly inducible protein in response to many CNS disorders, however, there 
is not change in expression in MS patients	 [160]. Our study provides a potential mechanism for 
the lack of remyelination seen in MS, as well as the lack of TIMP-1 induction. Briefly, we found 
that the astrocyte secretome is important to foster a permissive environment to promote OPC 
differentiation and that this was mediated by TIMP-1 expression. We found that TIMP-1 
regulates Fn post-translationally, through proteolytic breakdown into peptides from the first type 
III Fn domain, shanestallin, an anastellin like peptide. Therefore, TIMP-1 regulation of the 
astrocyte proteome may be an important facet governing the extracellular microenvironment 
that contributes to the chronic nature of myelin lesions in MS.  
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Materials and Methods 
Primary Mixed Glial Cultures.  
Animal protocols were performed in compliance with the University of Connecticut Health 
Center Institutional Animal Care and Use Committees (IACUC). Primary mixed glial cultures 
were prepared, as previously described. [323] Briefly, cortices of mouse pups (postnatal day 0-
3) were obtained from wild-type C57BL/6 mice or TIMP-1 knockout (TIMP-1 KO) mice of the 
same genetic background, stripped of meninges, separated from the cerebellum, and 
hippocampi removed. The cortices were dissociated using a neural tissue dissociation kit 
according to the manufacturer’s protocol (Miltenyi Biotec, Auburn, CA) and cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) culture medium (Gibco/Life Technologies, 
Carlsbad, CA). Media containing non-adherent cells was removed the following day and 
replaced with fresh media. For experiments analyzing the effects of replacing TIMP-1 protein to 
TIMP-1 KO cultures, recombinant murine TIMP-1 (rmTIMP-1, R&D Systems, Minneapolis, MN; 
10ng/mL) was added 24 hours prior to harvesting of protein/RNA.  
 
Isolation of Rat Oligodendrocyte Progenitor Cells (OPCs).   
Rat OPC cultures were generated, as previously described. [324] Cortices were obtained from 
rat pups (postnatal day 0-2), stripped of meninges, and had hippocampi removed. Cortices were 
mechanically minced, then manually homogenized with a flame polished pasteur pipet. The 
cellular suspension was spun at 1800 rpm for 9 min at room temperature and the pellet was 
resuspended and plated on poly-l-lysine (0.3mg/mL; Sigma Aldrich) coated flasks with 
DMEM/F12 mixed cell culture medium (F12 media, Gibco). When a confluent monolayer of cells 
was formed, flasks were placed in an incubated shaker at 55 rpm for one hour. Media was 
changed to fresh F12 media to remove cell debris and microglia contained in media from first 
shake. Cultures were allowed to sit in a 37°C incubator for 2-4 hours, followed by shaking at 255 
	 141	
rpm overnight to lift OPCs. During shaking of flasks, glass coverslips were washed in sterile 1N 
HCl for 30 min at room temperature, followed by coating with poly-l-ornithine (0.05mg/mL; 
Sigma) for 3 hours. Supernatant from shaken flasks was spun down at 1800 rpm for 10 min and 
pellet was resuspended in F12 media and incubated for 3-4 hours. OPCs contained in F12 
media were plated on poly-l-ornithine coated coverslips and cultured in either differentiation 
media (get the contents) or Fn depleted astrocyte conditioned media (ACM) for 4 days; method 
of depletion is explained below. 
 
Human Astrocyte Cultures. 
 Adult human astrocytes were isolated from post-mortem subcortical white matter of healthy 
subjects and patients with multiple sclerosis, as described previously [325]. Astrocyte cultures 
used were at least 97% pure. The cells were plated in 10 cm dishes (1.0 × 106/dish) or 8-well 
chamber slides (10 000/well).  
 
Immunodepletion of Fibronectin.  
Mixed glial cultures were grown as described above. ACM was collected in a 15mL conical tube, 
and antisera against Fn was applied to the media (1:100; ab23750, Abcam) and then incubated 
at room temperature for 30 min to bind Fn in media and functionally deplete media of Fn. 
Following depletion, Fn was added to OPC cultures for analysis of Fn effects on OPC 
differentiation. A species matched IgG control (normal rabbit IgG; Santa Cruz Biotechnology, 
Dallas, TX) was added to media, obtained from the same mixed glial cultures, to serve as a 
control for the immunodepletion. 
 
Function blocking Peptides. 
Peptides used were purchased from commercial sources or synthesized by Peptide 2.0. These 
include full length fibronectin (1-10 μg/mL; Sigma Aldrich), Anastellin (1-10μg/mL; R&D 
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Systems) ,small homolog of Anastellin (1-10μg/mL; synthesized by Peptide 2.0 Inc.; Sequence: 
MTTNEGVMYRIGDQWDKQHDLGHMMRCTCVGNGRHHHHHH), FTY720  (5μg/mL; Echelon 
Bioscience.) 
 
Protein-Fractionation Two Dimensional (PF-2D) Proteomic Analysis. 
 Confluent monolayers of wild-type and TIMP-1 KO primary mixed glial cultures were grown for 
24 hours in media free of serum and collected. The media was dialyzed in varying 
concentrations of phosphate buffers to remove the salt from the media. The conditioned media 
was then run through a size filtration column to separate out the proteins by their molecular 
weight and collected. Eluted proteins were run through protein fractionation 2-dimensional 
(PF2D), where the proteins were then further separated by a gradient of isoelectric point and 
then hydrophobicity, as previously described (Beckman Coulter, Pasadena, CA). [319] Identities 
of proteins differentially produced in TIMP-1 KO and wild-type mixed glial cultures were 
determined by mass spectrometry (MS/MS). 
 
Western Blot.  
Western blot analysis was performed, as previously described. [46] Briefly, cells from mixed glial 
cultures were collected and protein was digested using a lysis buffer containing Triton X-100 
(Sigma Aldrich, St. Louis, MO) and supplemented with protease and phosphatase inhibitors 
(Roche Diagnostics, Indianapolis, IN). A PierceTM bicinchoninic acid (BCA) assay (Thermo 
Scientific, Waltham, MA) was used to determine protein concentration. Protein was loaded onto 
a precast Mini-PROTEAN TGX SDS polyacrylamide gel (4-15%; Bio-Rad, Hercules, CA) and 
electrophoresed at 200v for 30 minutes. Protein was transferred to a PVDF membrane by 
electrophoresis for 2 hours at 100v. Membrane was blocked in a blotting buffer containing NaCl, 
Tris-HCl, and Tween-20 (Sigma) supplemented with 5% non-fat dry milk for 1 hour. Membrane 
was exposed to primary antisera in blotting buffer supplemented with 2% milk overnight at 4°C. 
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The primary antibody used to identify Fn protein levels was ab6584 (anti-rabbit, Abcam). 
Following wash with blotting buffer, membrane was exposed to secondary antibody against 
rabbit, conjugated with horseradish peroxidase (1:10,000; Vector Laboratories, Burlingame, CA), 
in blotting buffer for 1 hour. Following wash, membrane was exposed to Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare Life Sciences, Pittsburgh, PA) and 
developed onto CL-XPosureTM UV film (Thermo Scientific). Relative band density of protein 
was determined using ImageJ Software (NIH) (Tan and Ng, 2008). Fn protein levels were 
compared to a beta-actin loading control. 
 
Immunocytochemistry.  
OPCs plated on poly-l-ornithine coated OPCs, after 4 days of differentiation, were fixed with 4% 
paraformaldehyde (Sigma) at room temperature for 20 min. Cells were blocked with PBS 
containing 0.3% Tween X-100 (PBS-T) and normal goat serum (5%, Sigma) for 1 hour at room 
temperature. Cells were then incubated overnight at 4°C with PBS-T containing 2% NGS and 
antisera against Olig-2 (1:500,Millipore) A2B5 (which stains for OPCs) (1:200, Invitrogen), or 
MBP (which stains for myelinating oligodendrocytes) (1:500, Millipore). The following day the 
cells were exposed to Alexa-fluorophore-conjugated secondary antisera (1:500; Invitrogen). and 
counterstained DAPI (Sigma) for 1 hour at room temperature. Coverslips were mounted with 
Fluoromount G (Southern Biotech, Birmingham, AL) and visualized using an inverted Olympus 
IX71 microscope outfitted with digital image capture software.  
 
Antibodies.  
Anti-Fibronectin antibody (Biotin) (ab6584) (Abcam, Cambridge, UK; rabbit, 1:5000), Anti-
Fibronectin antibody (ab23750) (Abcam; rabbit, 1:100-immunodepletion), Anti-Myelin Basic 
Protein antibody [12] (MBP) (Milipore; rat monoclonal, 1:500), Mouse anti-A2B5 (Invitrogen, 
Carlsbad, CA; 3ug/mL), 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, 1:1000), Mouse anti-
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glial fibrillary acidic protein (GFAP) (Millipore, 1:500), Beta-actin (Sigma Aldrich, St. Louis, MO; 
mouse, 1:10,000). All immunostaining was visualized using Alexa-fluorophore-conjugated 
secondary antisera (1:500; Invitrogen). 
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR).  
RNA was harvested from primary mixed glial cultures using TRIzol reagent according to 
manufacturer’s protocol (Invitrogen). Following DNase treatment using a TURBO DNase kit (Life 
Technologies, Carlsbad, CA), RNA was reverse transcribed into complementary DNA (cDNA) 
using an iScript cDNA synthesis kit (Bio-Rad). Both procedures were performed according to 
the manufacturer’s protocol. The PCR reaction was carried out, according to manufacturer’s 
protocol (Bio-Rad), using Sso FastTMEvaGreen® Supermix. The reaction included primer 
sequences specific to Fn (Integrated DNA Technologies-IDT, Coralville, IA), constructed 
according to a previous experiment (forward 5’-AGA CCA TAC CTG CCG AAT GTA G-3, 
reverse 5-GAG AGC TTC CTG TCC TGT AGA G-3) (Morita et al., 2007). Primers for the 
housekeeping gene GAPDH were used as an internal control for RNA loading, and used to 
determine the relative gene expression of Fn, in each RNA sample (forward 5’-ACC ACC ATG 
GAG AAG GC-3’, reverse 5’-GGC ATG GAC TGT GGT CAT GA-3’) (IDT). qRT-PCR was run 
using a CFX Connect Real-Time PCR Detection System (Bio-Rad). The comparative cycle 
threshold analysis (∆∆CT) was used to determine the relative mRNA expression as previously 
described (Schmittgen and Livark, 2001). 
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Figures 
Figure 7-1. Proteomic 
Identification of Differential 
peptides in Wt and TIMP-1 
KO astrocyte secretome and 
post transcriptionally 
regulation of Fn in TIMP-1 
KO cultures and human MS 
astrocytes. (A). PF-2D on 
wildtype (Wt) and TIMP-1KO 
conditioned media samples. 
Asterisks indicate samples 
selected for LC/MS/MS 
based on (B) unique and/or 
differential abundance curves 
as determined by 
ProteomeLab. (C) LC/MS/MS 
identification of peptides in 
each sample identified 
differential detection of Fn 
IIIc domain peptide, 
Anastellin. D. Representative 
western blot of Fibronectin 
(abcam) in Wt and TIMP-
1KO astrocytes. 
Densitometric analysis of Wt 
and TIMP-1KO astrocytes 
Data represent n=3 and 
expressed as arbitrary units. 
(*,P <0.05).   qPCR analysis 
of Fn mRNA levels in Wt, 
TIMP-1KO, and TIMP-1 
treated with rm-TIMP-1 
astrocytes E. Analysis of 
primary astrocyte cultures 
from normal (non-diseased 
control) and MS cases and analysis of TIMP-1 expression as a ratio to Fn expression. n=5. 
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FIGURE 7-2. Fibronectin 
mediated dysregulation of 
Oligodendrocyte differentiation in 
TIMP-1KO astrocyte conditioned 
media. (A.) Analysis of OPC 
differentiation in primary cultures 
treated with increasing 
concentrations of recombinant 
Fibronectin, Representative 
images of OL-lineage cells were 
stained with MBP (red) and 
Olig2 (green) and quantification 
of MBP+Olig2+ cells per 
treatment normalized to control 
revealed a significant impairment 
of differentiation with increased 
Fn. (*, P<0.05, ***, P<0.001). 
(B.) Fibronectin 
immunodepletion in TIMP-1KO 
astrocyte conditioned media 
(ACM) restores OPC 
differentiation to Wt levels. 
Representative images of WT 
ACM, TIMP-1KO ACM, TIMP-
1KO ACM with αFn, and TIMP-
1KO ACM with IgG control 
treated OLs stained with MBP 
(red) and DAPI (Blue), as 
indicated. Analysis of MBP+ 
(green), nucleated (DAPI+, blue) 
cells per treatment revealed a 
significant effect of blocking Fn 
in the TIMP-1KO ACM. (*, P<0.05) 
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Figure 7-3. Characterization of Anastellin and a murine small homolog of Anastellin 
(shanastellin) for its inhibitory effects on oligodendrocyte differentiation and cooperative 
inhibition with Fn. (A.) Representative images of Control, Anastellin, Fn or Anastellin with Fn 
treated OPCs revealed a potent effect of Anastellin on the arresting of OPC differentiation as 
indicated by immunostaining for MBP (red) and Olig2 (green) (B). Analysis of MBP+Olig2+ cells 
treated with vehicle or Anastellin normalized to control (C.) Analysis of MBP+Olig2+ cells 
treated with Fn or Anastellin and Fn normalized to control (*,P<0.05). (D.) Analysis of 
MBP+Olig2+ cells treated with vehicle or small homolog of anastellin, as indicated normalized to 
control (E.) Analysis of MBP+Olig2+ cells treated with Fn, and  small homolog of anastellin with 
Fn, as indicated normalized to control (*,P<0.05).  
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Figure 7-4. Anastellin inhibits S1P1 regulation of OPC maturation. (A,B) Representative images 
of PFTY72-treated and Anastellin (“Ana”) treated OPC cultures and immunostained for MBP 
(red) and DAPI (Blue) to identify OL lineage cells. (C) Quantification of mature oligodendrocyte 
(MBP+) in each treatment determined that pFTY720 enhanced OPC differentiation and this was 
impaired by co-administration with Anastellin normalized to control **, P<0.01. 
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Figure 7-5. Representative schematic of Fibronectin Functional Domains and Amino Acid 
Sequences of Anastellin and novel Anastellin like peptide. Blue arrow indicates the location of 
the Fn fragments, anastellin and shanestallin within the 1st type III domain. Additionally, partial 
sequence of mouse Fn showing the sequence localization of anastellin and shanestallin 
peptides. Blue highlighting depicts the sequence of anastellin, while green highlighting shows 
the sequence of the Fn fragment shanestallin found in the TIMP-1 KO ACM. The first green 
highlighted portion depicts the sequence of Shanestalin. Red highlighting represents the Fn 
fragments present in the Wt ACM.  
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Chapter 8: Discussion and Future Directions  
 The extracellular matrix has only been recently appreciated as a major 
orchestrator of brain function. More specifically, the ECM is now appreciated to play 
major roles in promoting glial cell functions, including proliferation, differentiation, and 
activity level. In my thesis, I explored how extracellular proteins, specifically how the 
ECM molecules, Ln, TnC, Fn, Vn and the secreted molecule, TIMP-1 impacted glial 
cells in the CNS. My data found that these extracellular factors exerted dramatic effects 
and influenced their ability to differentiate, promote myelination, and recover from 
inflammation and injury. 
 My thesis work can broadly be applied to a variety of CNS disorders where there 
are major changes in the ECM environment that can influence the behavior of the glial 
cells, such as astrocytes and OLs, and in turn can result in a worsened outcome. 
I. ECM and astrocytes 
Astrocytes are not passive or static cells of the CNS; rather, they are dynamic 
and active. Data I generated for my thesis highlighted the concept that astrocytes do not 
only secrete proteins that comprise the ECM, but are also directly regulated by the ECM 
[295]. For my thesis, I focused on how the effects of the ECM on astrocyte influenced 
their behavior and signaling. For these studies, I used an in vitro scratch wound model, 
a valuable cell culture model to study cell behavior, specifically ability to recover from an 
injury [206]. In addition, it is a reliable and reproducible model to mimic astrocytic injury. 
However, there are some limitations of the model, specifically, to its relation in the 
context of glial scaring. Most prominently is that it only models astrocyte responses, 
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whereas, glial scaring involves many cell types in the CNS, like microglia and OPCs[132, 
144, 275, 326, 327]. In my thesis studies, I also used IL-1β to mimic an inflammatory 
stimulus in the context of a CNS insult as well. The purpose of these studies was to 
determine if ECM regulates astrocytes behavior in the context of repair and recovery, 
and in the broad terms, how this may be associated with astrogliosis and glial scaring in 
the CNS in association with CNS diseases and pathology.  
Extracellular Matrix Composition Determines Astrocyte Responses to Mechanical and 
Inflammatory Stimuli: 
 The ECM is always changing and represents a primary means by which cells 
respond to the environment. I studied the impact of ECM on astrocyte function, as 
described in Chapter 4 [295]. I focused on four ECM molecules that have been 
implicated in MS pathology: Ln, TnC, Fn, Vn. These ECM components have also been 
shown to have altered expression in a variety of CNS disorders [13, 119, 191, 228, 252, 
266, 267, 269]. I studied the astrocytic behavior or “reactivity” by using an in vitro 
scratch injury to model glial scaring, a hallmark of many CNS diseases, and how the 
ECM affected how the astrocytes responded. I found that in fact, the ECM did modulate 
astrocytes behavior, specifically their ability to react and recover from a mechanical 
injury (in vitro scratch) and inflammatory stimuli (IL-1β). Interestingly, I found that this 
behavior was mediated through integrin signaling, specifically β1-integrin, however, the 
molecules activated different signaling cascades. In summary, what this portion of my 
thesis concluded was that the ECM has strong regulation of astrocytes behavior, 
specifically in response to injury (mechanical and inflammatory). Specifically, the ECM 
substrates influenced the astrocytes ability to recovery from a scratch injury, as well as, 
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from injury and inflammation	 [295]. In addition, these effects were mediated through 
differential integrin signaling, depending on the ECM substrate [295]. These data 
emphasize that astrocytes are a heterogeneous population of cells that are differentially 
activated and thus behave differently depending on their surroundings.  
 There is a growing understanding that astrocyte dysfunction underlies a variety of 
CNS diseases. My work may contribute to this and could have broad implications for 
CNS dysfunction. Specifically, my work contributes to the thinking on the hallmark 
features CNS of astrogliosis or glial scaring in CNS diseases. Interpreted differently, my 
work also contributes to the growing area of research about the heterogeneity of 
astrocytes and how understanding astrocytic behaviors may help to understanding the 
underlying cause and pathology of many CNS disorders, including MS. Dysfunction of 
the astrocytes, which may be due in part to the changing extracellular environment 
could enhance the non-permissive environment for OLs and neurons seen in MS. A 
better understanding of how astrocytes will behave in response to changing ECM could 
lead to a better understanding of the lesioned environment and how astrocytes might 
influence the other CNS cells.  
 Because of the broad area of study in this portion of my thesis, there are a lot of 
interesting avenues of research that could stem from these findings and to further the 
goal of understanding astrocytic behavior in response to the ECM.  Firstly, astrocytes 
are known as a source of ECM	 [119, 328, 329]. Changes in the expression of ECM from 
astrocytes may promote or make the environment inhibitory for other CNS cells, such as 
OPCs. Knowing what controls differential secretion of factors from astrocytes in 
response to not only the ECM, but the ECM after injury or inflammation could provide a 
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deeper understanding about intracellular communication, astrogliosis, and the 
environment of the glial scar. Specifically, we have been collaborating with Dr. Tony 
Vella (UCHC Immunology) to apply a proteomics technique called PF2D, which is able 
to fractionate and compare secreted proteins from our astrocytic cultures. Peaks are 
compared between the different groups and samples can be sent for mass spectrometry 
to identify the differential production of proteins in the samples between the groups. This 
technique was used to identify Fn in TIMP-1 astrocyte samples as described in Chapter 
7 of my thesis. In future studies, we could compare the secreted proteins from 
astrocytes that are grown on Ln to those grown on Fn (we see recovery in astrocytes on 
Ln and minimal growth on Fn) and additionally compare the proteome of cells when 
grown on on these ECM substrates and in response to injury. Understanding the 
differential production of secreted proteins, we can further study those proteins impact 
on both astrocytes and also OL maturation. For instance, different proteins promote a 
reactive effect on the astrocytes or if they inhibit recovery, these could be measured 
using astrocyte scratch assays. Additionally, we could apply candidate proteins to OL 
cultures and determine if they impact the ability of OLs to grow, survive, differentiate, 
and potentially myelinate in vitro.  
An ultimate goal of this line of study would be to examine the impact of the ECM 
molecules in the CNS environment in vivo. As previously described, not all ECM KO 
mice are viable; we would have to use conditional KO mice, preferably a tamoxifen 
inducible lines of ECM KO to have control over the timing of gene expression. Using a 
model for glial scaring and brain trauma, such as a needle poke into the cortex of a 
mouse, the glial response could then be monitored to see whether altering a specific 
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ECM molecule differentially affected astrogliotic responses by measuring markers, such 
as GFAP immunoreactivity. This approach could be applied to knockout for Ln	 [330], 
TnC	 [331], Fn	 [332], and Vn	 [333] whether there were differences between the different 
ECM to compare the glial scaring between the inducible KOs. This would further 
elucidate the impact of the ECM molecules on astrocytes behavior in vivo and would 
also show the impact of the astrocytes behavior onto the other CNS cells, such as 
neurons and OLs.  
TIMP-1 Couples RhoK Activation to IL-1β-induced Astrocyte Responses:  
 Another aspect of my thesis studies was my examination of the role of TIMP-1 
and its impact on astrocyte behavior. Previous work reported by our lab had shown that 
TIMP-1 stimulates the astrocytes’ reactivity	 [46]. In my studies, we wanted to better 
understand the mechanism of this control and if TIMP-1 impacted astrocytic behavior. 
Using the in vitro model for glial scaring, the scratch injury model, we were able to 
determine that TIMP-1 does in fact have an effect on astrocytes ability to react/recover 
from an injury. More specifically, without TIMP-1, astrocytes cannot recover from an 
injury, however, with an inflammatory stimulation (IL-1β), we see the opposite effect, 
significant recovery. This observation revealed an inverse relationship in TIMP-1 KO 
astrocytes compared to Wt astrocytes by regulating Rho-kinase activity. With the lack of 
TIMP-1, rho-kinase activity is dysregulated and the IL-1β effect is inverted, again 
suggesting that TIMP-1 directly regulates astrocytes behavior and function through a 
previously unreported mechanism of rho kinase activity, and that TIMP-1 couples these 
effects of mechanical and inflammatory stimulation.  
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 Dysfunction of astrocytes is now appreciated as an underlying causing to many 
neurodegenerative diseases, where astrocytes are shown to prevent repair and 
recovery in the CNS	 [290]. We hypothesized that TIMP-1 is a component of this 
dysfunction. TIMP-1 has been shown to be elevated in response to many CNS diseases 
and is one of the top most upregulated genes during astrogliosis	 [125]. My study 
(Chapter 5) examined how rho kinase (ROCK) activity, which has been studied in many 
CNS disorders, is regulated by TIMP-1. It is important to note that ROCK inhibitors have 
been suggested as potential therapeutics for certain CNS diseases	 [300]. Minte is the 
first study to link TIMP-1 to rho-kinase regulation, as we determined that there was a 
direct effect on astrocytic function. Further study into the implications of this 
dysregulated pathway and how it effects astrogliosis and glial scaring could lead to a 
better understanding of the underlying cause of many CNS diseases. In the context of 
MS, where there is limited remyelination and a lack of TIMP-1 induction, further study of 
how the rho-kinase pathway is implicated in remyelination could lead to potential 
unappreciated mechanisms and understanding the role of the rho-kinase in the context 
of astrogliosis and glial scaring. As well as understanding how astrocytes behave 
differently with the lack of TIMP-1 with inappropriate rho-kinase activity and how this 
may affect other CNS cells such as OL, which have limited remyelination potential in 
MS. Essentially, further understanding of the lesioned environment, in the context of the 
astrocyte and its functions could lead to a better understanding of the underlying causes 
of many CNS disorders, including MS. 
My thesis work on TIMP-1 regulation of rho Kinase activity in astrocytes was an 
interesting and significant conclusion in in the context of astrogliosis, and this work 
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helps expand the understanding of the mechanisms regulating glial scaring. Briefly, it 
would be interesting to study this mechanism in vivo. By using the cortical stab model to 
study astrogliosis, we could study the differences in the glial scarring between Wt and 
TIMP-1 KO mice by measuring GFAP immunoreactivity. Additionally, I would cross a 
mouse with constitutively active rho-kinase	 [334] with a TIMP-1KO mouse to determine 
if active rho kinase rescued the ability of astrocytes to react/recover. We would measure 
this both in vivo and in vitro. Studying in vivo, we would compare the astroglial response 
after cortical stab between TIMP-1KO, constitutively active rho-kinase, and TIMP-
1KO/constitutively active rho-kinase and measure the GFAP immunoreactivity. 
Additionally, we would make astrocytic cultures from all of the above mentioned mouse 
lines and perform the in vitro scratch wound and measure recovery. We would 
determine if constitutively activating rho-kinase could rescue the TIMP-1KO phenotype 
that we see, and also if it remedied the inverse IL-1β affect.  
II. ECM and OLs 
Another portion of my thesis studies focused on how the extracellular 
environment affects OLs and their ability to differentiate and ultimately myelinate. In 
particular, it is known that astrocytes can influence the extracellular environment 
through secretion of proteins, including extracellular matrix molecules and trophic 
factors. However, astrocytes can be harmful and promote and inhibitory and negative 
environment for OL differentiation	 [123]. In the second portion of my thesis, I focused on 
the extracellular environment and how it affected OLs. I focused on how the CNS 
microenvironment, in the context of the MS lesion, could promote or inhibit OPC 
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differentiation into myelinatings OLs, and what in this environment could negatively be 
impacting the OLs inability to differentiate.  
 
TIMP-1 regulates Oligodendrocyte Differentiation by non-canonical of β-catenin 
Signaling 
We have previously shown that TIMP-1 acts as a trophic factor for OPC 
differentiation	 [46]. For my thesis, we further wanted to determine the mechanism of 
action on how TIMP-1 promoted OPC differentiation. Through our unpublished gene 
array data, we found that some of the top candidate genes of TIMP-1 regulation were 
also β-catenin mediated genes, such as cyclin D1. Previous studies have reported a 
receptor-mediated complex that TIMP-1 interacts with CD63: β1-integrin	 [173]. This lead 
us to hypothesize that TIMP-1 mediates β-catenin signaling leading to OPC 
differentiation through a previously unreported receptor complex that was MMP-
inhibition independent.  
The potential implications of TIMP-1 regulation of β-catenin signaling are quite 
complicated and interesting. Wnt/ β-catenin signaling has long been an area of interest 
with respect to MS and OPC differentiation, leading to conflicting results [59]. In MS, it 
has been found that there is both an upregulation of Wnts, as well as dysregulated 
signaling through the Wnt/ β-catenin signaling pathway [59, 311, 313]. My data would 
suggest a potential role for TIMP-1 in this process. Additionally, certain Wnt ligands 
have been shown to have various and differing effects on OPC differentiation, such as 
Wnt3a, which has been shown to inhibit OPC differentiation in culture	 [39, 312]. If β-
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catenin is a master pathway regulator of OPC differentiation then a better understanding 
of mediators that both promote and inhibit β-catenin signaling may lead to a better 
understanding of OL maturation, and the potential to elucidate the way remyelination is 
limited in this disease.  
An interesting and significant conclusion that came from my work is the potential 
parallel regulation of β-catenin by TIMP-1 that is independent of the canonical Wnt/ β-
catenin signaling. A recent study has found that non-canonical β-catenin signaling does 
in fact lead to increased OPC differentiation	 [318]. To our knowledge, there have been 
very few studies that have examined the potential of non-canonical regulation of β-
catenin to promote OPC differentiation, showing an important niche for our work by 
placing TIMP-1 in the process of OPC differentiation and identifying a novel mechanism 
by which TIMP-1 functions as a trophic factor.  
Unfortunately, studying Wnts and β-catenin signaling in vivo remains challenging 
because this signaling mechanism is essential for embryogenesis. Therefore, utilizing 
the culture system has answered many questions with regards to OPC differentiation, 
and further use of cerebellar slice cultures to measure remeylination is also essential. 
We would like to confirm all of our recent findings in our OPC cultures of the receptor-
mediated complex being essential for the TIMP-1 trophic effect in the slice culture 
model to in fact look at the process of remyelination of neurites. In addition, this system 
would better elucidate the role of TIMP-1 in the context of remyelination, as opposed to 
additional effects TIMP-1 may have with regards to the immune system that may be 
seen in the EAE model.  
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Currently, Joel Levine (SUNY) has a line of inducible β-catenin KO mice in OL 
lineage cells in the CNS	 [132]. It would be interesting cross these mice with our TIMP-1 
KO mice and make cerebellar slice cultures of the double KO and the β-catenin KO. 
Using lysolecithin on the slice cultures, we could then measure remyelination at various 
time points. We would hypothesize that in the absence of β-catenin, that there will 
minimal remyelination, similar to that seen in just TIMP-1 KO mice. Additionally, we 
would want to cross the β-catenin KO mice with the TIMP-1 overexpressing mouse and 
perform EAE. We hypothesize that the lack of β-catenin will in fact inhibit the beneficial 
effect of TIMP-1 of promoting remyelination after EAE, thus confirming our hypothesized 
pathway and TIMP-1 regulation of β-catenin. 
 In addition to the hypothesized pathway of TIMP-1’s mechanism of action 
mediating β-catenin signaling, previous work has shown that TIMP-1 does in fact 
regulate Wnts and Wnt signaling in mesenchymal stem cells via miRNA expression[335].  
We would also want to further understand the regulation by TIMP-1 of Wnt ligand 
production and its context with OPC differentiation, as well as the differential gene 
expression of β-catenin-mediated signaling with regards to Wnt/ β-catenin and TIMP-1/ 
β-catenin. Firstly, using an ELISA, we can measure the production of Wnts in media and 
serum in Wt and TIMP-1 KO mice to compare differences in the production of certain 
Wnt ligands that have been previously reported to play a role in MS pathology such as 
Wnt 3a, Wnt 5a, Wnt 7a, and Wnt 9a	 [59]. We would measure this at both basal 
conditions as well as in injury or diseased conditions. Second, using gene array 
comparisons of OPC cell culture, we would compare gene expression of OL cultures 
treated with or without rm-TIMP-1, and with or without Wnt3a to look for differential gene 
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regulation between TIMP-1 mediated gene transcription and Wnt mediated gene 
transcritption to further elucidate the differential regulation of β-catenin and how this can 
lead to both promoting OPC differentiation and inhibition OPC differentiation.  
 In summary, the field of β-catenin signaling to promote/inhibit OPC differentiation 
is quite complex. However, work from my thesis has provided additional understanding 
of how TIMP-1 mediates this signaling, differently from Wnt canonical signaling, to 
promote OPC differentiation.  
Identification of a TIMP-1 Regulated Novel Anastellin-like Peptide that Impairs 
Oligodendrocyte Differentiation 
 ECM molecules have long been studied for the changes seen in MS lesions. 
Specifically, Fn has been shown to be upregulated in MS lesions by astrocytes and 
inhibit remyelination. The mechanism of this Fn upregulation was previously unknown. 
In my work (Chapter 7), we identified a previously unreported regulation of Fn 
production by TIMP-1. More specifically, we identified a” small homolog of Anastellin” 
(shanestallin), a Fn breakdown product, present in media from our TIMP-1 KO 
astrocytes that was not present in our Wt cultures. I also determined that shanestallin 
could inhibit OPC differentiation. Additionally, anastellin has been shown to promote Fn 
aggregation, and is known to be present in MS lesions, suggesting a previously 
unrecognized mechanism for how Fn and high molecular weight Fn aggregation occurs 
in MS. The model for our current understanding on this is that without TIMP-1, there is 
Fn breakdown that leads to the build up of shanestallin, this both directly inhibits 
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remyelination, and potentially facilitates the aggregation of Fn to further impair 
remyelination and modify the ECM.  
 MS is a multifactorial disease, meaning that it does not have one known cause, 
but has been shown to have both immune and brain dysfunction. Currently, all major 
MS therapies do not slow down disease course, but do improve quality of living by 
limiting the amount and severity of relapses. Unfortunately, there is currently no 
treatment for SPMS or PPMS. An underlying cause of the MS is the failure of 
remyelination, which leads to the progressive decline. Currently, MS therapies do not 
target remyelination, and promotion of remyelnation is now being stressed as a major 
target of research. Therefore, understanding what in the environment of the lesion is 
preventing remyelnation has major implications for understanding the disease etiology. 
In MS, there is a lack of TIMP-1, which has previously been shown to be important for 
myelin and remyelination. In my work, we have now discovered a small peptide, 
shanestallin, that is regulated by TIMP-1 and shown to inhibit the differentiation of OPCs. 
In the context of MS, it is possible that there is a build up of this small peptide in the 
lesion that is preventing OPCs from differentiating into myelinating OLs because there is 
a lack of TIMP-1. In MS, it has been shown that there is an imbalance of MMPs, such 
as MMP-3. We hypothesize that this is MMP-3 mediated for two reasons. (1.) In our 
gene array data, we found that MMP-3 is not only regulated by TIMP-1 through its 
protease activity, but it is also transcriptionally regulated. (2.) Fn is a target of MMP-3 
degradation	 [336]. Specifically we hypothesize that without TIMP-1 to inhibit MMP-3, 
there is increased breakdown of the ECM molecule Fn into protolytic products such as 
shanestallin and anastellin, which leads to inhibition of OPC differentiation through, in 
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part, direct effect onto the OPCs, but also in promoting the aggregation of Fn and thus 
inhibiting OPC differentiation. This is a previously unknown mechanism of action in the 
context of astrocytic influence of the environment of the MS lesion leading to a poor 
environment for remyelination, specifically through regulating Fn and its breakdown 
products: anastellin and shanestallin.  
 In the future, it would be interesting to look directly at the aggregation of Fn in 
vitro using the deoxycholate assay to determine if shanestallin does in fact trigger Fn 
aggregation. In addition, if there was increased aggregation of Fn by shanestallin, and if 
the aggregation, it would be important to determine whether this has a 
pathophysiological role inhibiting remyelination. One could look at the role of aggregates 
on remyelination in two ways. (1.) By determining if the aggregates block OPC 
differentiation in vitro. (2.) Using the lysoletchin slice culture model to determine if the 
aggregates can block remyelination in intact tissue. One caveat of this is that there is no 
way to look directly at shanestallin. To develop new less cumbersome assays to identify 
Anastellin or Shanestallin, one could extend these experiments to look at shanestallin in 
the context of a biomarker in MS patients. Since we observed shanestallin in astrocyte 
conditioned media, we know that is secreted. To assay this in MS patients, one could 
look at the serum of MS patients for shanestallin to determine if there is an elevated 
presence of it in the serum of MS patients. GFAP, an astrocyte specific protein, has 
already been identified in blood and serum and thought to be a potential biomarker for 
acute brain injuries	 [337]. Therefore, it is plausible and possible to identify astrocytic 
proteins in our blood to be used as a potential biomarker for CNS diseases. 
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 Our lab has previously shown that TIMP-1 KO have limited remyelination as 
compared to Wt in chronic EAE	 [46]. 	 We want to look at differences in Fn aggregation 
in Wt compared to TIMP-1 KO mice in EAE. We hypothesize that there would be more 
Fn aggregation in the KO compared to wt mice after EAE and this could, in part, lead to 
some of the pathology seen in TIMP-1 KO mice and their inability to remyelinate after 
EAE. In conjunction, we also want to make a double KO of Fn and TIMP-1KO and 
compare remyelination in the chronic phase of the double KO to the Fn KO and the 
TIMP-1KO. The hypothesis to be tested would be that deleting Fn from TIMP-1 KO 
would remedy the lack of remyelination seen in our TIMP-1 KO mice. This would 
suggest the pathogenic role of Fn aggregation due to lack of TIMP-1 in the CNS that fits 
with observations in MS. This can be brought out further because of the Fn aggregates 
seen in MS lesions and the lack of TIMP-1 in MS patients. 
 Lastly, it would be interesting to further elucidate the role of MMP-3 in the context 
of its regulation by TIMP-1 and the mechanism of remyelination and Fn aggregation. 
One could cross MMP-3 KO and TIMP-1 KO mice and perform EAE. One might expect 
this to alter the inability to remyelinate seen in TIMP-1KO and improve remyelination 
after injury in adult TIMP-1 KO mice. We would also look at the Fn aggregation in this 
context to determine if there was decreased aggregation with the lack of MMP-3 to 
determine if MMP-3 has a pathogenic feature in the Fn aggregation.  
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